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Summary
A proper control of T cell activation, proliferation and differentiation, and of 
antigen responsiveness is central to the development of protective immunity. 
Activation of CD4^ T cells requires that the T Cell Receptor (TCR) and a 
costimulatory receptor, such as CD28, are simultaneously engaged. This initiates a 
number of intracellular events that lead to cell cycle entry and to the production of 
the autocrine growth factor IL-2. Following IL-2/IL-2R interaction, the cells 
proliferate and acquire effector capabilities. Several studies have indicated that in 
the absence of costimulation, and/or cytokine-initiated signals, T cells fail to 
proliferate and to differentiate. In particular, the engagement of the T cell receptor 
in the absence of proliferation has been shown to mediate the induction of clonal 
anergy, which has been proposed as one of the mechanisms by which peripheral 
tolerance to self-antigens is maintained.
Following antigen re-encounter anergic T cells fail to transcribe the IL-2 
gene, and to proliferate and are specifically arrested in the G1 phase o f the cell 
cycle. It was suggested that the failure of these cells to respond to optimal 
stimulation could be attributed to the presence of a putative anergic factor, uniquely 
expressed by the engagement of the TCR in the absence of proliferation. This model 
predicted that forcing proliferation, or G1 to S transition of anergic T cells would 
lead to dilution/degradation of the putative anergic factor, and by that restore the 
ability of the cells to properly respond to antigenic re-challenge. In the hope to 
restore antigen responsiveness, proliferation of anergic cells was forced by anti- 
CD3 and anti-CD28 mAbs. In contrast to antigenic stimulation, which failed to
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bypass the G1 cell cycle arrest, CD3/CD28 mAbs-mediated activation of anergic T 
cells resulted in T cell proliferation. Indeed, optimal engagement of CD3 and CD28 
elicited up-regulation o f cyclin D3, o f p21^^^, hyperphosphorylation of Rb, 
downregulation of the cell cycle inhibitor p27^'^ and cell proliferation. However by 
following the fate o f individual T cells, we showed that, in spite o f several rounds 
of cell division, clonal anergy was maintained. In contrast, anergic T cells allowed 
to proliferate in response to exogenous IL-2 re-acquired the ability to further 
proliferate upon antigenic rechallenge. Interestingly, while Rapamycin, an inhibitor 
of the Serine/Threonine kinase mTor (mammalian target o f Rapamycin), only 
partially blocked IL-2-mediated proliferation, it completely abolished the ability of 
IL-2 to restore antigen responsiveness. This indicated that clonal anergy could be 
maintained in spite of both G l-S transition and cell proliferation, and thus that 
antigen responsiveness and cell cycle progression are independently regulated, and 
revealed a critical role for mTor. Indeed, mTor proved not only to be involved in the 
cell growth response, but also to be critically needed for proper regulation of 
antigen responsiveness.
While both CD3/CD28 and IL-2/IL-2R activate mTor-dependent events 
(namely, phosphorylation of the p70^^^) in normal T cells, only IL-2 was capable of 
the Rapamycin-sensitive anergy reversal. Most likely the failure of CD3/CD28 to 
restore antigen responsiveness could be attributed to the inability of this stimulation 
to properly activate mTor-dependent pathways in anergic cells. Indeed, while 
CD3/CD28 and IL-2-driven T cell stimulation of control cells elicited Rapamycin- 
sensitive p70^^^ phosphorylation in several residues, only IL-2, but not CD3/CD28 
stimulation, induced optimal activation of this mTor substrate in anergic cells.
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These findings indicated that antigen responsiveness is uniquely regulated by an IL- 
2/IL-2R-induced signalling event, which is delivered independently of IL-2-driven 
cell proliferation, and relies on intact mTor signalling.
To further investigate the role of mTor, we exploited a model o f in vitro 
antigen driven T cell differentiation, and analyzed the effect o f mTor blockade by 
Rapamycin. In our model, antigen driven CD4^ T cell activation resulted in both T 
cell proliferation and differentiation of type 1 (IFN-y-producing), or type 2 (IL-4- 
producing) effector Th cells. The addition of Rapamycin at the time o f T cell 
activation allowed comparable T cell expansion, but completely prevented 
polarization of effector cells. Indeed, T cells activated in the presence of Rapamycin 
produced IL-2 and proliferated as effector cells upon re-stimulation, but failed to 
produce either IFN-y or IL-4. Moreover, Rapamycin completely impaired 
differentiation of antigen-specific CD8^ T cells towards IFN-y-producing cytotoxic 
T cells, without preventing their expansion.
Together our results indicate that the intracellular events that dictate T cell 
proliferation are distinct from the intracellular signals that modulate the functional 
phenotype of activated T lymphocytes and suggest that, while mTor-dependent 
signalling is dispensable for T cell proliferation, it is primarily involved in the 




The intracellular events that regulate lymphocyte proliferation upon antigen 
encounter and the ability of the cells to respond to subsequent stimulation and to 
differentiate into effector cells remain largely to be understood. Several studies have 
linked T cell proliferation with the maintenance of antigen responsiveness and with 
the ability of the cells to differentiate and to acquire proper effector functions.
The aim of my Ph.D. research project was to investigate the role o f the TCR, 
CD28, and IL-2 generated intracellular events dictating CD4^ T lymphocyte 
proliferation and differentiation.
In a model of CD3-induced clonal anergy, we have shown that antigen 
responsiveness was uniquely regulated by an IL-2/IL-2R-induced signalling event, 
which was delivered independently of IL-2-driven cell proliferation, and which was 
Rapamycin-sensitive. This indicates that proliferation and antigen responsiveness 
are independently regulated and that the latter specifically requires intact signalling 
through mTor, the mammalian target of Rapamycin.
Moreover, we have shown that proper activation o f p70^^\ one the known 
target of mTor, might play a crucial role in the maintenance o f T lymphocyte 
responsiveness.
We have also investigated the role o f mTor in a model o f in vitro antigen 
driven naïve T cell differentiation. In this model, blocking mTor activity by the 
addition of Rapamycin during T cell activation, allowed comparable T cell 
expansion, but completely prevented polarization of effector cells.
Together our results indicate that the intracellular events that dictate T cell 
proliferation are distinct from the intracellular signals that modulate the functional
V
phenotype of activated T lymphocytes and suggest that, while mTor-dependent 
signalling is dispensable for T cell proliferation, it is primarily involved in the 
acquisition of proper T cell effector functions.
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1. Introduction
1.1 The development of an immune response: general features
The immune system is a multiparameter and multicellular complex system 
whose physiologic function is to protect the organism against foreign (non-self) 
aggressions, such as bacteria, viruses, parasites, while not reacting harmfully to 
individual’s own (self) structures. The balancing between effective immunity and 
tolerance is a crucial feature o f the immune system, and a number o f regulatory 
mechanisms are in place to maintain this equilibrium.
Upon encounter with an infectious agent or a foreign body, several coordinated 
events occur with the final aim of eliminating the pathogen. Schematically, one can 
distinguish between the early reaction of the so-called innate immunity, which 
represents the first line of defense of the organism, and the later response of the 
adaptive immunity. These two types of responses are very different in term of 
cellular components, anatomical organization, specificity and tim ing o f 
development, but are strictly coordinated, regulating each other at different levels. 
Indeed, the innate immune response to pathogens stimulates the adaptive immune 
response and influences its nature, while, in turn, the adaptive immune response 
uses many o f the effector mechanisms o f the innate immunity to eliminate 
pathogens, and often amplifies its response.
The principal components of innate immunity are: 1) the physical and chemical
barriers, such as epithelia and antimicrobial substances produced at the epithelial
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surfaces, 2) phagocytic cells (neutrophils, macrophages), and natural killer (NK) 
cells, 3) blood proteins, including members of the complement system, and other 
mediators o f inflammation, such as cytokines and chemokines that mediate and 
coordinate many cellular functions.
The innate immune response is rapid, does not distinguish fine differences between 
foreign substances, and reacts in essentially the same way to most infectious agents 
and to repeated infections.
In contrast, the adaptive immune response represents a more evolved defense 
mechanism characterized by high specificity and the ability to develop a memory of 
the antigenic encounter, which ensures that the system can perform a more rapid 
and effective response at subsequent challenges with the same antigen. The major 
players o f the adaptive immune response are T and B lymphocytes, regulating cell- 
mediated and humoral immunity, respectively. These cells express unique surface 
receptors able to recognize a given antigen (Ag) (the T cell receptor, TCR, for T 
cells, and the B cell receptor, BCR, for B cells), which confer the cells a single 
specificity.
Lymphocytes originate in the bone marrow from hematopoietic stem cells 
precursors. During maturation, a tightly regulated program o f sequential gene 
expression leads to changes in the phenotype of the developing cells, to the 
generation of a diverse repertoire, to the acquisition of functional competence, and 
to selection events, which ensure that most of the lymphocytes that enter peripheral 
tissues are useful, in that they respond to foreign antigens, but not to many self 
antigens. The lymphocyte repertoire is extremely diverse, indeed it is estimated that 
it can discriminate 10  ^ to 10^  ^ distinct antigenic determinants. The frequency of
lymphocytes specific for any given antigen is extremely low (= 1/100,000), and for 
this reason the immune system has evolved to allow rapid clonal expansion of 
antigen-specific effector cells (see below). Once matured, lymphocytes leave the 
primary lymphoid organs and recirculate between blood and lymph with 
intermediate stops in secondary lymphoid tissues, such as the lymph nodes and the 
spleen, where the initial encounter with the specific foreign antigen occurs and 
where the adaptive immune response initially develops.
At the time of infection, the breaking of natural physical barrier, such as skin 
and mucosal surfaces, by pathogen entry represents the first danger signal for the 
immune system. Indeed, this event elicits the activation of cells o f the innate 
immune response, such as neutrophils and macrophages, and o f dendritic cells 
(DCs). This event leads to secretion of soluble factors, such as pro-inflammatory 
mediators (interleukin (IL)-l, and tumor necrosis factor (TNF)-a), cytokines and 
chemokines that mediate the recruitment o f circulating cells toward the site o f 
inflammation. Among the cells recruited are natural killer (NK) cells, which are 
able to lyse infected cells. At the site o f infection, antigens are captured and 
internalized by resident antigen presenting cells (APCs), such as macrophages, 
dendritic cells, and B lymphocytes. Among these, DCs are the most effective, and 
commonly referred to as professional APCs. Upon Ag internalization, DCs are 
activated, mature and migrate through the lymph and the blood towards secondary 
lymphoid organs, where they get in contact with T lymphocytes. Antigen and Ag- 
bearing APCs draining to the secondary lymphoid tissues increase the possibility 
that any given antigen is recognized by the small numbers o f specific T and B 
lymphocytes, and thus that an adaptive immune response is initiated. Internalized
Ags are degraded by different enzymatic or chemical processes, that lead to the 
generation of peptides able to be displayed on the surface of APCs in association 
with class I or class II major histocompatibility complex (MHC) molecules. 
Antigenic peptides presented in the contest of MHC molecules are recognized by T 
lymphocytes expressing an appropriate T cell receptor (TCR), and either the CDS 
coreceptor (CD8^ T lymphocytes) in case of Ag/MHC class I molecule, or the CD4 
coreceptor (CD4^ T lymphocytes, or helper T lymphocytes) in case of Ag/MHC 
class II complexes.
Ag recognition by T cells expressing the appropriate TCR, elicits T cell 
activation and proliferation. The selective clonal expansion of the small number of 
T cells that share specificity, but express unique TCRs, is a critical feature in the 
development o f the adaptive immune response. During Ag-driven T cell 
proliferation in the peripheral lymphoid tissues, T cells also differentiate and 
acquire effector function capabilities. CD4^ T cells acquire the ability to secrete a 
number of soluble factors and up-regulate surface molecules critical for their helper 
function. CD8^ T cells also acquire the ability to produce and secrete several 
soluble factors, such as interferon (IFN)-y and TNF- a, or perforin and granzyme B 
through which they exert their cytolytic function.
Ag recognition by B cells, via their specific Immunoglobulin B Cell 
Receptor, and the interaction of the B cells with Ag-specific CD4^ T cells cause the 
B cells to proliferate and differentiate into memory B cells and plasmacells. At the 
stage of plasmacells, B cells secrete immunoglobulins that disseminate into the 
biological fluids (blood and lymph) o f the organisms allowing pathogen 
neutralization at long distances.
Following proliferation and differentiation, T and B lymphocytes acquire the 
ability to migrate out from the lymphoid organs and to reach the peripheral tissues 
where they then recruit and interact with components o f the innate response, thus 
allowing the complete development of protective immune responses.
1.2 The central role of CD4^ T lymphocytes
CD4^ T lymphocytes are crucial for the development o f both adaptive and innate 
immunity. Indeed, by direct cell-cell interaction and by secreting soluble factors, 
they can amplify and modulate the activity of distinct cell types of the immune 
system. For instance, during the development o f adaptive immune responses, CD4^ 
T cells can mediate AFC activation (APC licensing), which results in the 
upregulation of costimulatory ligands and in the production o f inflammatory 
cytokines (1, 2). This facilitates the activation of CD8  ^ T cells that get in contact 
with the activated APCs. Furthermore, CD4^ T cells, by direct interaction with 
CD8  ^ T cells, can favor their proliferation and differentiation, participating to 
cytotoxic and inflammatory reactions (3). Moreover, interaction o f CD4^ T cells 
with B lymphocytes is necessary for immunoglobulin secretion by B cells, and for 
the generation o f an effective humoral immune response (4). Finally, through 
ligand/receptor interaction and through secretion of chemokines and effector 
cytokines, CD4^ T lymphocytes are also able to interact with and regulate the 
activity of the cells of the innate immunity, among which macrophages, NK cells, 
eosinophils, and mast cells (5).
Given such a crucial role played by CD4^ T lymphocytes in coordinating the 
immune response, understanding the molecular mechanisms that regulate their 
activation and differentiation is critical to clarify how adaptive immunity develops, 
and to design new immunotherapeutic approaches for clinical conditions, such as 
organ transplantation, autoimmunity, cancer.
1.3 CD4^ T cell activation
1.3.1 The “two-signal” model
CD4^ T cell activation is a dynamic process, involving the interaction of 
several surface proteins, expressed by T cells, with their specific ligands expressed 
on the surface of APCs. These interactions initiate integrated intracellular signalling 
cascades, collectively defined as the commitment phase, which eventually induce 
the expression of an orderly sequence of genes whose products are necessary for 
cell-cell interaction, proliferation, immune functions, cell death and memory.
The critical requirement for CD4^ T cell activation is the engagement o f the 
TCR by the specific antigenic peptide bound to MHC class II molecules expressed 
on the surface of professional APCs (6). Studies initiated by Schwartz and co­
workers provided, however, the initial evidence that TCR engagement alone (signal 
1) was not sufficient to induce proper T cell activation, and that the simultaneous 
engagement o f another cell surface receptor, defined as costimulatory receptor 
(signal 2), was required for proper T cell activation. These studies originated the 
“two-signal” model o f T cell activation (7).
The two-signal concept of lymphocyte activation was originally proposed to 
explain discrimination between self and non-self, and has proven to explain in 
several instances either T cell activation, or T cell tolerance.
1.3.2 T cell costimulation: the central role of CD28
Over the past decade, a number o f T cell costimulatory proteins and their 
ligands on the surface of APCs have been identified. These costimulatory receptors 
can be divided in two groups on the basis of ligand specificity and structural 
similarities. The first group includes members of the immunoglobulin superfamily 
such as CD28, the T cell inducible costimulator (ICOS), and PD-1 (8, 9). The 
counter-receptors for these costimulatory molecules are members o f the B7 protein 
superfamily, which are expressed on the surface of APCs: B7.1 (CD80) and B7-2 
(CD86) are ligands for CD28, B7-H2 is the ligand for ICOS, and B7-H1 for PD-I 
(8, 9) (Fig. I). While CD28 is constitutively expressed by naïve T cells, ICOS is 
rapidly induced upon T cell activation. Thus, while CD28 might be critically needed 
for naïve T cells, ICOS might provide co-stimulatory signals to activated T cells 
(9). Similarly to ICOS, also PD-1 is not expressed by naïve T cells, but it is up- 
regulated following T cell activation (9).
The second group of costimulatory molecules includes members of the TNF 
receptor family: CD40L, 4 -IBB, OX-40, CD30, CD27 and HVEM (herpes-virus 
entry mediator) (10). Their ligands CD40, 4-lBBL, OX-40L, CD30L, CD27L, and 
LIGHT are found to be constitutively expressed, or up-regulated following 








^  H —YV-
TCR
patt #7 HI) rv—
PO-L2S7-OQ
87-H3
^demain ^Vdomam  ^ Y Tyrosme | McfiKs;. MVPff’Y ard FC3PfW |
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Figure IL T cell costlmulatloii. Schematic representation of the members 
of the TNF receptor family of costimulatory r^:eptors expressed on the 
surface of the T cells, and their ligands expressed on the surlace of the 
APCs.
Adapted from Croft, 2003 (10).
low levels in naïve T cell, CD40L, OX-40, 4-lBB, and CD30 are up-regulated 
following both TCR and CD28 engagement (10).
In addition to these factors, several molecules, known to regulate cell 
adhesion, have been proposed to have costimulatory activity. For instance, LFA-1 
(CD 11 a/CD 18) and LFA-2 (CD2) integrins, which respectively bind to ICAM-1 
(CD54) and to LFA-3 (CD58), are expressed on the surface of both hematopoietic 
and non hematopoietic cells, and rapidly and transiently promote cell adhesion upon 
TCR engagement (11-15).
Among the above mentioned costimulatory molecules, the best characterized 
is CD28, a disulphide-linked homodimeric glycoprotein, constitutively expressed on 
the surface of naïve T cells, and able to bind, as previously mentioned, to B 7-1 and 
B7-2 membrane proteins on the surface of APCs.
The engagement of CD28 does not elicit a physiological response in the absence of 
TCR signalling, but it is critically needed to enhance and sustain TCR-initiated T 
cell responses. For instance, it has been shown that CD28 can synergize with the 
TCR to mediate the upregulation of several growth factor receptors, including IL-2 
receptor (IL-2R) a ,  P, and y chains (16, 17), to increase the transcription and the 
stability of cytokine mRNAs, in particular those encoding for IL-2 and IL-4 (18- 
20), and to enhance T cell proliferation (8, 21, 22). Moreover, CD28 signalling is 
capable o f preventing apoptosis in activated T cells. Indeed, it has been reported 
that CD28 costimulation upregulates the expression of anti-apoptotic gene products, 
such as B c1-Xl , able of protecting lymphocytes from F as-induced cell death (23). 
TCR/CD28 stimulation also induces the expression o f CTLA-4 (Cytotoxic T 
lymphocyte-associated antigen-4), a molecule highly homologous to CD28, which
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binds to B7-1 and B7-2 with much higher affinity than CD28, and which inhibits 
fiirther T cell activation (24). This suggests that CD28 might not only positively 
regulate T cell activation, by promoting T cell expansion and survival, but might 
also play a critical role for the termination of the T cell response.
The crucial role of CD28-mediated costimulation in T cell priming in vivo is 
demonstrated by the observation that CD4^ T cell responses are greatly impaired in 
CD28’^ ’ mice (25, 26), or when B7-CD28 interactions are prevented by the use of 
monoclonal antibodies, or of a CTLA-4-Ig fusion protein (8, 27, 28). For instance, 
blocking B7 in vivo prevented autoimmunity and graft rejection (27, 29-31), while 
triggering of CD28 greatly enhanced anti-tumor immune responses (32-34).
In addition to the in vivo generated evidences, a number of other studies have 
underlined a critical role for CD28-induced signals. Indeed, the engagement o f the 
TCR in vitro, in the absence of CD28 costimulation, rather than T cell activation, 
induces a long-lasting state o f T cell unresponsiveness (clonal anergy) (7, 35, 36) 
(see section 1.6). Moreover, it was shown that, while T cells required a very high 
TCR occupancy and a prolonged stimulation in the absence of CD28 engagement, 
they responded more rapidly to lower levels of TCR occupancy when costimulated 
through CD28 (37, 38). These studies indicated that CD28 costimulation could be 
critically needed when the level of antigenic stimulation is limiting, such at low 
antigen doses, or in the presence of low affinity TCR ligands. Consistent with this 
possibility is the finding that only repeated injections with high doses o f antigen 
elicited a T cell response in CD28-deficient mice (25, 26, 39). Altogether the 
existing data support the possibility that CD28 costimulation might lower the
threshold needed for T cell activation, thus providing a quantitative contribution to 
increase the intensity and/or duration of TCR-mediated signals.
Lanzavecchia and coworkers first analyzed the contribution of CD28 to the 
kinesis and stoichiometry of the TCR-peptide-MHC interaction, and to the lowering 
o f T cell activation threshold. By measuring intracellular calcium elevations to 
monitor sustained TCR signal (see section 1.4.1), and TCR downregulation as 
reliable readout o f the number of TCRs triggered, these authors discovered a 
dynamic type of interaction between the T cell and the APC. Indeed, at the level of 
T/APC contact site, they showed that a large number o f TCRs could be serially 
engaged, triggered and downregulated by a few specific peptide-MHC complexes 
(40). This process o f serial TCR triggering resulted in the generation and 
maintenance of a sustained level of second messengers that was required to initiate 
and maintain transcription at specific loci. Sustained signal for optimal T cell 
activation required continuous engagement of TCRs by peptide/MHC complexes on 
APC, demonstrating that the signal emanating from triggered TCRs was short lived 
(41, 42). These authors calculated that, irrespective of the nature o f the triggered 
ligand, T cells count the number of triggered TCRs, and respond when a threshold 
o f approximately 8000 TCRs is reached (37). Costimulation by CD28 lowered the 
activation threshold to approximately 1500 TCRs, thus making T cells more 
sensitive to antigen stimulation (37). In addition, in these studies, CD28 
costimulation also decreased the time required to have full T cell commitment (43).
From all these experiments it is believed that CD28 costimulation, by 
sustaining the signal inside the T cell and by increasing response longevity, allows a
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lower number of triggered TCR and a shorter duration of T cell/APC contact to be 
effective for full T cell activation.
1.4 CD4^ T cell commitment
The simultaneous engagement of the TCR and o f CD28 initiates a complex 
network of intracellular signals, which render the cell competent to proliferate and 
eventually to differentiate. This initial phase of T cell activation has been defined as 
“the commitment phase”.
A number of studies, mostly performed in vitro on transformed T cells and long­
term T cell clones, and identified by the use of agonistic anti-receptor antibodies 
(Abs), have generated important information of the intracellular signalling pathways 
activated upon TCR and CD28 stimulations. Much of this information has now 
been validated in vivo by analyses performed on primary T cells, and on genetically 
modified mice.
1.4.1 TCR-induced signalling
The engagement of the TCR elicits an intracellular signal transduction 
cascade, which can be schematically divided in an early phase, that involved 
sequential tyrosine phosphorylation events, and a later phase o f a complex network 
o f downstream events, such as the activation o f small GTPases and o f 
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Figure III. TCR-induced signalling. Schematic representation of the 
main intracellular signalling { ^ w ay s activated upon TCR/CD3 
crosslinking.
Adapted from Pitcher et ah, 2003 (47).
The early tyrosine kinases cascade
The T cell antigen receptor complex comprises the polymorphic TCR a  and 
P subunits, that recognize peptide/MHC complexes, and the tightly associated y, Ô, 
8 , and Ç signal transduction subunits, which form the CD3-Ç complex.
The capacity of the TCR to transduce signals across the T cell membrane 
relies on the cytoplasmic tails o f the CD3-Ç subunits that contain common motifs, 
called immunoreeeptor tyrosine-based activation motifs (ITAMs) that are 
phosphorylated upon TCR triggering (45-47). Even though phosphorylated ITAMs 
pre-exist in resting T cells, ITAMs phosphorylation is the earliest known event in T 
cell signalling, and is regulated by a pool o f active Src protein tyrosine kinases 
(PTKs) (mostly Lck), and by protein tyrosine phosphatases (PTPs), such as CD45 
(45, 46). It has been suggested that the binding of TCR with peptide-MHC complex 
favours ITAM phosphorylation not only by recruiting the kinases to the receptor, 
but also by mediating the exclusion, on a size-base, of phosphatase molecules away 
from the TCR-ligand complex (48).
ITAMs phosphorylation initiates the early PTK signalling cascade. Indeed 
phosphorylated ITAMs recruits ZAP-70, a Syk family PTK, which binds to the 
ITAMs via its tandem Sre-homology 2 (SH2) domains (49). ITAM-bound ZAP-70 
is then tyrosine phosphorylated and bound by the SH2 domains of Lck (50). It has 
been shown that the physical interaction between Lek and ZAP-70 and the Lck- 
mediated phosphorylation of ZAP-70 greatly increases ZAP-70 catalytic activity 
(51, 52). The Lck/ZAP-70 complex is critical for TCR-induced activation (53). 
Indeed it amplifies TCR-induced signalling by promoting continued ITAMs
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phosphorylation with subsequent additional reeruitment of ZAP-70 and other Lck 
substrates such as the Tee PTK Itk (54).
Stable ITAM phosphorylation is only led to completion when the Ag/MHC-TCR 
interaction has a sufficient half-life. This is achieved by strong TCR-ligand 
interactions or by the help of CD4 eoreceptor (55). It has been shown that Lek binds 
a cysteine m otif present in the tail of the CD4 eoreceptor (56), and by that it 
stabilizes the association of Lck with ZAP-70, with consequent amplification of 
phosphorylation reactions that create a positive feedback loop between the TCR and 
the intracellular signalling pathways (44).
Downstream signalling pathways: Ras/Rho, PLCyl, and PI3K
Upon the early tyrosine kinase reactions, a cascade of downstream signalling 
events is induced. This is initiated by phosphorylation of adapter molecules, such as 
LAT (linker of activated T cells) and SLP-76 (SH-2 domain containing lymphocyte 
protein o f 76 kDa) (57, 58), mediated by ITAM-bound ZAP-70. Tyrosine 
phosphorylation of these adaptors represents the link between antigen receptors and 
downstream signalling pathways. Indeed, upon phosphorylation in tyrosine 
residues, adaptors act as scaffolding proteins, which recruit to the plasma membrane 
important signalling molecules, and assemble them with their regulatory partners. 
This leads to the activation of different pathways that disseminate TCR signals from 
the plasma membrane to the cytosol and the nucleus (44).
The key pathways assembled and activated by phosphorylated LAT and SLP76 are 
the Ras-and Rho-, and the inositol lipid-dependent networks. The induction of the 
latter requires activation of two key enzymes, the phospholipase C gammal
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(PLCyl) and the phosphatidyl inositide-3 kinase (PI3K), which in turn regulate the 
intracellular calcium concentration, and the activity o f several serine-threonine 
kinases
Ras plays a crucial role in T cell activation, regulating both cytokine gene 
transcription and cellular proliferation (59). Ras is a guanine nucleotide binding 
protein with GTPase activity, which cycles between an active GTP-bound and an 
inactive GDP-bound form (60). The guanine nucleotide binding cycle o f Ras is 
controlled by guanine nucleotide exchange proteins (GLFs), that promote transition 
from GDP-bound to GTP-bound form, and thus activate Ras, and by GTPase 
activating proteins (GAPs), that stimulate the intrinsic GTPase activity of Ras, and 
lead to Ras inhibition. GTP-bound form o f Ras accumulates in T cells upon 
activation (44). One important GLF for Ras is Sos, the mammalian homologue of 
the Drosophila “Son of Sevenless” protein. Sos forms a complex with the adaptor 
Grb2, which is able to bind, through its SH2 domain, to phosphorylated tyrosines in 
the LAT tail, thus recruiting Sos to the plasma membrane. This leads to the 
recruitment and the activation of Ras at this site (60). Activated GTP-bound Ras in 
turn regulates the mitogen-activated protein kinase (MAP kinase) pathway, a kinase 
cascade that transmits signals from the membrane to the nucleus, activating several 
transcription factors involved in cytokine gene induction (60, 61). The first kinase 
recruited to the plasma membrane and activated by GTP-bound Ras is the 
serine/threonine kinase Raf-1, a MAP kinase kinase kinase (MKKK). Activated 
Raf-1 in turn phosphorylates and activates MAP kinase kinases (MLK 1, 2), which 
then directly activate the two MAP kinases, Lrkl and Lrk2 (extracellular signal- 
regulated kinase 1 and 2) (62). One o f the known functions o f Lrks is the
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phosphorylation of the transcription factor Elk-1, which in turn regulates the 
transcription of the Fos gene (63). Fos transcription factors are members of the AP- 
1 (Activator Protein-1) complex and are required for IL-2 gene expression (see 
section 1.4.3).
TCR-mediated PLCyl activation initiates a cascade of lipid metabolism, 
generating several phosphatidylinositols endowed with signalling capabilities. 
Indeed, PLCyl allows the hydrolysis of phosphatidylinositol (4,5) biphosphate 
(P1 (4 ,5 )P2 ), and controls the production of inositol 1,4,5-triphosphate (1P3) and 
diacylglycerol (DAG). PLCyl activation by the TCR requires the PTKs activated 
during the early phases of T cell activation (Lck, ZAP-70 and Tec kinases, such as 
Rlk, and Itk), and the LAT and SLP76 adaptors (64-67). It has been proposed that 
LAT, which binds to SLP76, acts as a scaffold for the assembly of the PLCyl 
signalling complex with SLP76, thus allowing activation o f the phospholipase by a 
Tee family kinase that is associated with SLP76 (44, 57)].
The products of PLCyl activity, 1P3 and DAG, play key roles in T cell 
activation because they mediate an increase in the intracellular calcium 
concentration and activate serine/threonine kinases of the PKC family, respectively. 
The rapid and sustained 1P3-dependent elevation o f intracellular calcium 
concentration, that occurs within few seconds upon TCR triggering, is absolutely 
critical during the initial phases o f T cell activation (46, 6 8 ). Indeed, calcium 
regulates PKCs activity, the activity of the phosphatase calcineurin, required for 
proper activation of the Nuclear Factor of Activated T cells (NFAT) transcription 
factor (see section 1.4.3), and the stabilization of the T cell/APC contact zone 
required for the formation of the immunological synapse, which then allows proper
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signalling (69, 70). The production of DAG is critical for the activation of the 
different PKC isoforms expressed by T cells and activated upon TCR engagement. 
The PKC isoforms can be divided into two groups, one composed by the classical 
PKCs (a , pi, p ll and y), which are regulated by calcium, DAG and phospholipids, 
and novel PKCs (5, 8 , T| and 0), which are Ca^^-independent and are regulated by 
DAG and phospholipids (71). Even though different members of the PKC protein 
family can activate different target molecules and hence regulate distinct biological 
functions, the contribution of the different isoforms to TCR-mediated activation 
events is only partially known. In T cells the relevant PKC appears to be PKC0 (72, 
73). This protein is the only known member of the PKC family to localize in the T- 
cell supramolecular activation complex (SMAC), a region o f membrane and 
cytoplasmic polarization formed at the contact site between a T cell and an APC 
during recognition of cognate antigen (73). Correct localization o f PKC0 is 
critically needed for T cell activation (74). PKC0 cooperates with Ca^ "^  and MAPK- 
dependent signals for the activation of NFAT, AP-1 and NF-kB transcription 
factors, required fox IL-2 gene induction (see section 1.4.3). PKC0 activation is Ca^^ 
independent, and is regulated by binding to DAG. In addition, a tyrosine kinase- 
stimulated Vav/Rac pathway (see below) also mediates selective membrane 
transloeation and activation of PKC0(75). In addition to mediate PKC activation, 
PLCyl-generated DAG links the lipid metabolism to the Ras pathway. Indeed, 
DAG can bind to RasGRP, a GEF for Ras, and localize it at the plasma membrane, 
where it can activate Ras (76).
In addition to PLCyl, TCR-dependent signalling activates the PI3K and thus 
stimulates the inositol lipid turnover. PI3K phosphorylates PI(4,5)P2 on the D-3
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position of the inositol ring to produce PI(3,4,5)P3 (77). Through binding to 
different target molecules, PIP3 regulate many cellular events, such as cell growth 
and survival, and cytoskeletal remodelling (PI3K-dependent signalling will be also 
discussed in section 1.5.2).
There are multiple isoforms of PI3K, but the form biochemically linked to T cell 
activation comprises a regulatory 85-kDa (p85) subunit and a catalytic 110-kDa 
(pi 10) subunit (78). While the stimulatory effect of the TCR alone on PI3K activity 
is small, the combined triggering of the TCR and CD28 optimally activates the 
enzyme (79). It is believed that the p85 regulatory subunit, via its SH2 domains, 
binds to tyrosine phosphorylated LAT (80), and brings the enzyme to the plasma 
membrane. PI3K-generated PI(3,4,5)P3, in turn, serve as plasma membrane- 
associated docking sites for pleekstrin homology (PH) domain-containing proteins, 
and favour their reloealization to the plasma membrane where they can be activated 
(81). Among the PH domain containing proteins recruited following PI3K 
activation, are members o f the Tec tyrosine kinases (82), two serine/threonine 
kinases, the phosphoinositide-dependent protein kinase (PDK) 1, and protein kinase 
B (PKB), also known as Akt (83, 84), and the GEFs for Rac, Rho and Cdc42 (85).
PDKl regulates the activity of many serine/threonine kinases, including 
members o f the PKC family, the p70 ribosomal protein S6  kinase, p70^^\ and PKB 
(84, 8 6 ), which play very important roles in T cell activation. p70^^\ for example, 
catalyzes the phosphorylation of the 40S ribosomal subunit protein S6 , and 
regulates protein synthesis and cell growth (87, 8 8 ).
PKB, also known as Akt, controls cell cycle progression by activating E2F 
transcription factors, and promotes cell survival (89-92). It exerts its functions by
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shuttling between the plasma membrane, where it gets activated, the cytosol and the 
nucleus, where it gets in contact with its substrates. In addition to its role in cell 
proliferation and survival, PKB plays also a role in the glycogen metabolism. 
Indeed it phosphorylates and inactivates glycogen synthase kinase-3 (GSK3) (93). 
Furthermore, PICB activity has also been shown to regulate, through GSK3, the 
nuclear export of NFAT transcription factor (94).
The best characterized GEF for the Rho family of GTPases in lymphocytes is 
Vav-1, that binds via its PH domain to PIP3, and is recruited to the plasma 
membrane where it is activated by TCR induced tyrosine kinases, such as Lek (95). 
Rho GTPases regulate several T cell functions by interacting with multiple 
effectors. One of the key events regulated by this class o f GTPases upon TCR 
engagement is the dynamic reorganization of aetin eytoskeleton (44). This is a 
crucial event that occurs during the formation of T cell/APC conjugate, required for 
the formation of a stable contact, which is needed for sustained T cell signalling and 
proper T cell activation.
1.4.2 CD28-induced signalling
A number o f intracellular signalling pathways activated upon CD28 cross- 
linking, and in some instances distinct from signals generated by TCR/CD3 
engagement, have been defined (96). These pathways integrate and enhance TCR 
signals both during the early phases o f tyrosine phosphorylations and also 
downstream, at the level of gene expression (Fig. IV). For instance CD28-mediated 
costimulation increases the phosphorylation of the Ç chain of the TCR and of ZAP-
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Figure W. CD28-induc€d signallrag. Schenmtic représentation of the 
main intracellular signalling pathways activated upon crosslinking of the 
costimulator>  ^receptor CD28.
Adapted from Frauwirth et af , 2002 (96).
70, and by that it possibly lowers the TCR activation threshold (97). Moreover, 
CD28 signalling promotes T cell activation by facilitating the recruitment of 
intracellular lipid rafts that contain kinases and adapter molecules to the site of TCR 
engagement (98, 99).
Even though CD28 contains a 41 amino-acid-rcsiduc cytoplasmic domain, 
which lacks an obvious catalytic capacity, upon ligation by specific Abs or by its 
natural ligands, it becomes phosphorylated on tyrosines by Src family kinases such 
as Lck and Fyn, and by Tcc family kinases such as Itk, which can be found 
associated with the receptor at a very low stoichiometry (100, 101). Lck and Fyn 
mediate phosphorylation of a specific tyrosine that is found within a single YMNM 
m otif in the cytoplasmic domain of CD28 (102). Phosphorylation of the YMNM 
motif permits recruitment o f the signalling proteins PI3K and Grb2, which bind to 
the receptor via their SH2 domains (103). PI3K plays a central role in CD28- 
induccd intracellular signalling (104, 105). Its binding to the cytoplasmic tail of 
CD28 anchors the enzyme to the inner face of the plasma membrane, and by that it 
facilitates its interaction with its specific substrates. Ovcrcxprcssion o f the PI3K 
target PKB/Akt in T cell lines mimics CD28 costimulatory signal and increases 
transcription of the IL-2 gene (106). Moreover, CD28-dcpcndcnt signalling directly 
elicits phosphorylation of p70^ *^^  and 4EBP-I, through Rapamycin-dcpcndcnt 
pathways (107, 108). This has been correlated with the role o f CD28 costimulation 
in increasing IL-2 mRNA stability and IL-2 production (108). It remains to be 
determined whether these signalling pathways induced by CD28 arc downstream to 
PI3K activation.
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The recruitment o f Grb2 to the phosphorylated YMNM m otif o f CD28, 
allows the recruitment o f Sos, of p85, and of Vav, thus connecting CD28 to a 
number of downstream signalling events (102, 103).
Upon binding to CD28, Vav-1 is rapidly phosphorylated in tyrosine residues. This 
can occur in the absence o f simultaneous ligation of the TCR, and leads to the 
activation of Rho family members, such as Rac-1 (102). CD28-dcpcndcnt Rac-1 
activation might also be mediated by the CD28-dcpcndcnt phosphorylation and 
inhibition of the Rac-inhibitor p62^ °*^  (109). Vav-1/Rac-1 activation links CD28 to 
actin remodelling events and contributes to the tightening and stabilization of the T 
ccll/APC conjugate (44). In addition to eytoskeleton rearrangements, Rac-1- 
dcpcndcnt signalling also regulates activation of the stress-related Jun N-tcrminal 
kinase (JNK) signalling pathway (110). This provides the link between CD28 
costimulation and gene expression during T cell activation (102). Indeed, through 
activation of the MAP kinase kinases MKK4, and MKK7, JNK is activated, and in 
turn it phosphorylates the transcription factor c-Jun. This leads to an increase of AP- 
I transcriptional activity (111, 112), thus regulating IL-2 gene expression. As in the 
case of PI3K, also activation of the JNK kinases is optimal only upon simultaneous 
TCR and CD28 engagement, thus representing a point o f convergence for TCR and 
CD28 signalling pathways.
CD28-mcdiatcd costimulation might not only favor T cell activation, but also 
participates in the shut down of the T cell response. Indeed, CD28-mcdiatcd 
recruitment of, and phosphorylation by Itk, at a site which is distinct from the 
YMNM motif, negatively regulates the amplitude of the CD28-induccd proliferative
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responses, thus suggesting that Itk could provide a means to modulate the strength 
and potentially the outcome of T cell activation (113).
1.4.3 IL-2 gene transcription
The simultaneous deployment o f the signalling cascades described to be 
activated by TCR/CD3 and CD28-mcdiatcd stimulations results in the transcription 
o f genes encoding for cytokines and cytokine receptors, which promote 
proliferation and differentiation of mature T lymphocytes (114, 115). One of the 
first and most important cytokine-encoding gene regulated by the simultaneous 
activation of the TCR and of CD28, is the IL-2 gene. The expression of the IL-2 
gene cannot be induced by single intracellular signalling pathways, but requires that 
the critical transcription factors arc simultaneously induced and assembled at the 5’ 
promoter/enhancer region of the IL-2 gene, and that stable activation complexes arc 
formed. Among the required transcription factors arc AP-1, NFAT, NF-kB, and 
Oct-1 (116, 117).
The AP-1 complex is composed by members of the Fos (c-Fos, FosB, Fra-1, 
Fra-2), and Jun (c-Jun, JunB, JunD) families of bZip dimeric nuclear factors. These 
factors bind specific DNA sequences cither alone (as dimers at AP-1 site) or 
complcxcd with another nuclear factor, such as NFAT (at the NFAT site) or 
octamcr proteins (at OCT/GAP site), and enhance transcription (118). The activity 
of the AP-I complex is regulated by Ras-, JNK-, and PKCG-dcpcndcnt pathways 
both at the level o f gene transcription, and by post-translational modifications of its 
gene products (111, 119, 120). Ras, for instance, elicits Erk-dcpcndcnt
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phosphorylation of the ternary complex factor Elk-1, which in turn can bind and 
transactivate the c-Fos promoter, thus regulating c-Fos transcription (121, 122). 
Similarly, Ras-dependent signals also regulate the JunB promoter through Erk 
(123).
Similarly to Erk, also JNK participates to AP-1 activation. Indeed, CD28-dcpcndcnt 
JNK activation, mediates phosphorylation of c-Jun augmenting its transcriptional 
activity (124). Moreover, JNK increased activity also augments Elk-1 dependent 
transcription at the c-Fos gene (125). Interestingly, the JNK pathway has also been 
implicated in the enhancement o f IL-2 mRNA stability mediated by CD28 
costimulation (126).
Finally, PKC0, regulates AP-1 activation probably at the level o f c-Fos or c-Jun 
transcription ( 1 2 0 ).
NFAT proteins arc cytosolic in quiescent T cells, but they translocate into the 
nucleus in TCR-activatcd cells, where they bind to AP-I family members to form a 
functional transcriptional complex at the IL-2 enhancer region (127). Cooperation of 
NFAT with AP-1 is required for IL-2 gene transcription, as apparent from studies 
using a mutant NFAT protein unable to interact with Fos/Jun hctcrodimcrs (128). 
The IL-2 gene promoter contains at least four NFAT binding sites, o f which two arc 
composite NFAT/AP-1 binding elements (129). Each NFAT/A P-1 composite 
binding site is needed for IL-2 gene transcription. Binding sites for NFAT arc found 
in the enhancer o f a number of cytokine genes including IL-2, IL-4 and TN F-a 
(127), demonstrating a key role of those transcription factors in regulating several T 
cell responses.
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Nuclear transloeation o f NFAT factors is mediated by a calcium-dependent 
signalling pathway, induced by TCR/CD3-mediated PLCy activation, and involves 
the activation of the phosphatase calcineurin (130). Upon calcium-dcpcndcnt 
targeting of calcineurin to the regulatory domain of NFAT proteins, the phosphatase 
dcphosphorylatcs NFAT proteins mediating their nuclear transloeation (129). 
Because of the presence o f constitutivcly active intracellular kinases that rc- 
phosphorylatc and inactivate NFAT, calcineurin, and sustaindcd calcium signal arc 
continuously needed to maintain NFAT proteins in an active state. Both nuclear 
transloeation of NFAT and its activation of gene transcription arc reversed by 
treatment o f T cells with the calcineurin inhibitors Cyclosporin A (a cyclical 
undccapcptidc), and FK506 (a macrolidc antibiotic) (129). Once translocated into 
the nucleus, NFAT proteins bind to AP-1 family members and to the IL-2 enhancer 
region. Thus, NFAT-dependent transactivation is not only regulated by Ca^^ signals, 
but also by Ras activation (105, 131). NFAT transcriptional activity is also 
increased by PKC activation (132).
Thus, during optimal T cell stimulation through TCR/CD3 and CD28, the 
coordinate activation of calcium and MAP kinasc/PKC signalling pathways leads to 
the formation of the transcriptionally active NFAT/AP-1 complexes, which then 
bind to the IL-2 promoter and regulate IL-2 gene transcription.
NF-kB (nuclear factor-kB) transcription factors arc regulated by PKC 8  (133), 
and, like NFATs, they can associate with AP-1 complexes at specific composite 
binding sites within the 5’ regulatory regions of the IL-2 gene. In resting cells, NF- 
kB factors reside in the cytoplasm as dimeric proteins, associated with specific 
inhibitors, known as IkBs, that retain NF-kB in an inactive state in the cytoplasm
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(134). It has been proposed that, upon TCR eross-linking, PKC0 is activated and 
induces IKK (IkB kinase) complex-mediated serine phosphorylation of IkBs. 
Phosphorylation of IkBs targets the protein to the protcasome for degradation (133). 
Once released from IkB inhibitors, NF-kB transcription factors can enter into the 
nucleus and bind their specific target sequences, such as those within the IL-2 
promoter. Vav-dcpendent signals can syncrgize with PKC0 for NF-kB activation
(135). CD28 costimulation seems to be required for NF-kB activation, since it can 
mediate binding o f this transcription factor to the CD28 response elements 
(CD28RE) found in the IL-2 promoter (136).
Finally, in peripheral T lymphocytes and in several T cell lines, both the 
ubiquitous Octamcr family factor Oct-1, and the lymphocyte-specific factor Oct-2 
arc expressed and bind to the IL-2 promoter. Prominent octamcr binding sites of IL- 
2 promoter act as inducible enhancers in T cells, and their induction is inhibited by 
the immunosuppressant Cyclosporin A (CsA). The binding o f AP-1 and octamcr 
factors to the IL-2 promoter, and the tight association and functional cooperation of 
octamcr with AP-1 factors is of crucial importance for the inducible transcription of 
the IL-2 gene. Moreover, also NFAT and Oct factors, by binding simultaneously to 
the IL-2 promoter, and by tightly associating with AP-I factors, enhance the activity 
of the IL-2 promoter (137, 138).
1.5 CD4^ T cell proliferation
One ultimate effect of TCR/CD28 and IL-2 generated signals is to initiate cell 
proliferation, and influence the rate at which T lymphocytes divide. Stimulation o f
24
resting T lymphocytes by TCR/CD28 initiates cell cycle entry (139), and renders 
the cells competent for subsequent proliferation by inducing IL-2 production and 
the expression of the high affinity IL-2 receptor (IL-2R) (140). Binding of IL-2 with 
its newly expressed IL-2R mediates the coordinated activation o f several 
intracellular signalling events, and eventually induces cell division (141). Because 
of this, IL-2 can be considered as the third signal that, in addition to TCR and 
CD28, is required for T cell proliferation.
1.5.1 Cell cycle regulation
The sequence of events that occur during the cell cycle have been divided 
into four phases, designated G1 (gap 1), S (synthesis o f DNA), G2 (gap 2), and M 
(mitosis). Cell cycle regulation takes place mainly at the transition points, or 
boundaries, between the different phases, which serve as checkpoints. In mammals, 
most variation in cell cycle timing is due to variation in the length o f G l, and the 
Gl/S transition is tightly regulated. There are three main classes of proteins directly 
involved in checkpoint regulation: the eyelins, whose levels rise and fall in specific 
phases of the cell cycle; the cyclin dependent kinases (Cdks), a class o f serine- 
threonine kinases that are activated by the eyelins, and the Cdk inhibitors (CKIs), 
which inactivate Cdks. The sequential formation, activation and subsequent 
inactivation of a series of cyclin-Cdk complexes govern cell cycle entry and 
progression. The main eyclin-Cdk complexes are cyclin D-Cdk4 (and cyclin D- 
Cdk6 ), Cyclin E-Cdk2, cyclin A-Cdk2, and cyclin Bl-Cdc2 (now renamed Cdkl), 
acting in G l, at G l/S, in S, and at G2/M, respectively (Fig. V). Formation and
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Figure V. Cell cycle regulation. Schematic repr^ntation of cell 
cycle progression in mammalian cells. Cyclin-Cdk complexes (in red), 
and cell cycle inhibitors (in blue) regulating progression through the 
different phases of flie cell cycle are indicated
activation o f these complexes depend on cell cycle-regulated expression and 
assembling of eyelins with pre-existing Cdks (142-144). Cyclin-Cdk activity is both 
positively and negatively regulated by phosphorylation. Activation of cyclin-Cdk 
complexes requires phosphorylation of threonine residues of Cdks by constitutively 
expressed cyclin-activating kinases (CAKs). Cdks can also be negatively regulated 
by interaction with a group of proteins collectively termed Cdk inhibitors (CKIs). 
CKI levels, like cyclin levels, vary during the cell cycle and thus contribute to the 
periodicity of Cdk activation (145). Two classes of CKIs have been described: the 
INK proteins (pI5, p l 6 , p l 8 , and p i 9), which associate with Cdk4 and Cdk6 , and 
the Cip/Kip proteins (p2I and p27), which bind to eyelins D, E and A, and Cdks 
4/6/2 containing complexes (146, 147).
Progression through the G l phase of the cell cycle is also marked by the 
accumulation of specific transcription factors, including the proteins Fos, Jun and c- 
myc, which act on genes required for DNA replication (148, 149). A critical balance 
between cyclin/Cdk complexes and transcription factors is required for proper G l- 
to- S progression. If  this balance is not achieved, the cells stop dividing, and either 
enter the GO resting state, or die by apoptosis. In some instances, GO resting phase 
can also be induced by high levels of CDKIs.
A number of other factors can also inhibit progression through the G l/S  
boundary (150). One o f the most important is DNA damage. When the 
chromosomal DNA integrity is compromised, the CDKI p21^*^ is induced via 
pathways depending on tumour suppressor protein p53, and this blocks G l/S  
progression until the damage is repaired (151). Moreover, there are pathways that 
ensure that DNA replication is complete before mitosis begins (152), and others that
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ensure that the mitotic apparatus has been properly assembled before the cells 
attempts the completion of mitosis (153, 154).
Entry and progression into the cell cycle by resting cells mostly depend upon 
extracellular growth-controlling stimuli, such as mitogens. In most eukaryotic cells, 
these extracellular signals have their most profound effects on the transition from 
the G l to the S phase, an event also referred to as “restriction point” (139, 155). 
Beyond Gl/S restriction point, the cell cycle is largely insensitive to external factors 
(140).
Regulation o f G l/S transition
Addition of mitogens to GO/Gl quiescent cells induces the expression of the 
D-type eyelins (eyelins D l, D2, and D3) which assemble with their partners Cdk4 
and Cdk 6 . Mitogenic stimulation also mediates downregulation o f p27^^^^ a 
Cip/Kip protein that accumulates in quiescent cells, and that interacts with and 
inhibits the function of cyclin D/E-Cdk complexes (156-159). D-type cyclin 
complexes are activated in response to growth factors, and mediate phosphorylation 
of the anti-oncogene product Retinoblastoma (Rb). Rb, p i 07, and p i 30, the so- 
called pocket proteins, interact with various E2F family members and repress their 
transcriptional activity in GO/Gl quiescent cells (160). Hyperphosphorylation of 
pocket proteins, initially mediated by cyclin D-Cdk4/6, disrupts their association 
with E2F transcription factors, which are then able to induce the transcription of a 
series of genes whose activities are necessary for DNA synthesis, and for cell cycle 
regulation, such as cyclin E (161-164). As levels of cyclin D rise, it is thought that 
p 2 7 Kipi titrated away from cyclin E-Cdk2 complexes. This allows cyclin E-Cdk2
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to phosphorylate p27^^^\ leading to its ubiquitin-targeted degradation (165, 166). 
As molecules o f p27^^^^ are degraded, increasing numbers o f cyclin E-Cdk2 
complexes are released, and further phosphorylate Rb in late G l (167), thus creating 
a positive feedback autoregulatory loop.
Thus, the hyperphosphorylation of pocket proteins and the subsequent E2F 
activation represent a key step for transition through the G l/S restriction point.
1.5.2 G l/S transition in T cells
In T lymphocytes cell cycle entry is initiated by TCR-generated signals. TCR 
ligation induces the expression of cyclin D2 and D3 (T cells do not express cyclin 
DI), of Cdk4 and Cdk4 kinase activity (168). This occurs independently of IL-2 and 
mediates entry into early/mid G l phase of the cell eycle. TCR-induced signals are 
however insufficient to promote exit from the G I phase of the cell cycle. This is due 
to the fact that, while inducing expression o f G l cyclin-Cdk complexes, these 
signals fail to mediate their activation, because of the inability to inactivate the CKI 
p27^^P, which is found expressed at high levels in quiescent lymphocytes. Studies 
performed on T cell lines and on primary T cells have shown that IL-2-mediated 
signalling elicits the further upregulation of cyclin D2, D3, the expression of cyclin 
E and, importantly, the downregulation o f the CKI, p27^^^. This allows the 
activation o f cyclin D/E-Cdk complexes, the phosphorylation o f critical Cdk 
substrates and progression through the S phase of the cell cycle (140, 156, 168- 
170). Among the Cdk substrates associated with cell cycle progression are pRb and
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p i 30, whose hyperphosphorylation allows transcriptional activation of E2F factors, 
which regulate IL-2-driven S phase entry (89, 90).
Although IL-2 plays a critical role in controlling T lymphocytes proliferation, the 
intracellular signals responsible for IL-2-induced proliferation are still not fully 
understood. In addition, several evidenees for IL-2 independent T cell proliferation 
have recently been provided.
IL-2R-dependent G l/S transition
The IL-2 receptor is comprised of three distinct transmembrane subunits, 
a ,  p, and y chains (171). The high affinity IL-2R eontains all three chains, and, as 
mentioned above, it is up-regulated following TCR/CD28-mediated T cell 
activation (172). IL-2Ra chain contributes to IL-2 binding affinity but not to the 
recruitment of signalling molecules, and expression and heterodimerization of the P 
and Y chains (which represent the intermediate affinity IL-2R) is sufficient to 
mediate IL-2 signalling (141, 171) (Fig. VI).
IL-2 binding to the IL-2R induces the heterodimerization of the cytoplasmic 
domains o f the IL-2RP and Yc, and initiates an intracellular signal transduction 
cascade. Indeed, heterodimerization o f the IL-2R activates the preassociated 
tyrosine kinases, Janus kinase (Jak) 1 and 3, which phosphorylate key tyrosines on 
IL-2Rp. These sites serve as docking sites for downstream signalling molecules, 
including Stat5 (signal transducer and activator o f transcription 5) (Stat5a and 
Stat5b) and the adapter She, which coordinately induce the expression o f a variety 
o f genes, including c-myc, bcl-2, and bcl-x, critical for cell proliferation and 
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Figure VI. IL-2-dependent G l/S transition. Schematic representation of 
the IL-2-induced intracellular signalling pathways involved in T cell 
proliferation.
JAKs (177). The phosphotyrosines of Stat preferentially bind to Stat SH2 domains 
(178), causing Stat molecules to dimerize, release from the receptor, and entry into 
the nucleus. There, Stat5 dimers directly regulate transcription of target genes (176, 
177). A critical role for StatS in IL-2-mediated mitogenesis has been suggested by 
the observation that TCR-stimulated T cells from mice lacking both the Stat5a and 
StatSb genes have impaired proliferation in response to IL-2 (179). Moreover IL-2 
activation of StatS has been suggested to be important for IL-2 induction of DNA 
synthesis (180).
Similarly to Stat 5, also the recruitment of the adapter She initiates a series of 
intracellular events. Thus, once recruited to phosphorylated IL-2RP chain. She 
recruits two important protein complexes: Grb2/Sos, which activates the Ras/Erk 
pathway, and Grb2/Gab-2, which activates the PI3K pathway (175, 181-183). 
Although the role of Ras/Erk signalling in the regulation of cell cycle progression is 
well established in non-lymphoid cells (184), its role in IL-2R-mediated 
proliferative response remains largely to be clarified. In contrast, PI3K-induced 
signalling have been largely characterized and shown to play a pivotal role in IL-2- 
dependent regulation of cell growth and proliferation (89). To exert these important 
functions, PI3K-mediated signals integrate with nutrients-sensitive pathways, and 
result in a tightly coordinated series o f both transcriptional and translational 
activation events. Indeed, it has been shown that PI3K-dependent signals are 
required for the IL-2-induced upregulation of cyclin D3, for the downregulation of 
p27^‘P, and for the hyperphosphorylation of Rb and p i 30 (89). Moreover, PI3K 
activity has been shown to be necessary and sufficient for E2F transcriptional 
activity (89). Interestingly, while PI3K is sufficient for the induction o f E2F
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activation, it is not sufficient for DNA synthesis, and so for cell cycle progression 
into the S phase. This supports the idea that several signalling networks cooperate 
for cell cycle progression in T cells (89).
Follow ing IL-2-dependent PI3K activation, the enzyme activates two 
serine/threonine kinases, PKB and the p70^^^ (185). In addition, IL-2-induced PI3K 
signalling has also been shown to directly regulate the MAP kinase pathway, 
probably at the level of MEK (186).
Activation of both PKB and p70^^^ is initiated by PI3K-induced translocation 
o f these proteins to the plasma membrane, where they can get phosphorylated and 
activated by Ser/Thr kinases, such as PDKl and PDK2 (187-190). Overexpression 
o f a constitutive active form of PKB in T cell lines, is sufficient to drive E2F 
transcriptional activity, thus providing a link for PI3K to E2F activation (89). In 
addition, PKB directly phosphorylates Forkhead factors on several sites, causing 
their retention in the cytoplasm (191). These factors regulate transcription o f the 
cyclin inhibitor p27^^ and of the pocket protein p i 30 (191, 192). PKB-dependent 
phosphorylation and thus retention in the cytoplasm, reduces the transcription of 
these inhibitors and promotes progression through the cell cycle. Finally, it has been 
shown that PKB can also directly regulate p70^^^ activation (185).
p70^^^ is one of the two isoforms encoded by the S6K  gene, the other being 
p85^^^. p70^^\ the shorter isoform, is largely cytoplasmic and it is the most well 
studied, while p85^^^, the larger isoform, appears to be exclusively nuclear, having 
an additional 23-aminoacid sequence residing at its amino terminus, which has been 
shown to function as a nuclear localization signal (NTS) (193-196). With the 
identification of a highly homologous gene product, S6K2, p70^^Vp85^^^ have been
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collectively termed S6K1 (197). Activation of p70^^\ results in the phosphorylation 
of the 40S ribosomal protein S6 , and elicits the translation of 5’ TOP (terminal 
oligopyrimidin tract) mRNAs (198). These mRNAs constitute a small family o f 
abundant transcripts (up to 20% of cellular mRNA) that encode primarily ribosomal 
proteins and components of the translational apparatus (199). These are critically 
needed to satisfy the increased anabolic demand that occurs during the growth 
response (200). Since it has been demonstrated that the expression of many o f the 
components of the protein synthetic apparatus is regulated at the translational level, 
as occurs in the case of 5’ TOP mRNAs (201, 202), p70^^^ happens to play a crucial 
role during cell growth and proliferation.
Activation of p70^^^ not only depends on PI3K/PKB-induced signalling, but 
also on signalling induced by the serine/threonine kinase mTor (the mammalian 
target of Rapamycin), which, similarly to PI3K, plays a critical role in IL-2-driven 
T cell proliferation. Tor proteins were first identified in Saccharomyces cerevisiae 
through mutants that confer resistance to growth inhibition induced by Rapamycin 
(203). Yeast Tor proteins (Tor 1/2) control a variety of processes contributing to cell 
growth, in response to nitrogen availability, including translational initiation and 
early G 1  progression as well as the regulation of transcription, amino acid uptake, 
cytoskeletal organization, and protein degradation through autophagy (204).
mTor, the mammalian ortholog o f Tor, is a m ember o f the PIK 
(phosphoinositide kinase-related) family of kinases, and has homology to protein 
and lipid kinases (205). mTor is considered to be a central controller o f cell growth, 
it is conserved throughout evolution, and regulates cellular responses to nutrient 
levels (particularly those of aminoacids) and growth factors (206). Although several
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factors have been described to modulate mTor activity, the precise molecular 
mechanism responsible for the activation of this enzyme remains largely to be 
defined. For instance, mTor function seems to be regulated by the glucose, 
aminoacid and ATP levels (207, 208). Indeed, when aminoacids are limiting, 
uncharged tRNA pools accumulate in the cell and inhibit mTor signalling (207). 
Recently, two members of the nutrient sensing machinery, the tumour suppressor 
proteins o f the tuberous sclerosis complex (TSCl and TSC2) were identified as 
potential upstream negative regulators o f mTor (209). Growth factor-dependent 
PI3K/PKB mediates mTor activation, probably through phosphorylation and 
inactivation o f TSC2 (210). Similarly to TSCs proteins. Raptor (regulatory 
associated protein o f mTor), a recently discovered 150 kDa protein containing 
HEAT and WD40 repeats, forms a nutrient-dependent complex with mTor, and 
regulates its enzymatic activity positively and negatively, perhaps depending on 
nutrients levels (2 1 1 , 2 1 2 ).
Also the tumour suppressor protein p53 has been shown to inhibit mTor-dependent 
signalling, by a still unknown mechanism of action (213).
Finally, recent data indicate that, following growth factor stimulation, the p85 
regulatory subunit of PI3K forms a ternary complex with mTor and p70^^\ and by 
that it mediates p70^^^ activation, providing another potential pathway for growth 
factor-dependent mTor signalling (214).
In addition to phosphorylation of the p70^^\ mTor activation also elicits 
phosphorylation of the initiation factor 4E binding protein 1 (4EBP1) (215). While 
p 7 0 S6 k translation of Top mRNAs (see above), 4EBP1 mainly controls the
translation o f cap-containing mRNAs (206). Indeed, 4EBP1 is a translational
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inhibitor that acts by binding and repressing the activity of the eukaryotic initiation 
factor 4E (eIF4E). mTor-dependent phosphorylation of 4EBP1 mediates its release 
from eIF4E, thus allowing the initiation factor to mediate translation of cap- 
containing mRNAs (206). eIF4E function is also important in the translation of 
mRNAs containing a highly structured 5’ untraslated region (UTR), such as the 
transcripts encoding for the c-myc oncogene (216). This demonstrates that also 
4EBP1 could play a very important role in the regulation of cell proliferation.
mTor is the only known target o f the immunosuppressive drug Rapamycin. 
Rapamycin acts by associating intracellularly with the immunophilin FKBP12, and 
this complex negatively regulates mTor activity (217, 218). The use o f Rapamycin 
has allowed to comparing the signalling initiated by nutrients, to the one initiated by 
growth factors. Indeed, Rapamycin blocks growth factors-dependent p70^^^ 
activation to extents that are similar to the one found in limiting nutrient conditions
(219%
In T cells, Rapamycin blocks IL-2-induced G l/S transition, and inhibits IL- 
2-dependent kinase activation o f Cdk2 and Cdc2 (169), and downregulation of 
P2 7 K1P ( 2 YQ) Moreover, as mentioned above, Rapamycin completely blocks IL-2- 
induced activation of p70^^^(185). Importantly, Brennan et al. (90) observed that 
the IL-2-dependent PI3K/PKB- pathway, which regulates E2F activity, was 
Rapamycin-sensitive, and was rendered Rapamycin-insensitive by the expression of 
a p70^^^ Rapamycin-resistant mutant (90). Together these data indicate that, in T 
cells, p70^^^ represents a link between IL-2, PI3K/PKB, and mTor signals for the 
regulation o f E2F transcriptional activity, and that indeed p70^ *^^  regulates a G1 
checkpoint in T lymphocytes. However, expression of a p70^^^ Rapamycin-resistant
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mutant was not able to rescue Rapamycin inhibition of T cell cycle entry (90). This 
demonstrates that other pathways, controlled by Rapamycin, and independent from 
p70^^^ activity (such as, for example, 4EBP1), could be involved in IL-2-mediated 
cell cycle regulation.
IL-2-independent G l/S transition
As mentioned above, TCR-dependent signalling is not sufficient to promote 
exit from the G1 phase of the cell cycle, an event that was historically attributed to 
IL-2-dependent signalling. However, in the past years, evidences for IL-2- 
independent T cell proliferation were obtained both in vivo and in vitro, and a new 
picture on the role o f CD28-mediated costimulation in cell cycle regulation has 
emerged. Thus, several studies have indicated that CD28 costimulation, particularly 
at suboptimal levels o f TOR engagement, increases the fi’equency of cells entering 
the proliferative pool and the number o f mitotic events that responding cells 
undergo (220). This was previously attributed to the ability o f CD28 to enhance IL- 
2 production. However, the observation that T cells from IL-2-deficient mice have 
reduced, but significant, proliferative T cell responses (221) support the existence o f 
IL-2 independent T cell proliferation. In contrast to IL-2-deficient T cells, CD28- 
deficient T cells have dramatically impaired proliferative response. Moreover, while 
proliferation o f the former can be fully restored by the addition o f exogenous 
recombinant IL-2 (rIL-2) (222), proliferation of the latter is only partially increased 
by rIL-2 (25). This indicates that the failure of CD28-deficient cells to proliferate 
might not simply be due to the lack of IL-2 production, but rather to the absence of 
a CD28-dependent mitogenic signal. Accordingly, Ag/LPS-induced in vivo
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expansion of Ag-specific T cells did not require IL-2, but CD28 expression on T 
cells (221). These findings, together with the observation that the massive T cell 
expansion observed in CTLA-4-deficient mice could not be correlated with 
increased IL-2 production (223), but rather to unlim ited CD28-mediated 
costimulation, indicate that CD28-dependent signals might drive T cell proliferation 
directly and independently from IL-2.
Quite recently several reports have demonstrated a direct role o f CD28 in cell cycle 
progression (224-227). Boussiotis and co-workers (226, 227) have shown that, in 
vitro, CD28 costimulation could induce downregulation of the CKI p27^'^ via 
PI3K/PKB-dependent pathways in the absence of IL-2-mediated signalling. This 
CD28-mediated p27^^^-downregulation resulted in the activation o f cyclin D2- 
associated Cdk4/Cdk6 and cyclin E-associated Cdk2, and subsequent progression 
into the S phase. Thus, in the absence of IL-2, CD28 mediates initial entry into the 
cell cycle rendering the cells competent for progression into the S phase (226). 
Whether this would be sufficient in vivo, or require the synergy with cytokines other 
than IL-2 remains to be established.
1.6 CD4^ T cell anergy
1.6.1 The establishment of T cell anergy: the role of costimulation
Antigen encounter in the presence of costimulation allows T lymphocytes to 
undergo intense and prolonged proliferation, ensuring that the initial small number 
o f Ag-specific T cells is increased, and that the immune response is initiated. In 
contrast, antigen encounter in the absence of costimulatory signals, leads to T cell
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activation, but not to T cell proliferation and induces T cells to enter a state of long­
term antigen-specific unresponsiveness, defined as clonal anergy. This is 
characterized by the inability of the cells to produce IL-2, and to proliferate upon 
antigen restimulation (7), thus resulting in antigen-specific T cell tolerance.
Generally, tolerance to self-antigens is first established in the thymus 
(primary lymphoid organ) through negative selection o f autoreactive T cell 
precursors (228, 229). However, some antigens are not represented in the thymus 
(developmentally regulated antigens), or do not reach the concentration required to 
effectively delete reactive T cells. In these instances, several peripheral 
mechanisms, such as ignorance, peripheral deletion, clonal anergy and suppression 
have evolved to regulate, and possibly inhibit, the activation of mature T cells 
potentially able to recognize self-antigens (and thus auto-reactive) (230). Among 
these mechanisms, antigen-specific clonal anergy has been proposed to play a major 
role in controlling peripheral tolerance to self antigens, and its disregulation has 
been involved in auto-immune manifestation, graft rejection and, in some instances, 
in tumour escape. Thus, many efforts were and are being made to understand the 
molecular mechanisms regulating the induction of clonal anergy to either induce it, 
or overcome it in the many different clinical conditions (auto-immunity, organ 
transplantation, tumours).
The term “clonal anergy” was originally created to describe the functional 
phenotype of B cells derived from mice that were immunized with a soluble 
antigen, which were shown to be unable of responding to antigen restimulation 
(231). Antigen-induced T cell clonal anergy was first demonstrated in vitro. Indeed,
37
Feldmaim and co-workers (232) showed that the stimulation of T helper clones with 
low amount of the specific antigenic peptide, in the absence of autologous APCs, 
hampered the ability of the cells to further respond to APCs pulsed with the same 
antigen. These results suggested for the first time that professional APCs possessed 
special characteristics necessary for the productive presentation of antigen that T 
cells themselves lacked. It was indeed hypothesized that a second signal, distinct 
from the one generated by TCR-MHC/peptide interaction, was transduced from 
APC to the T cell, and the “two-signal” model of lymphocyte activation was 
proposed (7). The possibility that TCR-generated signals were not sufficient to 
drive optimal T cell activation was later supported by the observation that 
stimulation of CD4^ T cells with purified MHC/peptide complexes immobilized in 
artificial lipid bilayers, (233), or with chemically fixed Ag-pulsed APCs (234), 
induced unresponsiveness rather than T cell activation. Moreover, it was shown that 
the addition of untreated syngeneic APCs to these cultures restored optimal T cell 
activation, thus supporting the existence of a second signal molecularly distinct 
from that mediated by TCR-MHC interaction (235).
Similar results were also obtained by stimulating CD4^ T cell clones with 
immobilized anti-TCR, or anti-CD3 mAbs (236). In these cases, T cells were 
activated, but failed to produce IL-2 and to proliferate. Again, these cells resulted to 
be incapable of producing IL-2 upon optimal stimulation, mediated by either Ag- 
bearing APC or by anti-CD3 and anti-CD28 mAbs.
In contrast to IL-2, the production of IFN-y or IL-4 seemed to be unaltered in 
anergic T cell clones. Moreover, anergic T cells remained viable for extended 
period of time and showed to be capable of proliferating to exogenous IL-2 (237),
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thus suggesting that anergic cells failed to proliferate upon rechallenge because of a 
highly specific defect in IL-2 production.
Even though clonal anergy was first described in vitro, several evidences are 
now in place to support the idea that Ag stimulation o f T lymphocytes, in the 
absence of costimulation, results in anergy induction also in vivo. For instance, the 
injection of bacterial superantigens (BSAgs), which bind to the lateral surfaces of 
TCRp polypeptides and MHC glycoproteins, and is believed to be insensitive to 
CD28 costimulation, was shown to lead to potent activation and proliferation of a 
large proportion of T cells, but also to cause their rapid cell death, and the 
persistence of unresponsive T cells. Indeed, when optimally restimulated in vitro, 
these cells were unable to respond to antigenic rechallenge resembling the cells 
anergized via CD3-mediated stimulation (238-240). The establishment o f clonal 
anergy has also been demonstrated in mice adoptively transferred with a 
monoclonal population of TCR transgenic antigen-specific CD4^ T cells, and 
immunized with the specific Ag in the absence of adjuvant, which is required for 
the upregulation o f costimulatory ligands on the surface o f APC (241). In this 
model, intravenous injection of soluble antigen induced a transient accumulation 
and loss of adoptively transferred TCR transgenic T cells, among which some 
survived and persisted for several months but remained profoundly unresponsive to 
antigenic restimulation (221, 241-243).
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1.6.2 Molecular features of anergic CD4^ T cells
Several efforts have been made to characterize the molecular mechanisms 
that are in place in anergic T cells, and that prevent their activation upon optimal 
restimulation. The observation that anergic T cells seem to be selectively unable o f 
producing IL-2 has generated intense investigation on the molecular mechanisms 
responsible for this functional defect. Data obtained in different laboratories 
throughout the years, and mostly regarding anergic T cell clones, have altogether 
demonstrated that anergic cells are unable to transcribe the mRNA coding for IL-2, 
because of molecular defects at different levels along the TCR-induced intracellular 
signal transduction pathways.
Kang et al. (244) first demonstrated that the failure to transcribe the IL-2 gene in 
anergic T cell clones was associated with defective AP-1-dependent DNA binding 
and transactivation. This was later shown to be due to the defective induction o f the 
AP-1 family members c-Fos, FosB, and JunB proteins, which impaired DNA- 
protein interaction and transactivation at both AP-1 and NFAT DNA enhancer 
elements (245). Defective TCR and CD28 induced AP-1 protein expression 
correlated with defective activation of the Ras pathway in these cells (246), and 
with reduced phosphorylation and catalytic activity o f members o f the MAPK 
family, such as E rkl, Erk2 and JNK (247). In addition to AP-1, the altered 
expression of NF-kB transcription factors was also reported in anergic T cells in 
vivo (248). Furthermore, data against a loss-of-function signalling defect as the sole 
basis for clonal anergy induction were generated, which demonstrated the presence 
of a dominant-acting repressor molecule that inhibits signal transduction to the IL-2
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gene within viable anergic T cells (249-251). Indeed, Powell et al. (250) showed 
that the DNA binding activity o f the cAM P-response elem ent-binding 
protein/cAM P-response element m odulator (CREB/CREM) transcriptional 
inhibitory complex to enhancer elements in the IL-2 gene was increased in anergic 
T cells. Moreover, Telander et al. (251) demonstrated that the fusion of anergic 
murine T cells to human Jurkat T leukaemia cells, and formation of heterokaryons 
failed to result in a complementation of the signalling defect o f anergic cells and 
restoration of murine IL-2 mRNA inducibility. Instead, signal transduction to the 
human IL-2 gene became disrupted, demonstrating the existence of a negative 
regulatory factor in anergic cells.
In support o f this, it has been shown that anergy induction is inhibited by the 
addition, at the time o f the anergizing stimulus, o f Cyclosporin A and 
cycloheximide, demonstrating that the establishment o f anergy is an active 
mechanism, which requires TCR-induced signalling, and new protein synthesis 
(233,236,252).
Defective IL-2 gene transcription might be due to altered upstream TCR- 
induced signalling events, which have been reported in anergic T cells. Gajewski et 
al. (253) have revealed increased basal levels o f intracellular free calcium and 
phosphatidylinositol 1,4,5-triphosphate (IP3) in anergic T cells compared to control 
cells, and showed that these levels failed to increase significantly upon subsequent 
restimulation. These authors also reported an alteration in net tyrosine kinase 
activity in anergic cells, with preferred activation of the Src-family PTK Fyn (253). 
Quill et al. (254) also found a constitutively reduced amount o f Lck, and 
constitutively elevated levels of Fyn in anergic T cell clones. These data might
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suggest that an unbalanced TCR-linked Lck and Fyn kinases activation might 
determine the fate o f T cell activation. Thus, while Lck might be the predominant 
kinase involved in productively activated cells, Fyn might dominate the response in 
anergic T cells (255).
Selective TCR-induced intracellular events have not only been described 
when comparing responsive and unresponsive (anergic) T cells, but also when 
analyzing the intracellular signalling of optimally (TCR/CD28) or suboptimally 
(TCR, ionomycin, altered peptide ligands) stimulated cells. For instance, 
stimulation o f T cells by altered peptide ligands resulted in suboptimal 
phosphorylation of the TCRÇ chain, and lack of association with ZAP-70 (256, 
257). Moreover, while TCR engagement in the absence of costimulation was shown 
to result in preferential association of the TCR/CD3 complex with Fyn, co-ligation 
of the TCR and CD28 resulted in the recruitment of Lck (258).
These data, together with the observation that the establishment o f the 
anergic phenotype requires TCR-generated signalling and new protein synthesis, 
suggest that anergy induction could represent an alternative type o f activation. This 
could be initiated by selective signalling pathways resulting in a unique gene 
expression profile, which eventually accounts for the maintenance o f the anergic 
phenotype.
Recently, Maciàn and co-workers (259) have compared the gene expression profile 
o f control and ionomycin-induced anergic T cells. They found that, during 
ionomycin stimulation (anergy induction), a limited set of genes, distinct from those 
activated following productive stimulation, was induced. In particular, these authors 
demonstrated that ionomycin-induced anergy is mediated primarily by NFAT-
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dependent expression of a new set of genes, which are independent o f NFAT/AP-1 
cooperation, and which include genes encoding phosphatases, proteases, and 
transcriptional repressors (259). They defined these genes as anergy associated 
genes, and further proved their unique expression also upon in vivo anergy 
induction. Similarly, Soares and co-workers (260), examined early changes in gene 
expression after TCR-induced signalling in the presence (activation) or absence 
(anergy) of B7-mediated costimulation, and found that some genes were uniquely 
expressed in anergizing stimulation. Among these, for instance, is the ubiquitin E3 
ligase GRAIL (gene related to anergy in lymphocytes), whose activity correlated 
with the inhibition of cytokine gene expression, and which was uniquely expressed 
in T cells activated in the absence of costimulation (260).
In addition to IL-2 gene transcription, some reports have indicated that the 
posttranscriptional regulation of IL-2 is differentially regulated by anergizing 
stimuli. Indeed, Garcia-Sanz et al. (261) have shown that, following ionomycin 
stimulation, IL-2 mRNA was transcribed to somehow detectable levels but failed to 
associate with active ribosomes, and thus failed to be translated. These authors also 
showed that in anergic cells, IL-2 mRNA remained detectable but failed to be 
loaded on ribosomes upon restimulation (261).
Thus, many evidences indicate that the absence of T cell costimulation, at the 
time o f T cell activation, might be responsible for the induction o f selective 
intracellular signalling events dictating the establishment o f peculiar genetic 
programs that later regulate antigen responsiveness.
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1.6.3 Anergy and proliferation
Several in vitro and in vivo evidences suggest that, in some instances, T cell 
anergy can also be induced in the presence of costimulation. It was shown that 
clonal anergy could be induced in the presence of both TCR- and CD28-mediated T 
cell activation, by preventing IL-2/IL-2 receptor interaction (262), or IL-2- 
dependent T cell proliferation (263). Sloan-Lancaster et al. (256) similarly reported 
that partial agonists caused T cell activation, but failed to elicit proliferation, in spite 
o f the presence of CD28 costimulation, and induced clonal anergy. Similarly, 
TCR/CD28 optimally stimulated T cells became unresponsive when M-butyrate 
(264) or Rapamycin (265), which block Gl-to-S transition, were provided at the 
time of stimulation. In all these conditions, the addition of exogenous IL-2 induced 
extensive T cell proliferation and resulted in either prevention or reversal of clonal 
anergy (263, 266).
These data supported the possibility that negative regulatory factors could be 
normally produced, but also degraded during IL-2-driven Gl-to-S phase transition. 
In the case that IL-2 is not produced (suboptimal T cell stimulation), or IL-2 driven 
proliferation is prevented, these anergic factors might accumulate inside the cells 
and inhibit subsequent T cell responses (263, 267). The addition of exogenous IL-2 
could drive extensive T cell proliferation, dilution or degradation of the anergic 
factors, and by that it could restore antigen responsiveness. A number of reports 
have indicated the G1 cyclin-dependent kinase inhibitor p27^‘^  as a putative anergic 
factor, since its deregulated expression directly correlated w ith T cell 
unresponsiveness (268, 269). Boussiotis and co-workers (268) showed that sub-
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optimal stimulation with costimulatory deficient APC, which results in T cell 
anergy, failed to down-regulate p27^^^ , and elicited cell cycle arrest in early G l. 
Moreover, over-expression of p27^^^ not only prevented Gl-to-S transition upon 
optimal stimulation (269), but also inhibited IL -2  transcription (268). Thus, 
deregulated expression of p27^^^, or more generally the failure to progress from the 
G l to the S phase o f the cell cycle, might result in the establishment and 
maintenance of the anergic phenotype.
1.7 Aim of the project
Anergic T cells fail to transcribe the IL-2 gene, and to proliferate, and are 
specifically arrested in the G l phase of the cell cycle. It has been suggested that the 
failure of these cells to respond to optimal stimulation could be attributed to the 
presence of a putative anergic factor, uniquely expressed by the engagement o f the 
TCR in the absence of proliferation. This model predicted that forcing proliferation, 
or G l to S transition of anergic T cells would lead to dilution/degradation o f the 
putative anergic factor, and by that it would restore the ability o f the cells to 
properly respond to antigenic rechallenge.
Several reports have recently indicated that optimal engagement of the TCR 
and o f CD28 drives IL-2 independent cyclin/Cdks activation, p27^^^ degradation, 
and thus Gl-to-S phase transition.
We thus set out to investigate whether optimal engagement of the TCR and of 
CD28 on the surface of anergic T cells, could force cell cycle entry, and T cell
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proliferation. This would allow the dilution/degradation o f the putative anergic 
factor and the reversal of clonal anergy.
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2. Material and Methods
2.1 Mice and cells
Mice
BIO.BR (H-2^) mice were purchased from Harlan Laboratories (Milan, Italy) 
and used as donors of splenic APCs for the maintenance o f the A.E7 Th clone. 
BALB/c mice (H-2^) (Charles River Breeding Laboratories) were used as donors of 
splenic APCs for the maintenance of DO II . 10 T cell lines, and for the stimulation 
o f D O Il.lO  primary T cells. C57BL/6 mice (H-2^) (Charles River Breeding 
Laboratories) were used as donors of splenic APCs for the stimulation of OT-I 
primary T cells.
D O Il.lO  mice (H-2^) were obtained from Dr. Luciano Adorini (Bioxell, 
Milan, Italy). These mice express a transgenic (Tg) a(3 TCR specific for the CD4- 
restricted chicken ovalbumin (OVA) derived peptide (OVA323.339.) on the majority 
o f the CD4^T cells (270). OT-1 mice (H-2^) were generously provided by Dr. 
Matteo Bellone (DIBIT, Milan). These mice express a Tg a p  TCR specific for the 
CDS restricted OVA peptide (OVA257.264) on the majority of the CD8^ T cells (271). 
The transgenic mice were bred and maintained in the SPF animal facility according 
to the Institutional Guidelines. The animal usage was approved by the Ethical 
Committee of the San Raffaele Scientific Institute.
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Cells
The A.E7 T cell clone is a H-2^-restricted Thl clone, specific for the pigeon 
cytochrome c derived 81-104 peptide (PCC 8 1 . 1 0 4 ) (272). A.E7 cells (0.5x10^ T 
cells/well/24 well plates) were maintained in RPMI medium supplemented with 2 
mM L-glutamine, 100 U/ml streptomycin, 100 U/ml penicillin, 20 mg/ml 
gentamicin, and 50 pM p-mercaptoethanol (P-ME) (Invitrogen Life technologies, 
Milan, Italy), and 5% heat-inactivated fetal bovine serum (FBS, Euroclone, Milan, 
Italy) (complete RPMI medium) at 37°C in a 5% CO2  atmosphere, by periodic
stimulation with irradiated syngeneic splenocytes (3.5x10^ cells/well) pulsed with 
PCC 8 1 . 1 0 4  (0.5pM ) (Primm, Milan, Italy). Forty-eight hours (h) after antigenic 
stimulation, exogenous recombinant IL-2 (rIL-2; 10 lU/ml) (Roche, Milan, Italy) 
was added to the cultures.
The OVA specific DO 11.10 and IL-2" '^ D O Il.lO  T cell lines were generated 
by stimulating LN cells, respectively derived from D O Il.lO  and DOll.lO/IL-2'^' 
mice (2 2 1 ), with irradiated syngeneic splenocytes and OVA 3 2 3 . 3 3 9  (0.5 p M )  
(Primm). The cells (0.5x10^ T cells/well/24 well plates) were maintained in 
complete RPMI medium, and stimulated weekly with Ag and BALB/c splenocytes 
(3.5x10^ cells/well), and rIL-2 (10 lU/ml) . The peptides used to stimulate the cells 
were commonly referred to as “antigen” (Ag) in the text. All the experiments were 
performed at least 10 days from the last antigen exposure. At this time, the cells 
appeared to be in the GO/Gl stage of the cell cycle.
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Primary T cell cultures
Single cell suspensions were derived from peripheral LNs o f 6 - 8  weeks-old 
D O Il.lO  and OT-I TCR Tg mice, by smeshing the organs on sterile nylon filters 
(Falcon, Milan, Italy).
In selected experiments, CD4^ T cells were purified from the D O Il.lO  LN 
suspension. Purification was performed by negative selection (Dynal Biotech LTD., 
UK). Briefly, LN cells (10x10^ cells/1 OOpl) were incubated Ih at 4°C, with anti- 
B220 (clone TIB 146), anti-CD 8  (clone 53.6.72), anti-I-A/I-E (clone 2G9), and anti- 
MAC-1 (clone M l/70) rat Abs (final concentration of each Ab, 10 pg/ml), in RPMI 
medium containing 2% FBS, and 5 mM EDTA (Sigma, Milan, Italy). The cells 
were then washed and resuspended in complete RPMI medium in the presence of 
goat anti-rat-coated magnetic beads (20x10^ beads/IOxIO^ cells), and incubated 
under rocking 20 min 4°C. Beads-coated cells were then removed using the Dynal 
magnet (Dynal Biotech LTD.). The purity of the preparation was analyzed by flow- 
cytometry after staining of the cells with anti-CD4 mAh (BD Pharmingen, Milan, 
Italy). In all the experiments CD4^ cells were selected to a purity o f >95%.
2.2 Anergy induction
Where indicated A.E7 cells were cultured for 16 hours on plate bound anti- 
CD3-8 mAb (clone 145-2C11, 4pg/ml) (273) (25-30x10^ cells in 150 mm dishes). 
The cells were then removed from the Ab, and rested for additional 5 days in fresh 
medium (referred to as “anergic” T cells) (262). At the same time a similar number 
of A.E7 cells was harvested and rested in fresh medium (referred to as “control” T
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cells). Both control and anergic cells appeared to be in the GO/Gl phase of the cell 
cycle. Thereafter, viable cells were separated on a Lympholyte-M (Cederlane, 
Hornby, Ontario, Canada) density gradient and restimulated as indicated in the 
different experiments.
2.3 T cell activation
Where indicated control and anergic A.E7 cells were stimulated with Ag (0.5 
pM) and irradiated syngeneic splenocytes (1:4, T:APC ratio), with immobilized 
anti-CD3 mAb (2 pg/ml) and anti-CD28 mAb (clone 37.51) (5 pg/ml) (274), or 
with rIL-2 (10 lU/ml), in the absence or in the presence of Rapamycin (200 nM, 
Calbiochem, Merck, Milan, Italy), LY294002 (20 pM, SIGMA, Milan, Italy), or 
Cyclosporin A (0.5 pg/ml, Sandimmun; Novartis, Milan, Italy). Thereafter the cells 
were removed from the Abs, rested in fresh medium for 10 days, and then re­
stimulated with Ag/APC, or with rIL-2. At the time indicated in each experiment, 
the cells were either left untreated or restimulated as indicated in the figures, and 
analyzed by flow cytometry or by Western Blot analyses.
Wild type and IL-2'^' D O Il.lO  T cells were stimulated for the indicated 
periods of time with immobilized anti-CD3 mAb (0.1 pg/ml) and anti-CD28 mAb 
(5 pg/ml), or with immobilized anti-CD3 mAb (0.01 pg/ml) and rIL-2 (10 lU/ml), 
and then analyzed by flow cytometry, or by Western blot (see below).
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2.4 T cell differentiation
D O Il.lO  and OT-1 LN cells (0.5x10® CD4+ or CD 8 + TCR Tg T cells/well/24 
well plates) were cultured for 3-7 days in RPMI complete medium in the presence 
of irradiated syngeneic splenocytes (3.5xl0Vwell) and either the CD4-restricted or 
the CD 8 -restricted peptide (OVA 3 2 3 . 3 3 9  and OVA 2 5 7 .2 6 4 , respectively, 0.5 pM) 
(referred to as Ag in the text). Rapamycin (100 nM) was provided to some of the 
wells at the time of Ag stimulation.
In some experiments, purified D O Il.lO  CD4^ T cells were stimulated for 7 
days with latex beads (diameter around 5 pM) (Interfacial Dynamic Corporation, 
Oregon) coated with anti-CD3 (0.05 pg/ml) and anti-CD28 (5pg/ml) mAbs 
(2.5x10^ beads/1 xlO^ cells). Coated beads were prepared as follows: beads were 
incubated with the antibodies in PBS (pH 7.4-7.6 ; Euroclone, UK) at a 
concentration of 20x10^ beads/ml, for 20 min at 4°C, under rocking. The beads 
were then washed twice in PBS containing 2% PCS, and resuspended in RPMI 
complete medium containing 5% PCS, under rocking for 30 min at room 
temperature (RT). The beads were eventually pelleted and added to the cells.
Where indicated purified CD4^ D O Il.lO  T cells cells were cultured with 
anti-CD3/CD28 coated beads, in Thl or Th2 polarizing conditions. Briefly, rIL-12 
(0.5 ng/ml. Bender MedSystem, Milan, Italy), and neutralizing anti-IL-4 mAb (5 
pg/ml, BD Pharmingen), or rIL-4 (1 ng/ml. Bender MedSystem), and neutralizing 
anti-IL-12 mAh (5 pg/ml, BD Pharmingen) were provided to the cultures at the time 
of stimulation.
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2.5 Western blot analysis
Analysis o f cell cycle proteins
Control and anergic A.E7 cells were stimulated with anti-CD3/CD28 mAbs 
(2 mg/ml and 5 mg/ml respectively), or with rIL-2 (10 lU/ml) for 30 min. The cells 
were then harvested, washed twice with ice cold PBS, and lysed in Lysis buffer 1, 
containing 50 mM Tris-HCl pH 7.4, 0.5% Nonidet P-40, 150 mM NaCl, 10 mM 
MgCl2 , 1 mM DTT, 1 pg/ml PMSF, 1 pg/ml aprotinin, 5 pg/ml leupeptin (Sigma, 
Milan, Italy). Samples were incubated in the lysis buffer for 20 min on ice. The 
soluble fraction was separated by centrifugation at 13,000 rpm for 15 min at 4°C 
and the protein content was determined by the Bradford assay (Bio-Rad, Milan, 
Italy). Samples containing an equal amount o f proteins (10-20 mg) were mixed with 
an equal volume of 2X Laemmli buffer (275), boiled, and separated on a standard 
SDS-PAGE. Proteins were then transferred onto nitrocellulose membranes (Protran, 
Schleicher & Schuell, Milan, Italy). Non-specific binding sites were blocked by 
incubating the membranes in PBS containing 5% non-fat dry milk and 0.05% 
Tween-20. Immunodetection was accomplished by incubating the membranes with 
primary antibodies ( 1  pg/ml) first, and then with horseradish peroxidase-conjugated 
secondary antibodies directed against mouse IgG or rabbit IgG (1:5000 dilution) 
(Amersham Biosciences, Milan, Italy) diluted in PBS pH 7.4, containing 1% dry 
non fat milk, 1% bovine serum albumine (Sigma) and 0.1% Tween-20. The 
immunocomplexes were then detected by chemiluminescence (SuperSignal, West 
Dura Extended Duration Substrate, Pierce, Milan, Italy). Expression o f cyclin D3, 
P2 7 K1P, was analyzed by 12% SDS-PAGE (acrylamide:bis-acrylamide 29:1;
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Euroclone, UK). Expression and phosphorylation of Rb were analyzed by 6 % SDS- 
PAGE (acrylamide:bis-acrylamide 29:1) as described (268). The following 
antibodies were used: cyclin D3 (C-16), p27^^^ (C-19), p21^^  ^ (F-5), and Rb (C l5) 
antibody (Santa Cruz Biotechnology, Milan, Italy).
Analysis o f p7(f^^phosphorylation
Control and anergic A.E7 cells were stimulated with anti-CD3/CD28 mAbs 
(2 pg/ml and 5 pg/ml respectively), or with rIL-2 (10 lU/ml) for 30 min. Where 
indicated the cells were pre-treated with Rapamycin (200 nM) for 30 min at 37°C, 
and then stimulated in the presence of the drug. The cells were then harvested, 
washed twice with ice cold PBS, and lysed for 20 minutes on ice in Lysis buffer 2, 
containing 50 mM Tris-HCl pH 7.4, 1% Triton X-100, 150 mM NaCl, 10 mM 
MgCl2 , 1 mM DTT, 1 pg/ml PMSF, 1 pg/ml aprotinin, 5 pg/ml leupeptin, ImM 
NaF, 1 mM NaOvg (Sigma). Protein extracts were quantified by the Bradford assay. 
Where indicated, the samples were treated for Ih at 37°C with alkaline phosphatase 
(2 U enzyme /25 pg of extract) (Sigma). Samples containing an equal amount o f 
proteins (20-40 pg) were mixed with an equal volume of 2X Laemmli buffer, 
boiled, and separated on a standard 10% SDS-PAGE (acrylamide:bis-acrylamide 
10:0.16) (Sigma), as previously described (90). Western Blot analysis was 
performed as described above, by using an anti-p70^^’^ (C-18) Ab (0.5 pg/ml) (Santa 
Cruz Biotechnology).
For the analysis of phospho-Thr^^^-p70^^^, control and stimulated T cells 
were harvested, washed twice with ice cold PBS, and lysed in SDS sample buffer, 
containing 62.5 mM Tris-HCl pH 6 .8 , 2% w/v SDS, 10% glycerol, 50 mM DTT,
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0.01% w/v bromophenol blue (Sigma). The extracts were sonicated for 10-15 
seconds to shear DNA and reduce sample viscosity, and then boiled for 5 minutes. 
Proteins from 2x10^ cells were separated on a standard 10% SDS-PAGE 
(Acrylamide:bis-acrylamide 10:0.16), transferred onto nitrocellulose membranes, 
and analysed by Western blot with an overnight incubation at 4°C with the primary 
anti-phospho-p70^^*^ (Thr^^^) Ab (1:1000) (Cell Signaling Technology, Milan, Italy).
Where indicated, protein bands were quantified by densitometric analysis 
using the Image Quant analysis software (Amersham Biosciences).
2.6 2-D electrophoresis (2DE)
Cells were washed extensively with ice cold PBS, and lysed in Lysis buffer 
2. 400 pg of total proteins were resolved onto preparative 10% SDS-PAGE 
(acrylamide:bis-acrylamide 10:0.16). The portion of the gel corresponding to the 
p 7 0 S6 k by Western blot analysis o f an electrotransferred lane from the
same gel) was excised, and the contained proteins were eluted by an overnight 
incubation with 0.1% SDS. Proteins were then precipitated using 80% acetone. 
Where indicated, eluted proteins were concentrated by Vivaspin Concentrator 
(30000 MWCO) (Sartorius, Germany), treated for Ih at 37°C with alkaline 
phosphatase (2 U/25 pg  protein), and then heated for 15 minutes at 65°C. 
Eventually, samples were acetone precipitated. The pellet was resuspended in 2DE 
buffer (9 M Urea, 10 mM Tris, 4% CHAPS, 65 mM DTT, 2% IPG buffer 
ampholine pH 3-10, protease inhibitor cocktail; Sigma), and samples were applied 
to 7 cm IPGstrips pH 3-1 ONE (Amersham Biosciences) by in-gel rehydration at
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20°C. Focusing was performed with an IPGphor system (Amersham Biosciences) at 
50 |iA  max per IPG strip with a gradient voltage (5000 V max) for a total of 25 
KVh. Strips were equilibrated for 15 min in 50 mM Tris-HCl buffer pH 8 .8 , 
containing 6  M urea, 30% glycerol, 2% SDS and 2% DTT, then for 15 min in the 
same buffer replacing DTT by 2.5% iodoacetamide. The strips were then transferred 
onto 12% acrylamide SDS-PAGE gels for the second dimension separation. 2-D 
gels were transferred onto nitrocellulose membranes and analyzed by Western blot 
with the anti-p70^^^ Ab (see above). Densitometric analyses o f protein spots were 
performed by using the Image Master 2D Elite analysis software (Amersham 
Biosciences).
2.7 Analysis of T cell proliferation
H]-Thymidine incorporation assay
Control and anergic A.E7 T cells were stimulated in flat-bottomed 96-well 
plates (2x10^ cells/well) with increasing amounts of the PCC-derived peptide and 
irradiated syngeneic splenocytes (5x10^ cells/well), with immobilized anti-CD3 
mAb (2 jig/ml) and anti-CD28 mAb (5|Lig/ml), or with rIL-2 (10 lU/ml), until the 
total time of culture reached 48 h. Then, [^H]-Thymidine (1 mCi/well) was added, 
and the plates were harvested and counted 16 hr later.
Propidium iodide staining
T cells were stimulated as indicated in the figures, washed with PBS, 
counted and fixed overnight at 4°C in 70% ethanol. Cells were then pelleted,
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resuspended at a concentration of 1x10^ cells/ml in DNA staining buffer containing 
0.1% sodium citrate, 0.05% Nonidet P-40, 50 |xg/ml propidium iodide, and 50 
|Lig/ml Rnase A (Sigma), and incubated for at least 1 h at room temperature. PI 
contents were assessed by flow cytometry (FACScan, Becton Dickinson, Milan, 
Italy) using standard Cell Quest™ acquisition/analysis software.
Analysis o f CFSE dilution
T cells were washed twice with PBS, and resuspended at a density of 2x10^ 
cells per ml in PBS. An equal volume of a PBS solution containing 1.25 |iM  of the 
fluorescent dye 5-(and 6 -) carboxy-fluorescein diacetate, succinimidyl ester 
(CFDASE; Molecular Probes, Inc., Milan, Italy) was added, and the cells were 
gently mixed for 8  min at room temperature. In the case of A.E7 T cells, the final 
concentration o f CFDASE used was 2.5 \iM. Unbound CFDASE, or the 
deacetylated form, CFSE, was quenched by the addition o f an equal volume o f FBS. 
The labelled cells were washed twice in complete medium, and stimulated as 
indicated in the figures. When indicated, at the time of harvest, CFSE-labelled cells 
were washed twice in PBS, and the vital dye TO-PRO-3 (Molecular Probes, Inc.) 
was added to each sample (1 nM final concentration) before acquisition to 
distinguish live and dead cells. Cell division analysis was performed on a Becton 
Dickinson System (Milan, Italy) FACSCalibur® dual-laser cytometer using 
standard Cell Quest™ acquisition/analysis software. CFSE-labelling remained 
stable for up to three weeks in our cell cultures.
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2.8 Analysis of cytokine production
ELISA assay
The presence o f IL-2 in culture supernatants o f activated T cells was 
determined 24 h after stimulation by standard capture ELISA assay (BD 
Pharmingen). Functional assay was performed in 96-well plates using 1x10^ cells 
per well. The ELISA standard curve was generated using recombinant murine IL-2 
(BD Pharmingen), and the level of detection was 1 ng/ml.
Intracellular cytokine staining
The cells (0.5x10^ cells/ml) were either left untreated or stimulated for 4h 
with PMA (Phorbol 12-myristate 13-acetate) (50 ng/ml) and lonomycin (l|ig /m l) 
(Sigma). Following surface staining with anti-CD4 or anti-CD 8  mAh, the cells were 
fixed in 2% formaldehyde (Sigma) for 20 min at RT, then permeabilized by 
washing them in saponin buffer, containing PBS, 2% FBS, 0.2% sodium azide, 2% 
rat serum, and 0.5% saponin (Sigma). After fixation the cells were incubated for 20 
min in saponin buffer either with isotype control, or with anti-IL-2, anti-IFN-y, or 
anti-IL-4 mAbs (BD Pharmingen). The cells were then washed twice with saponin 
buffer, and twice with staining buffer, and analyzed by flow cytometry.
2.9 In vitro cytotoxic assay
OT-1 cells were tested for cytolytic activity in a standard 4 h ^^Cr release 
assay (276). RMA cells, a H-2^ Rausher virus-induced thymoma (277), were used
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as target cells. Target cells were labelled with ^^Cr, and left unpulsed or pulsed with 
1 |xM OVA 2 5 7 - 2 6 4  for 30’ in ice-cold RPMI complete medium. After extensive 
washing, target cells (1000 target/well) were seeded with OT-1 cells at effector to 
target ratios ranging from 6:1 to 50:1. The percentage specific ^^Cr release of 
triplicates was calculated as [(average experimental cpm - average spontaneous 
cpm)/(average maximum cpm-average spontaneous cpm)] x 100. ^^Cr release of 
target cells alone (spontaneous release) was always < 25% of maximal ^^Cr release 
(target cells in 0.25 M HCl).
2.10 Analysis of surface markers expression
At the indicated time, the cells were harvested and stained with anti-CD4 
mAh (Pharmingen). In the indicated experiments T cells were also stained with anti- 
CD69, CD25, CD44, CD62L, and CD 132 (common Yc) mAbs (Pharmingen). The 
cells were incubated in staining buffer (PBS, 2% FBS, 0.2% sodium azide) with the 
Ab for 15 minutes on ice. The cells were then analyzed by flow cytometry 
(FACScan, Becton Dickinson) using standard Cell Quest™ acquisition/analysis 
software.
2.11 RNase Protection assay (RPA)
DO 11.10 LN cells were stimulated for a week with Ag and irradiated 
splenocytes in the absence or in the presence o f Rapamycin (see section 2.4). 
Thereafter the cells were harvested and either left untreated or restimulated with
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PMA (50 ng/ml) and lonomycin (1 mg/ml) for 1-4 h. Total RNA was then obtained 
using the Total RNA Isolation Reagent (TRIZOL, Life Technologies, Milan, Italy). 
Briefly, 10x10^ cells were lysed in 500 jil TRIZOL, for 5 minutes at RT. Total RNA 
was extracted by phase separation with chloroform, precipitated with isopropyl 
alcohol, rinsed in ethanol and then solubilized in water. The presence o f the 
messages for different cytokines in the cells was analyzed using the multi-probe 
RNase protection assay (RPA) as previously described (278-280). Briefly, probe 
synthesis was driven by T7 bacteriophage RNA polymerase with -[^^P]UTP as the 
labelling nucleotide. The subsequent steps o f probe purification, RNA-probe 
hybridization, Rnase treatment, purification o f protected RNA duplexes, and 
resolution of protected probes by denaturing PAGE were performed as described 
(278). Probe bands were visualized by autoradiography, and were quantified by 
phosphor imaging analysis, using the Image Quant analysis software (Amersham 
Biosciences). The relative abundance of mRNA species was obtained dividing the 
values o f each specificity by the relative L32 value of the same sample, in order to 
obtain a relative expression value for each individual mRNA species. The 
expression of IL-2, IFN-y and IL-4 mRNAs in each group o f cells and in the 
different stimulation conditions was displayed as fold induction over the 
unstimulated condition (set as 1 ).
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3. Results
3.1 mTor signalling regulates CD4^ T cell antigen responsiveness
3.1.1 Optimal engagement of CD3/CD28 bypasses G1 cell cycle block and 
drives proliferation of anergic T cell
The engagement of the TCR in the absence of either costimulation or cell 
proliferation, elicits a state o f T cell unresponsiveness defined as clonal anergy. 
Upon optimal restimulation anergic T cells fail to produce IL-2 and to proliferate, 
and appear to be selectively blocked in the G1 phase of the cell cycle (7, 35, 36, 
268,269).
Starting from the observation that TCR- and CD28-generated signals mediate 
Gl-to-S phase transition via IL-2-independent mechanisms (224, 226, 227), we set 
out to investigate whether a combination of anti-CD3 and anti-CD28 mAbs would 
overcome the G1 cell cycle block reported for anergic T cells, and by that would 
cause reversal of clonal anergy.
T cell anergy was induced in cloned CD4^ T helper (Th) lymphocytes by 
chronic TCR engagement in the absence of costimulation as previously described 
(262). Non-proliferating A.E7 T cells were harvested and rested in fresh medium 
(referred to as “control” T cells), or cultured for 16 hours on plate bound anti-CD3 
mAb, removed from the Ab and rested for additional 5 days in fresh medium 
(referred to as “anergic” T cells) (Fig. lA). At the end of the resting time control 
and anergic T cells appeared to be in the GO/Gl phase of the cell cycle (refer to Fig.
60
Figure 1. Chronic TCR engagement results in the establishment of T cell clonal 
anergy. A) Schematic representation of anergy induction. B) Control (CT) and 
CD3-treated (anergic, AN) A.E7 T cells were challenged with irradiated splenic 
APC and the indicated amount of the pigeon cytochrome c derived peptide 
(PCC) (Ag/APC), with immobilized anti-CD3/anti-CD28 mAbs (2 and 5 pg/ml, 
respectively) (CD3/CD28), or with recombinant IL-2 (rIL-2) (10 lU/ml). After 
48h, pH]-Thymidine was added to each well, and the cells were harvested and 
assayed for proliferation after an additional 16h of culture. C) IL-2 production 
was measured in the supernatants of CD3/CD28-stimulated T cells after 24 
hours of culture by capture ELISA. The standard deviations of triplicate cultures 
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2 and 4). In addition, control and anergic cells expressed similar surface levels of 
the TCR (V(33, MFI: 41.66±0,34 vs. 41.35±0,12), of CD3 (MFI: 27.01±1.39 vs. 
23.83±3.66, see also (245)) and of CD25 (MFI: 23.87±0.07 vs. 26.54±0.I7). To 
investigate the functional capabilities o f these cells, control and anergic T cells were 
restimulated with either antigen-pulsed APCs (Ag/APC), or with a combination of 
anti-CD3 and anti-CD28 mAbs. Proliferation and IL-2 secretion were then 
measured by [^H]-Thymidine incorporation and by capture ELISA, respectively. 
Upon antigen rechallenge, anergic A.E7 T cells proliferated to much lower extents 
when compared to control T cells (Fig. IB), and showed defective IL-2 production 
even in response to optimal TCR and CD28 engagement (Fig. 1C), as previously 
described (245, 262). Interestingly, despite the failure to produce IL-2, control and 
anergic T cells produced comparable amounts o f IFN-y (not shown). Most 
importantly, anergic cells proliferated to similar extents to control cells in response 
to immobilized anti-CD3/CD28 mAbs (Fig. IB).
The observation that anergic cells proliferated to larger extents when 
stimulated with CD3/CD28, than when stimulated with Ag/APC, prompted us to 
investigate whether these types of stimulation could differentially regulate Gl-to-S 
transition in control and anergic T cells.
We first analyzed the expression of G1 cell cycle proteins by Western blot 
(Fig. 2). While antigen-dependent stimulation of control cells resulted in the up- 
regulation of cyclin D3, and of p21^'^, in the down-regulation of p27^'^ levels, and 
in the hyperphosphorylation of Rb (Fig. 2A), it failed to induce G 1-related events in 
anergic T cells. Thus, as also reported elsewhere (264, 269), anergic A.E7 T cells
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Figure 2. CD3/CD28-, but not Ag/APC-mediated stimulation, drives anergic cells 
to exit from the G1 phase of the cell cycle. T cell anergy was induced as described 
in Fig. 1. Control (CT) and anergic (AN) T cells were stimulated with either Ag- 
pulsed irradiated syngeneic splenocytes (Ag/APC) (A) or with anti-CD3/CD28 
mAbs (CD3/CD28) (B) for 24 hours. As a positive control the cells were stimulated 
for 24 hours also with rIL-2. Thereafter, the cells were lysed and protein expression 
was analyzed by SDS-PAGE and Western blot analysis with the antibodies 
indicated in the figure. p27^‘P and p2U*P were detected on the same membrane filter 
by sequential hybridization. The relative mobility of the proteins is indicated in the 
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Figure 2
were unable to progress through the G1 cell cycle checkpoint upon Ag/APC 
encounter.
In contrast, stimulation with anti-CD3/CD28 mAbs elicited comparable up- 
regulation of cyclin D3 and of p21^^^, down-regulation o f p27^*^ expression, and 
hyperphosphorylation of Rb (Fig. 2B), in control and anergic T cells. Moreover, this 
stimulation also induced up-regulation of cyclin D2 and cyclin E levels in both 
groups of cells (not shown). These results indicate that optimal engagement of TCR 
and CD28 drives the transition through the Gl/S restriction point in anergic T cells.
To determine the fraction of anergic T cells able to proceed from G1 to S, 
and then to G2/M phases o f the cell cycle upon CD3/CD28-mediated stimulation, 
we measured DNA content by Propidium Iodide (PI) staining. This technique 
allows to discriminate cells in GO/Gl phase, recognized by a typical DNA content 
equal to IN, from cells in S/G2M phases which have a DNA content > IN  (2N for 
cells in the M phase). Preliminary experiments indicated that by 48h of both 
Ag/APC and CD3/CD28-mediated stimulations, 20-40% of control A.E7 T cells 
had entered the S/G2M phase of the cell cycle (Fig. 3).
Control and anergic T cells were therefore stimulated with either Ag/APC or 
immobilized anti-CD3/CD28 mAbs for 48 hours, fixed, stained with PI, and 
analyzed by flow-cytometry (Fig 4). As expected, while control cells increased their 
DNA content upon Ag/APC-stimulation, anergic T cells failed to do so (Fig. 4A). In 
contrast, upon CD3/CD28 stimulation, both control and anergic cells had a sizable 
fraction o f cells with a DNA content >1N, and thus in S/G2M phases 
(23.83%±3.92% and 34.89%±5.68% respectively. Fig. 4B). After 48 hours of 
stimulation, no differences were detected in the total number o f live cells or in the
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Figure 3. Analysis of cell cycle entry in control cells. Control T cells were 
stimulated with either Ag/APC (A) or with anti-CD3/CD28 mAbs (B) for the 
indicated times. Thereafter the cells were counted, fixed, stained with propidium 
iodide, and analyzed by flow cytometry. The percentage of cells in G1 (DNA 
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Figure 4. CD3/CD28-mediated stimulation of anergic T cells bypasses G1 cell 
cycle block and results in Gl-to-S phase transition. T cell anergy was induced as 
described in Fig. 1. Control (CT) and anergic (AN) T cells were then stimulated 
with either Ag/APC (A) or with anti-CD3/CD28 mAbs (B) for 48 hours. Thereafter 
the cells were counted fixed, stained with propidium iodide, and analyzed by flow 
cytometry. Representative FACS histograms of the DNA content of unstimulated 
(untreated or stimulated with APC only), Ag/APC-stimulated and CD3/CD28- 
stimulated control and anergic T cells are reported. C) The graph reports the 
percentage of cells in the S/G2M phase (DNA content >1N) in resting (untr.) and 
stimulated (Ag/APC, CD3/CD28) control (empty bars) and anergic (filled bars) T 
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fraction of the cells with DNA content <1N (sub-Gl, apoptotic cells), suggesting 
that anergic T cells were not preferentially dying in our cell culture conditions (see 
below).
To demonstrate that CD3/CD2 8-mediated stimulation could promote cell 
division, we labelled the cells with the fluorescent dye carboxyfluorescein 
succinimidyl ester (CFSE). This dye passively diffuses into the cells, it is retained at 
the cell surface, and segregates equally between daughter cells upon cell division, 
resulting in the sequential halving of cellular fluorescence intensity with each 
successive generation, and allowing one to trace the fate o f single cells by flow- 
cytometry (281). Thus, control and anergic T cells were labelled with CFSE, 
stimulated with Ag/APC or with anti-CD3/CD28 mAbs, and analyzed five days 
later by flow-cytometry. While only control cells divided upon Ag/APC-mediated 
stimulation, both control and anergic T cells completed several cycles o f cell 
division upon CD3/CD28-mediated stimulation (Fig. 5). Interestingly, a comparable 
fraction of control and anergic cells proliferated on immobilized anti-CD3/CD28 
mAbs, despite IL-2 was undetectable in culture supernatants o f anergic T cells 
(refer to Fig. 1).
Altogether these results suggest that optimal cross-linking o f the TCR and of 
the CD28 costimulatory receptor is able to overcome the G1 cell cycle block, and to 
drive anergic T cell proliferation, in an IL-2-independent manner.
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Figure 5. CD3/CD28-mediated stimulation drives comparable proliferation of 
control and anergic T cells. T cell anergy was induced as described in Fig. 1. 
Control (CT) and anergic (AN) T cells were then labeled with the fluorescent dye 
CFSE, and left untreated or stimulated with Ag/APC, or with anti-CD3/CD28 
mAbs for 5 days, and then analyzed by flow cytometry. A) Representative FACS 
histograms reporting the degree of CFSE dilution are shown. B) The graph reports 
the percentage of control and anergic T cells which divided more than once (and 
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3.1.2 CD3/CD28-induced signals drive IL-2 independent cell proliferation
To better define whether anti-CD3/CD28 mAbs could drive G l-to-S 
transition and cell proliferation in the absence of IL-2, we used a T cell line derived 
from DO 11.10 TCR transgenic IL-2 deficient mice (221), and analyzed the ability 
o f these cells to respond to CD3/CD28 stimulation. Wild type and IL-2'^' T cells 
were stimulated with immobilized anti-CD3 and anti-CD28 mAbs for 48 h. 
Thereafter, the cells were harvested and lysed, and protein extracts were analyzed 
by Western blot. Following stimulation, up-regulation of cyclin D3 and of p21^^^, 
and down-regulation of p27^^^ were detected in both wild type and IL-2'^" T cells 
(Fig. 6A), suggesting that optimal TCR/CD28 engagement can normally regulate 
G1 cell cycle proteins in the absence of autocrine IL-2. Interestingly, cyclin D3 up- 
regulation was less pronounced in both anergic (Fig. 2B) and IL-2'^' (Fig. 6A) T 
cells when compared to the control and wild type populations. This could be due to 
the fact that activation of both anergic and IL-2'^" T cells occurs in the absence o f 
IL-2, which has been shown to elicit and sustain cyclin D3 expression (140, 282).
We next asked whether anti-CD3/CD28 mAbs could drive complete cell cycle 
progression and could elicit cell division in the absence of IL-2. To this aim, wild 
type and IL-2'^' T cells were labelled with CFSE, stimulated with immobilized anti- 
CD3/CD28 mAbs, and analyzed by flow cytometry 5 days later (Fig. 6B). As 
control, T cells were stimulated with rIL-2 normally used to propagate this clone in 
culture. Results show that similarly to wild type T cells (not shown), IL-2'^" 
DO 11.10 T cells completed several rounds o f cell division as detected by serial 
CFSE dilution upon either CD3/CD28- and IL-2-mediated stimulation.
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Figure 6. CD3/CD28 engagement drives exit from the G1 phase of the cell cycle, 
and elicits proliferation of IL-2 T cells. A) Wild-type and IL-2' '^ DO 11.10 T 
cells were either left untreated (-) or stimulated with immobilized anti-CD3 and 
anti-CD28 mAbs (0.1 and 5 pg/ml, respectively) for the indicated times. Western 
blot analysis of total cell lysates were then performed with the Abs indicated in the 
figure. p27 '^P and p21^‘P were detected on the same membrane filter by sequential 
hybridization. B) IL-2 /' DO 11.10 T cells were labeled with the fluorescent dye 
CFSE, and either left untreated (thin line) or stimulated with anti-CD3/CD28 
mAbs (CD3/CD28) or sub-optimal anti-CD3 mAb (0.01 pg/ml) and rIL-2 (IL-2) 
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Together these results support the idea that CD3/CD28 can regulate cell cycle 
related events and induce T cell proliferation via IL-2 independent mechanisms.
3.1.3 CD3/CD28-induced T cell proliferation does not restore Ag 
responsiveness
Since IL-2-dependent Gl-to-S transition was previously shown to prevent 
and reverse clonal anergy (263, 266), we next investigated whether proliferation 
induced by anti-CD3/CD28 mAbs could restore antigen responsiveness in anergic T 
cells.
Control and anergic T cells were first allowed to proliferate in response to 
immobilized anti-CD3 and anti-CD28 mAbs or to rIL-2 (“First stimulation”, refer to 
Fig. 7A for a schematic representation of the experiment). Proliferation during this 
time was monitored by CFSE dilution in separate samples (not shown). Thereafter, 
the cells were rested for 10 days, labelled with CFSE and restimulated with 
Ag/APC or rIL-2. CFSE dilution in response to Ag/APC rechallenge was then used 
to compare antigen responsiveness in untreated, CD3/CD28- and IL-2-treated cells. 
As expected, only untreated control cells proliferated in response to Ag/APC, and 
completed up to four rounds of cell division, while untreated anergic T cells did not 
divide in response to Ag/APC (Fig. 7B, left panels). Surprisingly, similar results 
were obtained also with cells allowed to proliferate in response to immobilized anti- 
CD3/CD28 mAbs (Fig. 7B, middle panels). Indeed, only CD3/CD28-stimulated 
control T cells, and not CD3/CD28-stimulated anergic cells, divided in response to 
Ag/APC restimulation (Fig. 7B, middle panels, and Fig. 1C). This indicates that, in
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Figure 7. Proliferation of anergic T cells induced by optimal CD3/CD28 
engagement does not restore antigen-responsiveness. A) Schematic representation 
of the experimental design. T cell anergy was induced as described in Fig. 1. 
Control (CT) and anergic (AN) T cells were then allowed to proliferate in response 
to immobilized anti-CD3/CD28 mAbs for 5 days as described in Fig. 4 , and rested 
for the following 10 days. In parallel, the cells were also stimulated with rIL-2. 
Thereafter control and anergic T cells were labeled with CFSE, and either left 
untreated, or stimulated with Ag/APC or with rIL-2 (IL-2), and analyzed by flow 
cytometry 5 days later. B) Representative FACS histograms reporting the degree of 
CFSE dilution in the absence (thin line) and in the presence (thick line) of 
stimulation are depicted. C) The graph reports the percentage (mean ± SD of three 
independent experiments) of control and anergic cells pretreated as indicated in the 
figure (First stimulation), dividing to secondary rechallenge with Ag/APC (Second 
stimulation).
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spite of completing several rounds of cell division, anergic T cells still fail to 
respond to antigenic rechallenge.
In contrast to anergic T cells which had divided in response to immobilized mAbs, 
anergic T cells allowed to proliferate in response to rIL-2, re-gained, at least in part, 
the ability to respond to Ag/APC (Fig. 7B, right panels and Fig. 7C). The IL-2- 
dependent anergy reversal was detected, although to variable extents, in several 
independent experiments (the average proliferative response to Ag/APC rechallenge 
of rIL-2-treated anergic T cells was 77.81%±36.42% of control cells).
IL-2-driven proliferation not only restored the ability o f anergic T cells to 
proliferate in response to an antigen rechallenge, but also to produce IL-2 (data not 
shown). Thus, while the IL-2 produced by CD3/CD28-stimulated anergic cells 
represented only 2.5% of the IL-2 produced by control cells, the amount of IL-2 
produced by anergic T cells allowed to proliferate in response to rIL-2 was 
87.5%±22.5% of the amount produced by control T cells. By contrast, IL-2 was 
never detected upon restimulation of anergic T cells allowed to proliferate on 
immobilized anti-CD3/CD28 mAbs (not shown).
Finally, all the cells proliferated to similar extents in response to rIL-2 (dotted lines 
in Fig. 7B) indicating that untreated and CD3/CD28-stimulated anergic cells were 
viable in our cultures, but specifically unable to respond to Ag/APC.
In spite o f several rounds of cell division, the total number of viable cells 
recovered from the cultures of CD3/CD28-stimulated control and anergic T cells 
was only 100-200% of the one recovered from the untreated population. To exclude 
the possibility that CD3/CD28-activated anergic T cells could die shortly after 
activation, and that an unresponsive population could be selected by this
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stimulation, cell survival was monitored by flow cytometry over time in two 
independent sets of experiments.
In the first set of experiments, control and anergic T cells were labelled with 
CFSE, stimulated with anti-CD3/CD28 mAbs or rIL-2, and then stained with the 
fluorescent dye TO-PRO-3 at the time of the flow cytometric analysis (Fig. 8). This 
dye has been previously used to identify viable and dead cells in each pool of 
divided cells (283). Although a higher fraction of TO-PRO-3^ cells was detected in 
CD3/CD28 stimulated cells when compared to IL-2-stimulated cells (-30%  and 
-2%  respectively), the fraction of TO-PRO-3^ cells was similar in CD3/CD28- 
stimulated control and anergic cells (30.52% and 20.24%, respectively). This 
indicated that the majority of the cells that proliferated in response to immobilized 
mAbs were viable at the end of the culture, and that there was no preferential loss of 
proliferating cells over non-responding cells.
In a second set of experiments, control and anergic T cells were labelled with 
CFSE, rested in fresh medium or allowed to proliferate on immobilized anti- 
CD3/CD28 mAbs, and then restimulated with either Ag/APC or with rIL-2 (Fig. 9). 
A further dilution of the CFSE content during the second stimulation would 
measure antigen responsiveness o f cells that proliferated during the first 
stimulation. As shown above (Fig. 7), while control cells proliferated to Ag/APC 
and to rIL-2, anergic T cells failed to respond to Ag/APC and instead proliferated to 
rIL-2 (Fig. 9, left panels). As also shown above, while both control and anergic T 
cells proliferated in response to CD3/CD28 during the first stimulation (Fig. 9, right 
panels, thin lines), only control cells, and not anergic cells further diluted their 
CFSE contents upon Ag/APC restimulation (right panels, thick lines). By contrast
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Figure 8. Survival of control and anergic T cells undergoing CD3/CD28-induced 
stimulation, T cell anergy was induced as described in Fig. 1. Thereafter control 
(CT) and anergic (AN) cells were labeled with CFSE, and then, either left 
untreated, or allowed to proliferate in response to immobilized anti-CD3/CD28 
mAbs (CD3/CD28) or rIL-2 (IL-2) for 5 days. Right before the analysis, TO- 
PRO-3 was added to each sample. Representative dot plots reporting the degree of 
CFSE dilution (proliferation) and TO-PRO-3 staining (cell death) are depicted. 
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Figure 9. Control, but not anergic T cells expanded to CD3/CD28, further 
proliferate upon Ag re-encounter. T cell anergy was induced as described in Fig. 1. 
Control (CT) and anergic (AN) T cells were labeled with CFSE, and cultured for 5 
days in fresh medium (left panels), or on anti-CD3/CD28 mAbs-coated plates 
(CD3/CD28, right panels). Thereafter the cells were rested for 10 days, and either 
left untreated (thin lines), re-stimulated with Ag/APC (thick lines) or with rIL-2 
(dotted lines). Representative FACS histograms of one out of two similar 
experiments (performed with duplicates) are reported in the figure. The overlays 
demonstrate that the cells, which proliferated during the first stimulation, are still 
able to divide upon rechallenge, as indicated by further dilution of their CFSE 
content.














all the cells further diluted their CFSE content in response to rIL-2 (right panels, 
dashed lines), supporting the idea that anergic T cells, which proliferated to 
CD3/CD28, remain viable and able to respond to rIL-2, but incapable of responding 
to Ag/APC.
Together these results indicate that antigen unresponsiveness can be 
maintained in spite o f several rounds o f cell division, demonstrating that 
proliferation per se is not sufficient to reverse clonal anergy, and that instead anergy 
reversal specifically requires an IL-2-generated signal.
3.1.4 IL-2-induced mTor-dependent signalling, and not IL-2-induced T cell 
proliferation, regulates CD4^ T cell antigen responsiveness
Previous findings and our own data indicate that IL-2-generated signals are 
important in preventing the induction of T cell anergy (263, 266, 284), and in 
restoring antigen responsiveness in already anergized T cells (Fig. 7). It has been 
shown that the ability o f IL-2 to prevent the induction of T cell anergy was 
completely prevented by the addition of the immunosuppressive agent Rapamycin 
(265). This drug blocks the function o f the serine/threonine kinase mTor (the 
mammalian target o f Rapamycin), which is considered a central controller o f cell 
growth since it regulates translational activity of the cell in response to nutrients and 
mitogens levels (206). We therefore investigated whether Rapamycin, beside its 
role in anergy induction, would also prevent the ability o f IL-2 to reverse clonal 
anergy. Control and anergic T cells were thus labelled with CFSE, and either left 
untreated or stimulated with IL-2, in the absence or in the presence o f Rapamycin
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(200 nM) for 15 days (refer to Fig.lOA for the experimental plan). Thereafter the 
cells were collected, washed and either left untreated or restimulated for 5 days with 
Ag/APC s. We first analyzed the ability o f Rapamycin to block IL-2-driven 
proliferation. While Rapamycin partially blocked control T cell division in the first 
5 days of culture (Fig. lOB, left panels), no differences between IL-2- and IL- 
2+Rapamyein-treated cells could be observed after 20 days o f culture (Fig. I OB, 
right panels). The same result was obtained with anergic T cells (Fig. lOB). The 
failure of Rapamycin to block T cell proliferation was not due to drug inactivation, 
since the same effect was observed when Rapamycin was added to the culture every 
day (data not shown). Even though the inefficacy of Rapamycin to prevent cell 
cycle progression was initially surprising, this result is consistent with the 
possibility that Rapamycin does not completely prevent, but only delays, entry into 
the cell cycle (285).
We then compared the ability o f untreated, IL-2 and IL-2+Rapamycin- 
treated cells to respond to antigen rechallenge. As shown above (Fig. 7), while the 
vast majority o f untreated control T cells proliferated in response to Ag/APC, only a 
fraction of the anergic T cell population responded to the antigenic stimulation (Fig. 
IOC, left panels). As also shown above (Fig. 7), antigen unresponsiveness was lost 
upon IL-2-driven cell proliferation. Indeed, both control and anergic T cells 
stimulated for 20 days in IL-2 responded to a similar extent to Ag/APC (Fig. IOC, 
middle panels). By contrast, anergic T cells stimulated with IL-2 in the presence o f 
Rapamycin failed to further dilute their CFSE content upon Ag/APC rechallenge 
(Fig. IOC, right panels). This indicates that, while Rapamycin does not block T cell 
proliferation, it completely prevents IL-2 mediated reversal of clonal anergy. Thus,
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Figure 10. Rapamycin prevents IL-2-mediated reversal of clonal anergy, and not 
IL-2 driven proliferation. T cell anergy was induced as described in Fig. 1. A) 
Schematic representation of the experimental design. B) CFSE-labeled control (CT) 
and anergic (AN) T cells were either left untreated (thin lines) or stimulated with 
rIL-2 in the absence (IL-2, thick lines) or in the presence of Rapamycin (200 nM) 
(IL-2+Rap, dotted line). Cell proliferation was determined by flow cytometry after 
5 (left panels) and 20 days (right panels). Representative histograms are shown. C) 
CFSE-labeled untreated (medium), and IL-2 or IL-2+Rapamycin-treated cells were 
left unstimulated (untreated; thin line), stimulated with Ag/APC (thick line), or with 
rIL-2 (dotted line) for 5 days. Representative FACS histograms reporting CFSE 
content are shown (top, middle panel: the CFSE profile obtained with rIL-2 is 
underneath the profile elicited by Ag/APC). The overlays demonstrate further 
dilution of CFSE content upon secondary stimulation. A representative experiment 
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altogether our results indicate that IL-2-induced mTor signalling, independently of 
IL-2-driven proliferation, is absolutely required to reverse clonal anergy and thus to 
regulate lymphocyte responsiveness.
3.1.5 CD3/CD28-induced T cell proliferation involves mTor-dependent 
signalling
In addition to IL-2, also CD28 elicits mTor-dependent signalling pathways. 
Indeed, it has been shown that Rapamycin blocks CD28-dependent phosphorylation 
of p70^^^ (107) and 4EBP-1 (108). Thus we sought o f investigating whether 
CD3/CD28 could activate mTor in anergic T cells, and whether functional 
differences between CD3/CD28- and IL-2/IL-2R-generated signals might explain 
the different functional outcome elicited by these stimuli.
First we investigated whether CD3/CD28-induced T cell proliferation was sensitive 
to Rapamycin inhibition. To this aim, CFSE-labelled control and anergic A.E7 T 
cells were stimulated for 5 days with immobilized anti-CD3 and anti-CD28 mAbs, 
in the absence (Fig. 11, left panels) or in the presence (Fig. 11, right panels) o f 
Rapamycin. Proliferation of both control and anergic T cells was inhibited by the 
presence of Rapamycin. Even though control cells produced IL-2, the amounts were 
not sufficient to drive Rapamycin-insensitive proliferation (see section 3.3). This 
supports the idea that CD3/CD28 can induce IL-2 independent cell proliferation, 
and that to do so it requires proper mTor-dependent signalling.
To further investigate this possibility, similar experiments were performed 
with wild type DOl 1.10 and IL-2’^ ' T cell clones. To this aim the cells were labelled
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Figure 11. CD3/CD28 stimulation relies on mTor activity to drive IL-2- 
independent T cell proliferation. A) Control (CT) and anergic (AN) A.E7 cells, 
DOl 1.10 IL-2-/-, and DOl 1.10 wt cells were labeled with CFSE, and either left 
untreated or stimulated with anti-CD3/CD28 mAbs in the absence or in the 
presence of Rapamycin (Rap) (200 nM) for 5 days, and then analyzed by flow 
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with CFSE, and stimulated for 5 days with immobilized anti-CD3 and anti-CD28 
mAbs, in the absence (Fig. 11, left panels) or in the presence (Fig. 11, right panels) 
of Rapamycin. While Rapamycin-insensitive CD3-CD28-initiated proliferation was 
observed in IL-2 sufficient DOl 1.10, it was completely absent in IL-2 deficient 
cells.
Together these results indicate that CD3/CD28-mediated stimulation, in 
functionally (anergic) or genetically (IL-2'^') IL-2-defieient T cells, drives T cell 
proliferation in a Rapamycin sensitive manner, thus involving mTor in TCR/CD28- 
induced intracellular signalling pathways
3.1.6 CD3/CD28-induced signals fail to restore Ag responsiveness even in the 
presence of Cyclosporin A
The observation that CD3/CD28-mediated proliferation was sensitive to 
Rapamycin, indicated that either the TCR or CD28 elicited mTor activation. 
However, CD3/CD28 stimulation failed to restore Ag responsiveness. Thus, while 
IL-2-indueed mTor activation restored Ag responsiveness, CD3/CD28-induced 
mTor activation did not. Thus, we investigated the reasons for the failure of 
CD3/CD28-mediated stimulation to reverse clonal anergy.
First we investigated the possibility that the failure o f CD3/CD2 8 -mediated 
stimulation to reverse clonal anergy could be attributed to chronic engagement of 
the TCR by the immobilized anti-CD3 mAb. Indeed, this was previously 
hypothesized to induce the continuous production o f a putative anergic factor, 
possibly able to maintain the anergic phenotype. Since the addition o f Cyclosporin
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A, at the time of TCR stimulation, ean inhibit CD3-induced T cell anergy (233, 236, 
252), we asked whether the addition of Cyclosporin A to CD3/CD28-stimulated 
anergic cells would allow anergy reversal. In a preliminary experiment we verified 
the ability o f Cyclosporin A to prevent CD3-induced T cell anergy (Fig. 12). To this 
aim, we stimulated A.E7 T cells with immobilized anti-CD3 mAb for 16 hours (see 
“anergy induction” in Fig. 1), in the absence or in the presence o f Cyclosporin A 
(0.5 pg/ml). Thereafter the cells were rested in fresh medium for 5 days, labelled 
with CFSE, and restimulated for 5 days with Ag/APC or with rIL-2. A fraction of 
the cells was similarly treated with the exception of the initial CD3 stimulation. At 
the end of the restimulation, the CFSE content was determined by flow cytometry. 
As expected, while control cells proliferated in response to antigen stimulation 
(Fig. 12, upper panel), CD3-treated cells failed to do so (Fig. 12, middle panel). In 
contrast, cells stimulated with anti-CD3 mAh in the presence of Cyclosporin A, did 
proliferate to the antigen (Fig. 12, lower panel), indicating that, also in our hands. 
Cyclosporin A actively prevents the induction of clonal anergy.
We thus asked whether addition of Cyclosporin A during CD3/CD28- 
mediated restimulation of anergic cells, would allow the reversal o f clonal anergy 
(Fig. 13). Control and anergic A.E7 T cells were either left untreated (medium in 
the figure), or stimulated for 5 days with immobilized anti-CD3/CD28 mAbs, rIL-2, 
in the absence or in the presence of Cyclosporin A, or Rapamycin. The cells were 
then rested for 10 days, labelled with CFSE, and restimulated with Ag/APC, or with 
rIL-2 to determine their functional responsiveness. While untreated and CD3/CD28- 
stimulated control cells proliferated in response to the antigen, untreated and 
CD3/CD28-stimulated anergic cells failed to do so (Fig. 13, upper panels), as also
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Figure 12. Cyclosporin A prevents CD3-induced T cell anergy. A.E7 cells were 
either left untreated or stimulated with anti-CD3 mAh (a-CD3), in the absence or 
in the presence of Cyclosporin A (CsA) (0.5 pg/ml). After 16h the cells were 
removed from the Ab, and rested for an additional 5 days. Thereafter, the cells 
were labeled with CFSE, restimulated with Ag/APC or rIL-2, as indicated at the 
bottom of the figure, and analyzed by flow cytometiy. Representative FACS 
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Figure 13. CD3/CD28 stimulation fails to restore Ag responsiveness even in the 
presence of Cyclosporin A. A.E7 cells were either left untreated (CT) or induced 
into anergy (AN) as described in Fig.l. The cells were cultured for an additional 5 
days with medium only, with anti-CD3/CD28 mAbs, or with rIL-2, in the absence 
or in the presence of either CsA (0.5pg/ml), or Rapamycin (Rap) (200nM) (First 
stimulation). Thereafter, the cells were rested for 10 days in fresh medium, then 
labeled with CFSE and re-stimulated with Ag/APC, or with rIL-2 (Second 
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shown above (Fig. 7). Similarly to CD3/CD28-stimulated anergic cells, also the 
cells stimulated with CD3/CD28 in the presence of Cyclosporin A failed to respond 
to Ag restimulation, suggesting that the presence of Cyclosporin A did not allow 
CD3/CD28-dependent signalling to restore antigen responsiveness. As expected, 
IL-2 stimulated anergic T cells re-acquired the ability to proliferate in response to 
Ag stimulation, and this was insensitive to the presence of Cyclosporin A, but 
sensitive to Rapamycin (Fig. 13, last panels).
Altogether these results demonstrate that mTor activation by CD3/CD28- 
mediated signals is not sufficient to induce reversal of clonal anergy, and that this 
event specifically requires IL-2/IL-2R-induced mTor activation.
3.1.7 The engagement of CD3/CD28 elicits Rapamycin-sensitive p70^ *^^  
phosphorylation in control, but not in anergic T cells
Starting from the observation that both CD3/CD28 and IL-2 stimulations 
induced a Rapamycin sensitive proliferation, but only IL-2 restored antigen 
responsiveness, we asked whether TCR/CD28 and IL-2R could differentially 
regulate mTor functions. To address this question, we investigated the 
phosphorylation/activation status of the mTor target p70^^^.
A.E7 cells were either left untreated or stimulated with immobilized anti- 
CD3/CD28 mAbs or with rIL-2 for 30 min (Fig. 14). Thereafter the cells were 
lysed, and equal protein amounts were separated on SDS-PAGE, and analyzed by 
Western blot using an anti-p70^^^ Ab. Both CD3/CD28 and IL-2 stimulations 
induced a shift in the molecular weight o f p70^^^, revealed by a retarded
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Figure 14. CD3/CD28 and IL-2-mediated stimulations induce 
phosphorylation. A.E7 cells were either left untreated (-) or stimulated with anti- 
CD3/CD28 mAbs (3/28) or rIL-2 (IL-2) for 30 min. The cells were then lysed, 
and the protein extracts were analyzed by Western blot with anti-p70^^  ^ Ab. 
Where indicated, the extracts were treated with alkalin phosphatase (AP) before 
the electrophoretic separation.
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electrophoretic mobility o f the protein. This shift was previously reported to 
correlate with p70^^^ phosphorylation in multiple Ser and Thr sites (286). 
Accordingly, when the extracts were treated with alkalin phosphatase (AP), the 
mobility of the protein was comparable in untreated and stimulated cells. Thus, as 
previously reported (107), also in A.E7 cells CD3/CD28 engagement results in 
p 7 0 S6 k phosphorylation.
We next investigated whether, also in anergic T cells, CD3/CD28 and IL- 
2/IL-2R could drive p70^^^ phosphorylation. To this aim, control and anergic T cells 
were stimulated, and p70^^^ phosphorylation was analyzed by Western blot (Fig. 
15A). As described before, while both CD3/CD28 and IL-2 stimulations induced a 
shift in the electrophoretic mobility of p70^^^ in control cells, only IL-2, and not 
CD3/CD28, did so in anergic T cells. Indeed, in these cells, CD3/CD28 stimulation 
induced only a partial shift in the electrophoretic mobility o f the protein. As 
expected, in all stimulation conditions, the addition of Rapamycin at the time of 
stimulation reduced the electrophoretic mobility of p70^^^ to the one observed in 
unstimulated cells (Fig. 15B). This indicates that mTor signalling is required in both 
CD3/CD28- and IL-2- driven p70^ '^  ^phosphorylation.
3.1.8 CD3/CD28 stimulation fails to elicit proper Thr^ ^^  phosphorylation and 
post-translational modifications of p70^ "^^  in anergic cells
Phosphorylation of the threonine in position 389 was previously shown to be 
absolutely required for proper activation of p70^^^ (287). Thus, we analyzed protein 
extracts derived from untreated and stimulated control and anergic cells by Western
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Figure 15. CD3/CD28 and IL-2 stimulations differentially regulate in
anergic cells. Control (CT) and anergic (AN) cells were either left untreated, or 
stimulated for 30 min with anti-CD3/CD28 mAbs (3/28), or with rIL-2, in the 
absence (A) or in the presence (B) or Rapamycin (+Rap) (IpM). The cells were 
then lysed, and the protein extracts were analyzed by Western blot with anti- 
p7QS6k Ab.
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blot with an Ab specific for the phospho-Thr^^^(pThr^^^)-p70^^^ (Fig. 16). The 
results obtained show that, while both CD3/CD28 and IL-2 elicited the appearance 
o f pThr^^ -^pTO^^*  ^ in control cells, only IL-2 did so in anergic cells. Indeed, 
CD3/CD28 stimulation of anergic cells failed to elicit significant phosphorylation of 
this residue. As expected from previous findings (288), in all stimulation conditions, 
the addition of Rapamycin completely abrogated Thr^^  ^phosphorylation (data not 
shown).
In addition to Thr^^^, optimal activation of p70^^^ involves the ordered 
phosphorylation o f several residues, which are positioned within distinct 
intramolecular regulatory domains of the protein. To study in further details the 
nature o f p70^^^ post-translational modifications under different stimulation 
conditions, we analyzed protein extracts o f control and anergic T cells by two- 
dimensional electrophoresis (2DE) (Fig. 17-20). This technique allows to resolve 
proteins in a gel on the basis of both their isoelectric points (pi) and their molecular 
weight (MW), and by that it allows the discrimination of protein variants, deriving 
from different post-translational modifications, such as phosphorylation (289). 
Briefly, untreated and stimulated cells were lysed, and the proteins (400 |Lig) were 
separated on SDS-PAGE. Proteins with an apparent molecular weight o f 60-80 kDa 
were then eluted from the gel, acetone precipitated and resolved by 2DE (see 
Materials and Methods). The proteins were then transferred to nitrocellulose 
membrane, which were developed with an anti-p70^^^ Ab, and analyzed by Image 
Master 2D Elite analysis software. First we analyzed protein extracts from 
unstimulated control A.E7 cells (Fig. 17). The signal corresponding to p70^^^ 
appeared as a train of spots (pi ranging between 5.67 and 6.06 pH values), each of
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Figure 16. CD3/CD28 stimulation fails to elicit p70^ '^^ -Thr^ ^^  phosphorylation in 
anergic cells. A) Control (CT) and anergic (AN) cells were either left untreated, or 
stimulated for 30 min with anti-CD3/CD28 mAbs (3/28), or with rIL-2. The cells 
were then lysed, and protein extracts were analyzed by Western blot with anti- 
phospho ThE^^“p70^^  ^Ab (p- p70^ '^^ ). The filter was then stripped and re-probed with 
anti-actin Ab. Densitometric analysis was performed and the graph in panel B 
reports the relative optical density (OD) of phosphoThr^^ -^p70^^*  ^ specific bands 
normalized to the OD of actin on the same lanes.
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Figure 17. Rapamycin-sensitive phosphorylation of p70^^  ^in resting A.E7 T cells. 
A.E7 T cells were either left untreated (CT), or treated for 30 min with Rapamycin 
(IpM) (CT+Rap). The cells were then lysed, and the protein extracts were separated 
by SDS-PAGE. The proteins with an apparent molecular weight of 60-80 kDa were 
eluted from the gel, and resolved by 2D-PAGE, shown in the figure, by using an 
anti-p70^ '^  ^Ab (see Materials and Methods). Where indicated, cell extracts were 
treated with the alkalin phosphatase (CT+AP). 2D maps were analyzed by Image 
Master 2D Elite analysis software. Densitometric graphs are reported: the values on 
the X axis indicate the relative pixel position, expressed in arbitrary units, while the 
values on the Y axis indicate the optical density (OD) units. The pi range of the spots 

















them corresponding to a differentially modified protein variant (Fig. 17, upper 
panel). Treatment of the extracts with AP reduced the number of p70^^^ specific 
spots and revealed a more basic pi (pi range: 5.84-6.25). A similar picture was 
obtained when proteins were derived from control cells treated for 30 min with 
Rapamycin. When compared to the two-dimensional (2-D) maps obtained from 
control extracts, 2-D maps obtained from Rapamycin-treated cells showed a 
reduced number of p70^^^ specific spots with a lower pi (pi range: 5.79-5.98) (Fig. 
17, lower panel). These data demonstrate that, in the absence of stimulation, the 
electrophoretic profile of p70^^^ is consistent with constitutive phosphorylation of 
the protein (responsible for its acidification), which is controlled, at least in part, by 
mTor-dependent activity.
We thus compared, by 2-D analysis, protein extracts derived from control and 
anergic cell. The cells were either left untreated, or stimulated with CD3/CD28 or 
rIL-2, lysed and analyzed as described above (Fig. 18). When compared to 
untreated cells (CT), both CD3/CD28 and IL-2 stimulations resulted in an acidic pi 
shift of p70^^^ specific spots in control cells (Fig. 18, upper panels). Even though 
the p70^^"  ^ specific spots pi range was comparable in CD3/CD28 and IL- 
2-stimulated extracts (pi range for CD3/CD28: 5.72-5.87; pi range for IL-2: 5.64- 
5.89), densitometric analyses revealed that IL-2 stimulation induced a preferential 
accumulation of p70^^^ specific spots towards the more acidic pH values (refer to 
the densitometric graphs on top of each 2-D map). The addition of Rapamycin at the 
time of stimulation inhibited acidification o f p70^^\ and instead rendered the 
protein even more basic (pi range: 5.80-5.98) (Fig. 19). These data indicates that 
both CD3/CD28 and IL-2 stimulations of control cells elicit an overall acidification
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Figure 18. 2D analysis of post-translational modifications of Control (CT)
and anergic (AN) cells were either left untreated, or stimulated with anti- 
CD3/CD28 mAbs (CD3/CD28) or with rIL-2 for 30 min. Thereafter protein 
extracts were prepared as described in Fig. 17, and 2D-PAGE analysis was 
performed by using an anti-pTO^ *^^  Ab. 2D maps were analyzed by Image Master 2D 
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Figure 19. Rapamycin prevents post-translational modifications of p70^ ^  ^ in 
control T cells. Control (CT) cells were either left untreated, or stimulated with 
anti-CD3/CD28 mAbs (CD3/CD28), in the absence or in the presence of 
Rapamycin (1 |liM) (+Rap) for 30 min. Thereafter protein extracts were prepared 
as described in Fig. 17, and 2D-PAGE analysis was performed by using an anti- 
p7 QS6k 2D maps were analyzed by Image Master 2D Elite analysis software. 
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of p70^^\ which most likely reflect a number of phosphorylation events (see 
below), which require intact mTor- signalling capabilities.
We next analyzed p70^^^ electrophoretic profile in anergic cells (Fig. 18, 
lower panels). The distribution pattern o f p70^^^ specific spots in unstimulated 
anergic cells (pi range: 5.68-6.04) was similar to that obtained in untreated control 
cells (pi range: 5.67-6.06). In anergic cells, the more basic spots were more 
abundant than in control cells, suggesting that in these cells p70^^^ may be 
hypophosphorylated. Upon CD3/CD28 stimulation, no significant acidification of 
p70^^^ was detected in anergic cells (pi range: 5.68-6.18), and instead some of the 
more acidic spots detectable in the unstimulated counterparts were lost. Thus, while 
CD3/CD28 elicited p70^^^ acidification in control cells, it failed to do so in anergic 
cells. In these cells, instead, IL-2 stimulation induced a clear acidic pi shift of 
p 7 0 S6 k specific spots (pi range: 5.62 -5.88), which resulted comparable to the one 
obtained in control cells. Addition of Rapamycin to anergic cells at the time of 
stimulation (Fig. 20), similarly to control cells, induced a basic shift in the p70^^^ pi 
(pi range: 5.79-6.05), compared to untreated cells. Together these data support the 
possibility that, while IL-2-mediated signals drive acidification, probably due to 
phosphorylation, of p70^^\ CD3/CD28-mediated signals fail to properly induce this 
kind of post-translational modification in the protein.
Altogether the results reported in sections 3.1 and 3.2 indicate that mTor- 
signals are involved in both T cell proliferation and in T cell antigen 
responsiveness, and that the inability of CD3/CD28 to reverse clonal anergy, in 
spite of driving mTor-dependent T cell proliferation, could be correlated with its 
inability to properly activate p70^^^.
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Figure 20. Rapamycin prevents post-translational modifications of pyO^ *^^  in 
anergic T cells. Anergic (AN) cells were either left untreated, or stimulated with 
anti-CD3/CD28 mAbs (CD3/CD28), in the absence or in the presence of 
Rapamycin (+Rap) (1 pM) for 30 min. Thereafter protein extracts were prepared as 
described in Fig. 17, and 2D-PAGE analysis was performed by using an anti- 
p7 QS6k Ab. 2D maps were analyzed by Image Master 2D Elite analysis software. 
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3.2 mTor and PI3K-dependent signals synergize to drive CD4^ T cell 
proliferation
3.2.1 lL-2-driven T cell proliferation is only delayed, and not inhibited, by 
Rapamycin
The observation that T cell expansion was still detected in the presence of 
Rapamycin challenged the original idea that Rapamycin inhibits T cell responses by 
blocking T cell proliferation. To better investigate the ability o f Rapamycin to 
regulate cell cycle progression in T cells, we labelled A.E7 T cells with CFSE and 
analyzed lL-2-induced T cell proliferation in the presence or in the absence of 
Rapamycin at different times (Fig. 21). After 3 days of stimulation, control cells had 
already performed two-three division cycles. In contrast, in the presence o f 
Rapamycin, the cells failed to divide at this time (Fig. 21, upper panels). After 4 
days of culture, control cells had completed another 2 rounds of cell division. At 
this time, the cells stimulated in the presence of Rapamycin started to divide (Fig. 
21, middle panels) and by day 10 they showed a CFSE profile indistinguishable 
from that of control cells (Fig. 21, lower panels).
Increasing the concentration of Rapamycin, or providing the drug to the cells every 
day, did not prevent T cell expansion (data not shown), meaning that the failure of 
the drug to block cell cycle progression was not due to drug inactivation. These 
results suggest that, rather than inhibiting T cell proliferation, Rapamycin might 
only delay cell cycle entry. Once performed the first G l/S transition, Rapamycin-
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Figure 21. Rapamycin delays, but does not inhibit, T cell division. Control A.E7 
cells were labeled with the fluorescent dye CFSE, and either left untreated, or 
stimulated with rIL-2 (10 lU/ml) in the absence (IL-2; left panels) or in presence of 
Rapamycin (200 nM) (IL-2+Rap; right panels) for the indicated days and then 
analyzed by flow cytometry. Representative FACS histograms reporting the degree 
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Figure 21
treated eells eould then be able to progress into the eell eyele and to divide as mueh 
as untreated cells. These findings are consistent with previously published 
observations demonstrating that Rapamycin induced a prolongation of the G1 phase 
of the cell cycle in mitogen stimulated T lymphocytes (285).
3.2.2 mTor-dependent signalling is required when IL-2 is limiting
We next investigated whether Rapamycin insensitive T eell expansion eould 
be observed also in the presence of limiting amounts o f IL-2. To this aim, CFSE- 
labelled A.E7 eells were stimulated for 5 days with different doses o f IL-2 in the 
absence or in the presence of Rapamycin (Fig. 22). The percentage of dividing eells 
and the number of eell cycles performed by the T cell population varied depending 
on the dose of lL-2 in culture (Fig. 22, left panels). At the lowest dose of IL-2 tested 
(0.4 lU/ml), the percentage of dividing cells was about 20%, and increased to 70% 
and almost to 100% in the presence of 2 lU/ml and 10 lU/ml of IL-2, respectively. 
In addition, while at the lowest dose of IL-2 the eells performed only one division 
eyele, in the presence of 2 lU/ml and 10 lU/ml of IL-2, the eells performed two and 
more than four eell cycles, respectively.
In the presence of Rapamycin (Fig. 22, right panels), no cell division was observed 
at 0.4 lU/ml of IL-2. At 2 lU/ml, 50% of the eells failed to enter the cell eyele and 
the remaining 50% completed only one division eyele. At 10 lU/ml o f IL-2, only 
10% of the eells were still undivided, and the dividing eells had performed a 
number of eell cycles comparable to the one observed in cells stimulated in the 
absence of Rapamycin.
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Figure 22. Rapamycin inhibits IL-2-mediated proliferation only at low doses of IL-2. 
Control A.E7 cells were labeled with the fluorescent dye CFSE, and either left 
untreated or stimulated with the indicated amounts of rIL-2 (indicated beside the 
panels) in the absence (IL-2; left panels) or in presence of Rapamycin (200 nM) (IL- 
2+Rap; right panels) for 5 days, and then analyzed by flow cytometry. 
Representative FACS histograms reporting the degree of CFSE dilution are shown. 
The percentages of dividing cells is reported.
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These results indicate that, while mTor-induced signalling is required in the 
presence of limiting amounts o f IL-2, it is dispensable at saturating concentration of 
IL-2. In this latter situation, mTor-independent IL-2-dependent signalling pathways 
driving cell cycle progression are induced, and allow Rapamycin insensitive T cell 
proliferation.
lL-2-driven T cell proliferation has been previously shown to involve P13K 
activity (89). To investigate the role of P13K in our model, we stimulated CFSE- 
labelled A.B7 T cells for 5 days with rIL-2 (10 lU/ml) in the absence or in the 
presence of the PI3K inhibitor LY 294002 (LY), Rapamycin, or a combination of 
the two drugs (Fig. 23). As shown above (Fig. 21, 22), the CFSE profiles of 
untreated and Rapamycin- treated cells after 5 days of culture were very similar. In 
contrast, inhibition of P13K activity by LY treatment, almost completely inhibited 
lL-2-driven T cell proliferation. The residual proliferation observed with LY 
treatment was completely inhibited by the addition o f Rapamycin (Fig. 23, last 
panel). These data indicate that, at high doses of lL-2, T cell proliferation is mostly 
driven by PDK-dependent, mT or-independent signalling. The observation that the 
combination of Rapamycin and LY is more potent in blocking lL-2-mediated T cell 
proliferation, than either o f the two drugs alone, suggests that an mTor-dependent 
signal, activated independently of PI3K, is also required for cell cycle progression.
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Figure 23. PI3K and mTor signals synergize to drive optimal IL-2-induced T cell 
proliferation. Control A.E7 cells were labeled with the fluorescent dye CFSE, and 
either left untreated, or stimulated with rIL-2 (10 lU/ml), in the absence or in the 
presence of Rapamycin (200 nM) (IL-2+Rap), LY294002 (20 mM) (IL-2+LY), or 
the combination of the two drugs (IL-2+Rap+LY) for 5 days, and then analyzed by 






















3.3 mTor-dependent signals are required for T cell differentiation
The results obtained with A.E7 T cell clones indicated that mTor-dependent 
signals were critically required by CD3/CD28 to induce T cell proliferation, and by 
IL-2/IL-2R to maintain and restore antigen responsiveness.
To further analyze the role o f mTor during T cell responses, we investigated the 
effect o f Rapamycin on Ag-driven proliferation and differentiation of naïve CD4^ 
and CD 8  ^T cells. As model antigens, we used the chicken ovalbumin-derived class 
II and class I-restricted peptides, OVAP3 2 3 . 3 3 9  and OVAP 2 5 7 - 2 6 4  (referred to as 
“Ag”), respectively recognized in the context of lA^ and K^, by TCR Tg T cells of 
D O ll.lO , and OT-I mice (270, 271).
3.3.1 mTor signalling is dispensable for Ag-driven T cell proliferation
To analyze the effect o f Rapamycin on naïve T cell proliferation, LN cells 
derived from DO 11.10 TCR Tg mice were labelled with the fluorescent dye CFSE 
(281), stimulated with Ag and irradiated syngeneic splenocytes in the absence or in 
the presence of Rapamycin (200 nM), and analyzed by flow cytometry after 3 and 7 
days of culture. By 72 hours of stimulation (day 3), most o f the CD4^ T cells 
acquired an activated phenotype (CD69^*^^, CD44*^‘^ ^) in both control and 
Rapamycin-treated cultures (not shown). At this time, however, while Ag-driven 
stimulation of CD4^ T cells induced a fraction of the cells to complete up to three 
cell divisions, most of the cells derived from the Ag+Rapamycin treated cultures 
remained undivided (Fig. 24A, left panels). In contrast, by seven days of culture, the
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Figure 24. Rapamycin delays, but does not inhibit antigen-driven naïve T cell 
proliferation. A, C) CFSE-labeled DOll.lO LN cells were cultured with Ag and 
irradiated syngeneic splenocytes, in the absence (Ag), or in the presence of 
Rapamycin (100 nM) (Ag+Rap), and in the presence of Rapamycin and rIL-2 (10 
lU/ml) (Ag+Rap+IL-2). After 3 (A; left panel, and C) and 7 (A; right panel) days, the 
cultures were harvested, and analyzed by flow cytometiy following staining with anti- 
CD4 mAh. The histograms in A and C were obtained after gating on CD4+/CFSE+ 
cells. B) DOll.lO LN cells were stimulated with Ag and irradiated syngeneic 
splenocytes (Ag), or with anti-CD3/CD28 mAbs (CD3/CD28), in the absence (-) or in 
the presence of Rapamycin (100 nM) (+Rap). Twenty-fours hours after stimulation, 
culture supernatants were recovered and IL-2 was measured by capture ELISA. Data 
± SD of triplicate cultures are indicated.
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CFSE profile of control and Rapamycin-treated cells was mostly indistinguishable 
(the average number o f cell divisions in the absence and in the presence of 
Rapamyein, calculated over 7 independent experiments, was 7.5 ± 1.1 and 5.9 ± 1.1, 
respectively) (Fig. 24A, right panels). Thus, Rapamyein failed to prevent Ag-driven 
T cell proliferation. Even though this finding seems to contradict previously 
reported results, it should be noted that most o f the previous studies measured 
proliferation by [^H]-Thymidine incorporation 72 hours following Ag stimulation. 
In our own experiments Rapamyein prevented T cell proliferation at this time by 
either CFSE-dilution (Fig. 24A), or by [^H]-Thymidine incorporation (140,842 ± 
17,077 cpm and 40,516 ± 6,498 epm, control and Rapamyein-treated cultures, 
respectively), but failed to do so at later times (Fig. 24A). Repeated additions of 
Rapamyein did not prevent T cell division (not shown), suggesting that inactivation 
of the drug could not account for its failure to block T cell expansion. Moreover, 
even though Rapamyein reprodueibly inhibited IL-2 secretion (Fig. 24B), the 
addition of exogenous rIL-2 failed to restore Ag-driven T cell expansion (Fig. 
24C^L
Thus, our results are consistent with the possibility that Rapamyein only 
delays cell cycle entry (285), and indicate that, as shown for T cell clones, also 
naïve CD4^ T cells are capable of mTor-independent T cell expansion.
3.3.2 Rapamyein inhibits Ag-driven Thl and T el T cell polarization
Preliminary experiments indicated that Ag-driven T cell activation o f 
DO 11.10 T cells in our culture conditions favoured differentiation o f the CD4^ T
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cell population into IFN-y-producing cells (Thl). Thus, after a week in culture, a 
fraction of DO 11.10 T cells showed to be able to produce IFN-y, and in some 
experiments also lL-4, upon restimulation with PMA and lonomyein. Thus, we set 
to investigate whether Rapamyein could have an effect on T cell differentiation 
(Fig. 25). To this aim, LN cells from D O ll.lO  mice were labelled with CFSE, 
stimulated with Ag and irradiated syngeneic splenoeytes for a week in the absence 
(Ag) or in the presence of Rapamyein (Ag-Rap), and then either left untreated, or 
restimulated with PMA and lonomyein (PMA/lono). After 4 hours, intracellular 
cytokine release was assessed by flow cytometry. As shown above, by seven days 
o f culture the CFSE profiles o f control and Rapamyein treated cells were mostly 
indistinguishable (Fig. 25). Moreover, both control and Rapamyein-treated cultures 
were able to produce lL-2 upon restimulation. Thus up to 52.2% and 67.9% of 
CD4^ T cells were lL-2^ in control and Rapamyein treated culture, respectively 
(Fig. 25A and 25C). In contrast, while up to 65.3% o f the cells found in control 
cultures secreted IFN-y, only 12.0% of the cells in the Rapamyein-treated cultures 
were capable of doing so (Fig. 25B and 25C). The failure to produce IFN-y was also 
revealed by measuring the presence o f the cytokine in culture supernatants by 
capture ELISA. Indeed, while IFN-y was detected between 24 and 72 hours in the 
culture supernatant of cells cultured in the absence of Rapamyein and restimulated 
with PMA and lonomyein, this cytokine could never be detected in culture 
supernatant of restimulated Rapamyein-treated cells (data not shown). While lL-4 
was detected in some experiments in the culture supernatants o f restimulated control 
cells, neither lL-4 nor lL-10 could ever be found in culture supernatants o f 
Rapamycin-treated cells (data not shown).
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Figure 25. Rapamyein prevents antigen-driven Thl cell differentiation, independently 
of cell proliferation, CFSE-labeled DOll.lO LN cells were cultured for 7 days with 
Ag and irradiated syngeneic splenoeytes in the absence (Ag), or in the presence of 
Rapamyein (100 nM) (Ag-Rap). Thereafter, the cells were restimulated for 4 hours 
with medium only (-) or with PMA and lonomyein (PMA/lono), and analyzed 
following staining with anti-CD4 mAh, and either anti-IL-2 (A) or anti-IFN-y mAbs 
(B). Dot plots show events upon gating on CD4VCFSE+ cells. The percentage of IL-2+ 
or IFN-y" cells is reported. The quadrants were defined based on the CFSE/cytokine 
content of undivided/unstimulated cells (not shown). C) The mean percentage ± SD of 
naïve DOll.lO T cells, and of cells expanded for 7 days in Ag, Ag and Rapamyein 
(Ag-Rap), and Ag, Rapamyein and rIL-2 (Ag/IL-2-Rap) able to produce IL-2 or IFN-y 
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To verify that Rapamyein was inhibiting T cell polarization by blocking 
mTor signalling directly in T cells, and not in other cells present in the LN cultures, 
CD4^ T cells were purified, labelled with CFSE and stimulated for a week with 
anti-CD3/CD28 mAbs immobilized on latex beads, in the absence or in the 
presence of Rapamyein (Fig. 26). As shown for Ag stimulation, also CD3/CD28- 
driven T cell expansion was insensitive to the presence o f Rapamyein. Thus, all the 
cells diluted their CFSE content in response to CD3/CD28 and completed up to 9 
cell division cycles. Moreover, as in the case of Ag stimulated cultures, CD3/CD28 
cultured cells acquired the ability to secrete IFN-y upon PMA/lono restimulation, 
which was prevented by Rapamyein. Thus, while up to 22.4% of the cells derived 
from CD3/CD28 cultures produced IFN-y upon rechallenge, only 8.7% o f the cells 
derived from the Rapamycin-treated cultures did so. These results indicate that 
Rapamyein prevents a cell autonomous Thl differentiation program, revealing a 
critical role for mTor in T cell activation.
Similarly to CD4^ T cells, also OVA-specific CD8^ T cells failed to acquire 
proper effector functions when activated in the presence of Rapamyein (Fig. 27). 
Thus, CFSE-labelled OT-I T cells, stimulated for a week with the specific Ag, 
proliferated to similar extent in the absence or in the presence of Rapamyein, and 
completed up to seven cell divisions (Fig. 27A). However while up to 83.0% of 
CD8^T cells in control OT-I cultures produced IFN-y upon restimulation with PMA 
and lonomyein, only 21.5% of the cells derived from Rapamycin-treated cultures 
did so (Fig. 27A). Furthermore, while OT-I T cells expanded in Ag were able to 
recognize and kill OVA-pulsed target cells, no specific lytic activity was detected in 
cells derived from Rapamycin-treated culture (Fig. 27B).
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Figure 26. Rapamyein prevents cell-autonomous Thl cell differentiation. A) CD4+ 
DO 11.10 T cells were purified, labeled with CFSE and cultured for 7 days with anti- 
CD3/CD28 mAbs coated latex beads, in the absence (CD3/CD28) or in the presence 
of Rapamyein (100 nM) (CD3/CD28-Rap). Thereafter the cells were restimulated for 
4 hours with medium only (-) or with PMA and lonomyein (PMA/lono), and analyzed 
following staining with anti-IFN-y mAh. Dot plots show events upon gating on viable 
cells. The percentage of IFN-y" cells is reported. B) The graph reports the mean 
percentage ± SD of IFN-'y cells calculated over 3 independent experiments. The 
significance of differences in cytokine production by T cells expanded in the absence 
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Figure 27. Rapamyein prevents CD8+ T cell differentiation, independently of cell 
proliferation. A) CFSE-labeled OT-I LN cells were stimulated with Ag and irradiated 
syngeneic splenoeytes in the absence (Ag) or in the presence of Rapamyein (100 nM). 
(Ag-Rap). After seven days of culture, the cells were harvested and analyzed for their 
ability to secrete IFN-y upon restimulation (A), or to kill OVA-pulsed target cells (B). 
A) The cells were restimulated for 4 hours with medium only (-) or with PMA and 
lonomyein (PMA/lono), and analyzed following staining with anti-CD8 mAh, and 
anti-IFN-y mAh. Representative dot plots of events gated on CD8VCFSE+ T cells are 
shown in the figure. The percentage of IFN-y producing cells is reported. B) Ag, and 
Ag-Rap cells were tested in a standard cytotoxicity assay against unpulsed (RMA) or 
OVA-pulsed (RMA+OVA) target cells. Data are means ± SD of triplicates of the 
percentages of specific ^^Cr release at the indicated E:T ratios.
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Altogether these results indicate that Rapamyein, rather than blocking T cell 
expansion, prevents effector T cell polarization.
3.3.3 Rapamyein fails to establish T cell unresponsiveness
Results derived from in vitro and in vivo studies suggested that Rapamyein, 
by preventing IL-2/IL-2R signalling and IL-2-driven T cell expansion, induced a 
state o f T cell antigen unresponsiveness (265, 290). To investigate this possibility, 
we compared the surface and functional phenotype of DO 11.10 T cells expanded in 
the absence or in the presence of Rapamyein. To this aim, control and Rapamycin- 
treated cells were analyzed by flow cytometry following staining with anti-CD4^ 
and anti-CD44, CD25 and CD62L mAbs (Fig. 28). After a week in culture with the 
specific Ag, the vast majority o f CD4^ T cells in either control, and Rapamycin- 
treated cultures, had undergone more than five cell divisions and had up-regulated 
the surface expression of CD44 to similar extents (Fig. 28, upper panels). Similarly, 
in both control and Rapamycin-treated cultures, a comparable fraction o f the cells 
showed increased surface expression of CD25 (Fig. 28, middle panels). However, 
Rapamycin-treated cells showed suboptimal CD25 expression, as revealed by the 
MFI of these cells, which was reduced by 50% when compared to the MFI derived 
from control cells. Furthermore, while up to 84.7% o f control cells had 
downregulated surface expression of CD62L, only 42.4% of Rapamycin-treated 
cells expressed low levels o f this LN homing molecule. These data support the 
possibility that, in the presence of Rapamyein, Ag-stimulated T cells do not fully 
differentiate.
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Figure 28. Surface phenotype of Rapamycin-treated cells. CFSE-labeled DOll.lO 
LN cells were cultured for 7 days with Ag and irradiated splenoeytes in the absence 
(Ag) or in the presence of Rapamyein (100 nM) (Ag+Rap). Thereafter, the cells 
were harvested and analyzed by flow cytometry following staining with anti-CD4, 
and either anti-CD44, -CD25 or -CD62L mAbs. The percentage of cells with 
increased expression of CD44, and CD25, or with downregulated expression of 
CD62L is reported in the plots.
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Figure 28
To better characterize the state of differentiation o f cell expanded in the 
presence of Rapamyein, we analyzed the expression of several cytokine mRNAs. 
To this aim, D O ll.lO  cells eultured for a week with Ag, in the absence or in the 
presence of Rapamyein, were restimulated with PMA and lonomyein for 0, 1 and 4 
h. Total RNA was then obtained and analyzed by Ribonuclease protection assay 
(RPA) (Fig. 29) (see Materials and Methods). Interestingly, in the unstimulated 
condition (Oh PMA/lono), the level of expression of all mRNAs analyzed were very 
low in both groups of eells. Expression of the mRNAs for IL-2, TNF-a and P were 
induced to similar extents upon PM A/lono restimulation, in control and 
Rapamycin-treated cells. In contrast, while control cells up-regulated the expression 
of the mRNAs for IFN-y, IL-4 and IL-5 upon restimulation, these mRNAs failed to 
be expressed in Rapamycin-treated cells. This indicates that, while Ag driven 
differentiation confers the cells the ability to rapidly up-regulate mRNAs coding for 
effector cytokines (such as IFN-y and IL-4), this fails to happen if  Rapamyein is 
present at the time of activation. Thus, Rapamycin-treated cells appear to be Ag- 
experienced cells, lacking a fully differentiated effector phenotype.
We then investigated whether these cells could expand upon Ag-re- 
encounter. To this aim, D O ll.lO  T cells cultured for a week with Ag, in the absence 
or in the presence of Rapamyein, were labelled with CFSE, and restimulated with 
Ag and irradiated syngeneic splenoeytes (Ag/APC) (Fig. 30). Dilution of the CFSE 
content was then analyzed after 7 days o f culture by flow cytometry. As 
comparison, naïve T cells were also used. Interestingly, D O ll.lO  CD4^ T eells 
stimulated for a week with Ag demonstrated higher proliferative potential when 
compared to naïve D O ll.lO  CD4^ T cells, as demonstrated by the increased
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Figure 29. Analysis of cytokine genes transcription upon Rapamyein treatment, by 
RNAse protection assay. A) DO 11.10 LN cells were cultured for 7 days with Ag and 
irradiated splenoeytes in the absence (Ag), or in the presence of Rapamyein (100 nM) 
(Ag-Rap). Thereafter, the cells were harvested, restimulated for 0, 1, and 4 hours with 
PMA and lonomyein (PMA/lono), and total RNA was obtained and analyzed by 
RNase protection assay (RPA) as described in Material and Methods, by using a probe 
set specific for the indicated cytokine RNAs. Protected RNAs were then visualized by 
autoradiography. B) The relative amounts of the indicated cytokine RNAs were 
quantified by phosphor imaging analysis and normalized to the amount of the 
housekeeping mRNA encoding the ribosomal protein L32. The graph reports the 
relative amount of the indicated RNAs expressed as fold induction over the 
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Figure 30. Rapamycin-treated cells optimally expand upon Ag re-encounter. 
DOll.lO LN cells were cultured for 7 days with Ag and irradiated splenoeytes in 
the absence (Ag) or in the presence of Rapamyein (100 nM) (Ag+Rap). Thereafter, 
the cells were harvested, and either left untreated (-), or restimulated for 5 days with 
Ag and irradiated splenoeytes (Ag/APC). Naïve CD4+ T cells were similarly 
stimulated as comparison. At the end of the culture, the cells were stained with anti- 
CD4 mAh, and analyzed by flow cytometiy for their CFSE content. The histograms 









number o f cell divisions. No differences in the proliferative capacity could be found 
after comparing CD4^ T cells previously cultured with Ag, or with Ag and 
Rapamyein. This indicates that Ag stimulation in the presence of Rapamyein does 
not hamper the ability of the cells to further proliferate upon Ag re-encounter.
To further analyze the functional capabilities of T cells previously expanded 
in the presence of Rapamyein, we investigated whether the addition of exogenous 
polarizing cytokines at the time of Ag restimulation could drive these cells to 
differentiate into Thl or Th2 effector cells. To this aim, D O ll.lO  T cells were first 
stimulated with Ag for a week in the presence of Rapamyein, and then restimulated 
for another week with Ag, with Ag and rIL-12 (and neutralizing anti-IL-4 mAh; 
Thl polarizing condition), or with Ag and rIL-4 (and neutralizing anti-IL-12 mAh; 
Th2 polarizing condition) (Fig. 31). At the end of the second week, T cells were 
restimulated with PMA and lonomyein, and IFN-y and IL-4 release was measured 
by intracellular cytokine staining. A very small fi*action of Rapamycin-treated CD4^ 
T cells, restimulated during the second week only with Ag/APC, produced IFN-y 
(4.3%) and almost no cells produced IL-4 (0.9%) after PMA/lono restimulation. In 
contrast, stimulation of Rapamycin-treated cells during the second week with 
Ag/APC and rIL-12, or with Ag/APC and rIL-4, drove 17.3% and 10.3% of CD4^ T 
cells to secrete detectable amounts of IFN-y and IL-4, respectively.
Together these results indicate that Ag encounter in the presence o f 
Rapamyein does not hamper the ability of CD4^ T lymphocytes to either proliferate 
or to differentiate upon Ag re-encounter. Thus, rather than resulting in T cell 
unresponsiveness (265, 290), Rapamyein determines the accum ulation o f 
unpolarized Ag-experienced T cells.
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Figure 31. Rapamycin-treated cells are eapable of differentiating when eultured in 
Thl or Th2 polarizing conditions. A) Schematic representation of the experiment. 
DO 11.10 LN cells, cultured for 7 days in the presenee of Ag/APC and Rapamyein 
(Ag+Rap) (First stimulation), were re-stimulated for an additional week with 
Ag/APC (Ag), Ag/APC and rIL-12 (and anti-IL-4 mAb) (Ag+IL-12), or with 
Ag/APC and rIL-4 (and anti-IL-12 mAh) (Ag+IL-4) (Second stimulation). 
Thereafter, the cells were harvested, re-stimulated for 4 hours with medium only 
(not shown) or with PMA and lonomyein (PMA/lono), and analyzed by flow 
cytometry after staining with anti-CD4, anti-IL-4, and anti-IFN-y mAbs (B). Dot 
plots represent events after gating on viable CD4+ T cells. The percentage of 
eytokine producing cells is reported in the figure. In the absenee of restimulation 
the % of cytokine producing cells was < 2%. The experiment shown is 
representative of two independently performed experiments.
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3.3.4 Rapamyein prevents IL-4-driven T cell differentiation: a role for the 
common y chain
Polarization o f Thl and Th2 cells is normally initiated by TCR/IL-2 
generated signals, and then sustained by polarizing cytokines, such as IL-12 and IL- 
4, respectively (291, 292). It was of interest to investigate whether Rapamyein could 
also prevent T cell differentiation in the presence of polarizing conditions. To this 
aim, CFSE-labelled D O ll.lO  purified CD4^ T cells were stimulated with 
CD3/CD28 latex beads, in the presence of rlL-12 (and neutralizing anti-lL-4 mAh), 
or rlL-4 (and neutralizing anti-IL-12 mAh). After a week, the eells were harvested, 
restimulated with PMA and lonomyein, and analyzed by flow cytometry for IFN-y 
and lL-4 produetion, respectively (Fig. 32). The results reported in Fig. 32A and 
32B indicate that, in the presence of Rapamyein, Thl cell differentiation could 
occur if  rlL-12 was added to the culture. In contrast, lL-4-driven Th2 cell 
differentiation was inhibited by Rapamyein treatment (Fig. 32C, D). Thus, while up 
to 45.5% of the cells expanded in Ag and rlL-4 differentiated into lL-4-producing 
cells, only 12.7% of the cells cultured in the presence of Rapamyein did so (Fig. 
32C).
Interestingly, lL-2 and lL-4 are both required for optimal Th2 T eell 
differentiation (293-295), and lL-2 is required for proper Thl differentiation (221, 
282). These cytokines share the common jc (CD 132) o f the cytokine receptor to 
proper signal into the cells (296). We thus investigated whether Rapamyein could 
influence CD 132 expression, and by that hamper cytokine-driven T cell
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Figure 32. Rapamyein prevents IL-4-, but not IL-12-induced T cell polarization. 
CD4+ T cells were purified from the LNs of DOll.lO mice, labeled with CFSE and 
cultured for 7 days with anti-CD3/CD28 mAbs-coated latex beads in Thl 
(CD3/CD28/IL-12) or Th2 (CD3/CD28/IL-4) polarizing conditions in the absence (-) 
or in the presence of Rapamyein (100 nM) (Rap). Thereafter, the cells were 
harvested, restimulated for 4 hours with medium only (not shown) or with PMA and 
lonomyein (PMA/lono), and analyzed by flow eytometry after staining with anti- 
CD4, anti-IL-4, and anti-IFN-y mAbs. A, C) Dot plots represent events after gating 
on viable cells. The percentage of cytokine producing cells is reported in the figure. 
B, D) The graphs report the mean percentage ± SD of cytokine producing cells 
calculated over 3 independent experiments. The significance of differences in 
cytokine production by T cells expanded in the absence or in the presence of 
Rapamyein was tested with a two-tailed Student’s r test.
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differentiation. CFSE labelled purified CD4^ T cells were stimulated with 
CD3/CD28 latex beads, with or without rIL-4, in the absence or in the presence of 
Rapamyein, and analyzed by flow cytometry, either after 3 days or after 7 days of 
culture (Fig. 33). While stimulation of D O ll.lO  CD4^ T cells was able to elicit 
optimal up-regulation of CD 132 on the surface of the cells by day 3, suboptimal 
surface expression was detected in Rapamycin-treated cells. The same effect was 
observed with addition of rIL-4 to the culture. Indeed, as shown for CD25, also 
CD 132 was expressed to levels that were only 50% of those observed on control 
cells (MFI control cell: 37.3, MFI Rapamycin-treated cells: 16.9). By day seven, 
both control and Rapamycin-treated cells expressed CD 132 at the same level. 
Similar results were obtained in Th2 polarizing condition (MFI control cells + rlL- 
4: 42.0; MFI Rapamycin-treated cells + rIL-4: 24.7). These results suggest that the 
ability of Rapamyein to prevent optimal common Yc up-regulation during the early 
phases of T cell activation, might explain its ability to impair T cell polarization.
Altogether the results reported in this thesis indicate that proper mTor 
signalling is required for T cell proliferation, Ag responsiveness, and differentiation. 
In the absence of proper mTor activation, T cells lack the ability to proper respond 
to either cytokine or Ag driven T cell activation.
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Figure 33. Rapamyein inhibits optimal upregulation of the (CD 132) expression. 
CD4+ T cells were purified from the LNs of DO 11.10 mice, labeled with CFSE and 
cultured for 3 and 7 days with anti-CD3/CD28 mAbs-coated latex beads 
(CD3/CD28) or anti-CD3/CD28 mAbs-coated latex beads and rIL-4 (CD3/CD28/IL- 
4), in the absence (-) or in the presence of Rapamyein (Rap) (100 nM). Thereafter, 
the cells were harvested, and analyzed, together with freshly isolated purified CD4+ 
DOll.lO T cells (naïve), by flow cytometry after staining with anti-CD4 mAh, 
isotype control (not shown), and anti-CD 132 mAb. Dot plots represent events after 
gating on viable cells. The Mean Fluorecence Intensity (MFI) of the total viable 
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The results obtained during my thesis generated a number of new findings 
contributing to the current understanding of the molecular mechanisms dictating T 
cell activation, proliferation, and differentiation. Indeed these studies indicate that 
proper activation of the mammalian target o f Rapamycin (mTor) is absolutely 
required for (1) IL-2 mediated signalling in the reversal o f clonal anergy, (2) 
CD3/CD28-dependent, IL-2-independent T cell p ro liferation , and (3) 
CD3/CD28/IL-2 or IL-4-induced CD4^ and CD8^ T cell differentiation (Fig. VII). 
Thereafter I will discuss our results in light of the previously published data.
4.1 The role of mTor signalling in the regulation of T cell antigen 
responsiveness
While the simultaneous engagement o f CD3 (TCR) and CD28 elicits T cell 
activation and proliferation, chronic TCR engagement in the absence o f 
costimulation and proliferation results in the establishment o f clonal anergy (7). 
Anergic T cells are characterized by the inability to transcribe and produce IL-2, 
and to proliferate upon Ag re-encounter, and are arrested in the G1 phase o f the cell 
cycle (7, 268, 269).
It was suggested that defective anergic T cell responses could be caused by 
the presence of a putative anergic factor, induced at the time o f TCR engagement 
and accumulated in the cells in the absence of proliferation. This model predicts that 















Figure VII. Model of mTor-dependent regulation of T cell proliferation, Ag 
responsiveness, and differentiation. A) mTor signalling is required for 
CD3/CD28-induced T cell proliferation. B) mTor signalling is involved in 
IL-2-mediated T cell proliferation, and it is necessary for IL-2-driven 
reversal of clonal anergy. C) mTor signalling is required for Ag/IL-2-driven 
and IL-4-driven Thl and Th2 differentiation.
dilution/degradation of the putative anergic factor, and by that it might restore the 
ability o f the cells to properly respond to antigenic rechallenge (263, 267). Since 
optimal engagement of TCR/CD28 was reported to elicit Gl-to-S transition via IL-2 
independent mechanisms (226, 227), we investigated whether CD3/CD28 
stimulation of anergic T cells would elicit cell cycle progression or proliferation, 
and by that restore antigen responsiveness.
We show here that optimal occupancy of the TCR and of CD28 overcomes 
G1 cell cycle block and drives anergic cell proliferation, but fails to restore antigen 
responsiveness. Indeed, while antigenic stimulation o f anergic T cells failed to 
properly regulate the G 1-associated events required for S phase transition, optimal 
engagement of the TCR and of CD28 by plate-bound agonistic mAbs overcame G1 
cell cycle arrest and elicited the up-regulation of the cyclins D2, D3 and E, the 
downregulation of the inhibitor p27^‘^ , and the hyperphosphorylation o f Rb to 
extents which were found to be similar in control and anergic T cells. Furthermore, 
comparable numbers of control and anergic T cells entered the S phase (as detected 
by DNA content) and completed several rounds of cell division (as detected by 
CFSE dilution) upon stimulation with plate-bound anti-CD3 and anti-CD28 mAbs. 
CD3/CD28-induced Gl-to-S transition and proliferation occurred in the absence of 
IL-2. Indeed, plate-bound anti-CD3/CD28 mAbs drove proliferation o f anergic T 
cells and of IL-2-deficient DO 11.10 T cells, which are respectively functionally and 
genetically incapable o f producing IL-2. Appleman et al. (226) recently found that 
ligation of CD28, in the presence o f TCR engagement, resulted in p27^^^ 
ubiquitination and degradation, and in subsequent activation of cyclin D2-Cdk4/6 
and o f cyclin E-Cdk2 complexes. In our hands CD3/CD28 ligation elicited
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comparable down-regulation of p27^*  ^ in IL-2 sufficient (control A.E7 cells, wild 
type D O ll.lO  T cells) and IL-2-deficient (anergic A.E7 and DO 11.10 IL-2'^') T 
cells. In our cultures, down-regulation of p27^‘^  in CD3/CD28-activated D O ll.IO  
IL-2" "^ T cells, was accompanied by the up-regulation of cyclin D3 and by cell 
proliferation. In contrast to this finding, Powell et al. (297) reported that CD3/CD28 
stimulation of IL-2'^' cells induced downregulation of p27^*^, but failed to elicit T 
cell proliferation. It is possible that the discrepancy can be attributed to the fact that 
these authors used soluble and not plate-bound anti-CD3/CD28 mAbs, and only 
looked at p27^*^ expression early after stimulation. Thus, either stronger receptor 
cross-linking, or longer stimulation might need to be provided to elicit complete 
P2 7 K1P (jegj-adation and cell division. In spite o f this discrepancy, our finding 
indicate that CD3/CD28 either directly, or through secretion of a yet to be defined 
cytokine, different from IL-2, directly control cell cycle progression, via an IL-2- 
independent mechanism.
The reason for the failure of Ag/APC to elicit cell cycle progression in anergic cells 
remains to be elucidated. It is possible that the establishment o f T cell anergy lowers 
the sensitivity o f the TCR or of CD28, or that only optimal receptor engagement 
provided by anti-CD3/CD28 mAbs elicits the intracellular signals required for IL-2 
independent cell cycle progression. Even though these possibilities require further 
investigation, they seem unlikely since normal Ca^^-dependent responses were 
detected following Concanavalin A and Ag stimulation of anergic T cells, thus 
indicating a normal TCR sensitivity ((245) and unpublished data). Furthermore IL-2 
independent, CD28-dependent T cell proliferation was described during antigen 
recognition in vivo, indicating that, in addition to anti CD3/CD28 mAbs, also Ag
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stimulation drives IL-2 independent T cell proliferation (221, 298). It is interesting 
that, while maximal TCR and CD28 ligation bypassed the G1 cell cycle block, it 
failed to elicit detectable IL-2 production in anergic T cells. Boussiotis et al. (268) 
previously showed that the over-expression of p27^*^ sequestered JAB-1, a co­
activator of Jun transcription factors (299), and by that inhibited AP-1-dependent 
IL-2 gene transcription. For this reason these authors suggested the augmented 
expression of p27^*  ^ to be responsible for defective IL-2 transcription in anergic T 
cells (268). Our results do not support a role for p27^‘^  in defective IL-2 production 
in anergic A.E7 T cells. Indeed, in spite o f CD3/CD28-dependent efficient p27^*^ 
downregulation ((297), and the results reported in Fig. 2), IL-2 was barely 
detectable in culture supernatants o f anergic T cells (Fig. I). This suggests that the 
signals involved in IL-2 gene transcription and in the regulation of the G1 
checkpoints might be of a different nature in our anergized Th clone.
Regardless of the final mechanism that dictated CD3/CD28-dependent 
anergic T cell proliferation, this was not sufficient to elicit reversal of clonal anergy. 
As mentioned above, the idea that proper cell cycle progression and proliferation 
upon activation was required to maintain lymphocyte responsiveness, was originally 
proposed by Jenkins and Schwartz (234, 237, 300). These authors showed that TCR 
engagement in the absence of costimulation elicited T cell activation, but not 
proliferation, and resulted in the establishment o f clonal anergy. In this model, 
CD28 costimulation was proposed to promote escape from anergy by eliciting IL-2 
production and cell division. It was, however, later shown that proliferation was not 
the critical event required for escaping anergy induction, but that Gl-to-S transition 
had to occur to preserve lymphocyte responsiveness. Indeed, anergy was induced
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only if the cells were blocked in early G1 (Gig) at the time of stimulation, but not in 
GO, Gib, or S/G2 phases (264, 265). Our results expand these original observations 
and further indicate that neither Gl-to-S phase transition, nor cell proliferation, 
elicited by CD3/CD28, is sufficient to obtain anergy reversal.
The possibility that anergy reversal and proliferation are independently regulated is 
also supported by the finding that the addition of Rapamycin at the time o f IL-2 
stimulation failed to prevent T cell expansion, but completely prevented the ability 
o f IL-2 to restore Ag responsiveness (Fig. 10). Altogether these data show that, 
rather than cell proliferation, an mTor driven signalling event seems to specifically 
regulates Ag responsiveness in T cells.
Rapamycin not only prevented IL-2 mediated anergy reversal, but also 
inhibited CD3/CD28 induced T cell proliferation (Fig. II). This indicates that mTor 
is a common effector shared by either CD3/CD28 and IL-2R induced signalling. 
Indeed, we also found that, as previously reported (107), the engagement o f CD3 
and CD28 induced the phosphorylation o f the p70^^\ one of the known mTor 
substrates, in a Rapamycin sensitive way (further discussed below). In spite of this, 
CD3/CD28-induced signalling was not sufficient to restore Ag responsiveness.
We reasoned that this could be due to several reasons. For instance, it was possible 
that chronic TCR engagement provided by the immobilized anti-CD3 Ab, in the 
absence of IL-2, could result in the continuous production and in the accumulation 
of the putative anergic factor(s), and by that it could prevent mTor-dependent 
reversal of clonal anergy. Our results indicate that this does not seem to be the case. 
Indeed, the addition of Cyclosporin A, previously shown to inhibit anergy induction
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in Th cells (233, 236, 252), did not allow CD3/CD28 stimulation to restore antigen 
responsiveness in anergic cells (Fig. 13).
It was also possible that CD3/CD28 and IL-2 could activate mTor, or mTor- 
dependent signalling, through different pathways. Our analysis o f the mTor- 
dependent post-translational modifications o f p70^^^ indicate that this could be 
partially true (discussed below). However, more detailed analysis will have to be 
performed to correctly address this possibility.
Finally, it was also possible that, specifically in anergic T cells, only IL-2, 
and not CD3/CD28, could elicit optimal activation o f mTor. To address this 
possibility we analyzed the mTor-dependent post-translational modifications of 
p 7 0 S6 k Yhe current model proposed for p70^^^ activation has been derived from 
studies mostly performed on mitogen-activated cell lines, and involves an ordered 
sequence of phosphorylation events mediated by different kinase activities. p70^^^ is 
comprised o f at least three distinct functional domains, containing the crucial 
residues for its activation: a C-terminal autoinhibitory domain (or pseudosubstrate 
domain), a linker region, and an N-terminal catalytic domain (286, 288). Four 
proline-directed sites have been identified in the autoinhibitory domain (Ser"^^\ 
Ser"^ ^^ , Thr"^^\ Ser"^ "^^ ) (301), they are rapidly phosphorylated upon mitogenic 
stimulation, possibly by a Ras/MAPK-dependent pathway (302), are not sufficient 
for p70^^^ activation, but are required to modulate its kinase activity (303). Upon 
phosphorylation of the autoinhibitory domain, the catalytic domain is released, and 
this permits subsequent phosphorylation of Thr^^^ and Ser^^\ which are located in 
the p70^^^ linker region, and have to be phosphorylated for full p70^^^ activation 
(286, 287, 303). Once Thr^^^ is phosphorylated, PDKl directly phosphorylates
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Thr^^ ,^ lying within the catalytic domain (188, 189). Phosphorylation of Thr^^  ^ and 
Thr^^  ^is induced by growth factors and is prevented in the presence of Wortmannin 
(a PI3K inhibitor) and Rapamycin (the inhibitor for mTor) (303, 304). Even though 
it remains controversial whether Thr^^^ phosphorylation is directly mediated by 
mTor (287, 305, 306), or by the NEK6/7 kinases, which belong to the NIMA 
(never-in-mitosis-v46pgrgz//z/j^-like family kinases (307), phosphorylation of this 
residue correlates with p70^^^ activation (287). The activity o f p70^^^ is also 
modulated by the activity of phosphatases, such as PP2A, which directly binds and 
dephosphorylates p70^^^ (308). It has been shown that this event is inhibited by an 
m Tor-dependent signalling, suggesting that mTor could allow p70^^^ 
phosphorylation by protecting the protein from PP2A activity (308).
In our unstimulated A.E7 cells, p70^^^ was found to be constitutively 
phosphorylated, as demonstrated by the observation that, either the treatment o f the 
cells with Rapamycin, or the treatment o f the cell extracts with alkalin phosphatase, 
reduced the mobility of the protein in both mono and bidimensional SDS-PAGE 
analyses. This indicates that, as reported for other cell types (309), also A.E7 T cells 
have a constitutive level of mTor activity, possibly linked to normal nutritional 
conditions. CD3/CD28 and IL-2-driven T cell stimulation elicited Rapamycin- 
sensitive p70^^^ phosphorylation in Thr^^^ and in several additional residues, as 
detected by either mono and bi-dimensional analyses (Fig. 14-19). This finding 
confirms that, as reported by others (286), also in our control cells, mTor is 
involved in stimulation-dependent p70^^^ phosphorylation. Interestingly, IL-2 
elicited the appearance of several spots with a more acidic PI (possibly indicative of 
additional phosphorylations), compared to the ones found upon CD3/CD28
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stimulation, suggesting that IL-2 and CD3/CD28 might activate through
different pathways.
In contrast to control cells, only IL-2 stimulation induced Rapamycin-sensitive 
p 7 QS6 k phosphorylation in anergic cells. Indeed CD3/CD28 stimulation of anergic 
cells failed to elicit either Thr^^  ^phosphorylation, or general acidification ofp70^^\ 
and instead it induced the accumulation of the more basic variants o f the proteins 
(Fig. 15, 16, 18, 20). Thus, together these results indicate that the failure o f 
CD3/CD28 to restore Ag responsiveness could be attributed to the failure of this 
stimulation to optimally activate an mTor-dependent event involved in anergy 
reversal.
The failure o f CD3/CD28-mediated stim ulation to induce proper 
phosphorylation of p70^^^ could be due to several reasons. First, it is possible that 
the previously reported defect in the Ras/MAPK dependent pathway in anergic cells 
(247) hampers the MAPR-dependent phosphorylation o f the p70^^*  ^ catalytic 
domain. Furthermore, it is possible that, in anergic cells, CD3/CD28-induced 
signalling fails to optimally activate the kinase activity of mTor, which is required 
for initial p70^^^ phosphorylation. Similarly, CD3/CD28 might also fail to activate 
the NEK6/7 kinases, and thus fail to elicit phosphorylation of Thr^^^. Since mTor 
and the NEK6/7 kinases can be both regulated by PI3K activity (90, 210, 307), it is 
also possible that anergic cells have defective PI3K-dependent signalling. Finally, it 
is possible that anergic cells have a deregulated phosphatase activity. A possible 
candidate could be a member o f the PP2A phosphatase family, which has been 
shown to bind to the cytoplasmic domain o f CD28 (310). PP2A association to 
CD28 is inhibited by Lck-dependent CD28 phosphorylation (310). Since it has been
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reported that Lck activity is reduced in anergic T cells, in favour of Fyn activity 
(253, 254), it is conceivable that, in these cells, the CD28/PP2A complex might be 
more represented, thus impairing proper p70^^^ phosphorylation. Interestingly, we 
have preliminary results indicating that, in anergic cells, the addition of okadaic 
acid, an inhibitor of PP2A, at the time of CD3/CD28 stimulation, increased Thr^^  ^
phosphorylation.
Regardless of the reasons for the failure of CD3/CD28 stimulation to induce 
proper phosphorylation of p70^^^ in anergic cells, this correlates with the inability of 
CD3/CD28 stimulation to reverse clonal anergy. Even though, the proof that p70^^^ 
might directly control T cell anergy is still missing, given its crucial role in the 
regulation of the translational machinery, it is conceivable that its defective 
activation might account for the peculiar phenotype of anergic cells. Thus, the 
future characterization of the mTor-dependent p70^^^ activation will shed some light 
on the molecular mechanisms regulating antigen responsiveness.
4.2 The role of mTor signalling in the regulation of T cell proliferation
Proliferation of CD4^ T lymphocytes is controlled by both TCR/CD28 and 
IL-2/IL-2R-initiated signals. It was believed that the stimulation o f resting T 
lymphocytes by TCR/CD28 initiated cell cycle entry (139), and rendered the cells 
competent for proliferation by eliciting the production of the T cell growth factor 
IL-2, and the expression of its high affinity receptor. The binding of IL-2 to its 
receptor would then mediate the coordinated activation o f several intracellular 
signalling events, and would eventually induce cell division (140, 141). A number
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of studies, however, recently indicated that the engagement o f the TCR and of 
costimulatory receptors results in the activation and in proliferation of T cells, 
independently o f IL-2 (221, 222, 224-227, 282, 311). Here we showed that, in 
addition to IL-2, also CD3/CD28 could elicit G1 to S transition by directly 
regulating the critical cell cycle proteins such as cyclin D3, Rb, p21^‘^ , and p27^^^ 
(Fig. 2, 6).
While both TCR/CD28 and IL-2/IL-2R-driven proliferation were similarly 
sensitive to the PI3K inhibitor LY294002 (LY), only TCR/CD28 driven T cell 
proliferation was completely abrogated by the presence o f Rapamycin. Given the 
crucial role attributed in the past to mTor signalling in the regulation o f IL-2- 
mediated T cell proliferation, it was surprising to discover that IL-2-induced 
proliferation of A.E7 cells could occur also in the presence o f Rapamycin (Fig. 10). 
Indeed, we found that Rapamycin blocked cell division up to the third day of 
culture (Fig. 21). After this time Rapamycin-treated cells started to proliferate and 
by the end of the culture they have performed the same number of cell divisions o f 
their untreated counterparts. These findings are not consistent with the previous idea 
that Rapamycin inhibits G l-to S transition and T cell expansion (312). However, it 
should be noted that the previously reported ability o f Rapamycin to prevent T cell 
proliferation mostly derived from studies detecting proliferation by standard [^H]- 
thymidine incorporation assays, which measure cell proliferation after 48-72 hours 
of culture. Instead, by following single cell history over time, we found that, as 
previously suggested at the molecular levels (285), also at the functional level, T 
cells are capable to proliferate in the presence of Rapamycin.
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The finding that Rapamycin only delays, and does not inhibit cell division 
supports the idea that Rapamycin prolongs IL-2-induced Gl-to-S phase transition. 
Indeed Terada et al. (285) showed that Rapamycin induced a prolongation of the G1 
phase of the cell cycle, and attributed this effect to the ability o f the drug to inhibit 
the translation of ribosomal protein mRNAs, and thus the synthesis of total cellular 
proteins, and to delay the cell growth response. These authors also showed that 
Rapamycin-treated cells initiated DNA synthesis and entered the cell cycle as soon 
as they reached the size of the untreated counterparts (285), supporting a role for 
mTor in the cell growth response, rather than in the regulation of cell cycle proteins. 
Accordingly, we found that Rapamycin prevented proliferation at day 3 after 
stimulation, but failed to do so at later times, when cells stimulated in the absence 
or in the presence of Rapamycin had performed the same number o f cell divisions.
The peculiar sensitivity o f either CD3/CD28 and IL-2/IL-2R-induced 
proliferation to Rapamycin, might either indicate that these receptors use different 
intracellular signalling for the regulation of cell cycle progression, or that, in the 
presence of saturating amounts of IL-2, mTor-independent pathways are induced. 
Our results partially support both these possibilities. Indeed, while the 
downregulation of p27^‘^  induced by CD3/CD28 was Rapamycin-insensitive, IL-2- 
induced p27^‘^  downregulation was prevented by this drug (data not shown), thus 
suggesting that, at least for p27^‘^ , the intracellular signals induced following 
CD3/CD28 and IL-2/IL-2R are distinct. Moreover, while IL-2 driven T cell 
proliferation was Rapamycin-insensitive in the presence o f saturating IL-2 
concentration, it was Rapamycin-sensitive in the presence o f limiting amounts o f
100
IL-2 (Fig. 22). These findings indicate that Rapamycin-insensitive pathways might 
be uniquely induced upon maximal IL-2R occupancy.
The IL-2-induced mTor-independent T cell proliferation was still sensitive to the 
PI3K inhibitor LY. Indeed, the addition o f LY prevented IL-2-dependent 
proliferation either early (three days) (not shown) or late (seven days) (Fig. 23) 
after stimulation. The fact that both LY and Rapamycin were sufficient to prevent T 
cell proliferation at day 3, could either indicate that PI3K regulates mTor function 
as proposed elsewhere (90), or that both PI3K and mTor-generated signals are 
required to enter the cell cycle. Upon cell cycle entry, mTor could then become 
dispensable (Rapamycin-resistant proliferation was detected by day 7, and cell cycle 
progression was previously observed in spite of Rapamycin-dependent inactivation 
of the p70^^^ (313), while PI3K-dependent signals might still be required to sustain 
IL-2 mediated T cell proliferation. In support o f this, Slavik et al. (314) recently 
reported that freshly isolated CD8"^  T cells and CD8  ^T cell clones were capable o f a 
Rapamycin-resistant proliferation, which was inhibited by the PI3K inhibitor LY. 
Even though IL-2R (3 and y chain-generated signals, involving Bcl-2, c-Myc, and 
JAK3/STAT5-dependent transcription, have been shown to contribute to T cell 
proliferation (175, 180), no residual proliferation was observed in A.E7 T cells 
stimulated in the presence of both Rapamycin and LY, suggesting that proliferation 
of these cells critically requires PI3K-PKB-mTor pathways. It is interesting that in 
lower eukaryotes (such as Cenorabditis elegans), mTor and PI3K pathways are 
distinct and regulate in parallel the response to nutrients and growth factors, 
respectively. In higher eukaryotes, such as mammals, these two pathways seem to 
have converged at the level of PI3K, being mTor a downstream effector target o f
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this lipid kinase (90, 210), but still might regulate only partially overlapping 
intracellular signalling pathways. Indeed, our results showed that, in the presence of 
LY, a residual proliferation was observed, which was completely inhibited by the 
concomitant treatment with Rapamycin. Even though much more work needs to be 
done, the available data indicate that both PI3K and mTor play a crucial role in T 
cell proliferation, but that, while the former is absolutely required for T cell 
expansion, the latter might be dispensable.
Altogether, these findings contribute to the current understanding o f the 
molecular mechanisms that regulate TCR/CD28 and IL-2/IL-2R-induced 
proliferation, and underline the importance of performing additional investigation 
on the immunosuppressive activity o f Rapamycin. Indeed, the finding that 
Rapamycin was unable to block T cell expansion is in contrast to the previously 
reported immunosuppressive function of this drug, which was historically attributed 
to its ability to prevent the expansion of the pathogenic T cells. Our data instead 
indicate that the immunosuppressive activity o f Rapamycin could not be explained 
by inhibition of proliferation, but rather by its ability to prevent the mTor-induced 
signalling involved in the regulation of T cell antigen responsiveness (section 4.1), 
and T cell polarization (discussed in the following section).
4.3 The role of mTor signalling in antigen-driven T cell polarization
Following antigen stimulation, naïve T cells not only proliferate, but, 
provided that several conditions are in place, they also undergo a program o f 
differentiation that commits the cells to a specific effector function (292, 315). Our
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data indicate that, in addition to control T cell antigen responsiveness, and to some 
extent T cell proliferation, mTor signalling also controls T cell differentiation. 
Indeed, by using an in vitro model o f antigen driven T cell differentiation, we 
showed that, in the presence o f Rapamycin, T cells proliferated, but fail to 
differentiate into cytokine-producing effector T cells.
CD4^ T lymphocytes most commonly differentiate into Thl and Th2 effector 
cells (292, 315, 316). Thl cells are mainly capable o f producing IL-2, IFN-y, 
TNFP and lymphotoxin, they orchestrate cell-mediated immune responses, and can 
protect against intracellular pathogens. Th2 cells are mainly capable of producing 
IL-4, IL-5, IL-6, IL-10, and IL-13, and sustain both humoral immune responses and 
protection against extracellular infections (317-319). Several factors have been 
described to influence the fate of CD4^ T cell differentiation at the time of antigen 
encounter. Among these are: the dose of antigen, the strength of TCR stimulation, 
the presence of pro-inflammatory cytokines, and, in some instances, the ability of 
the cells to proliferate (294, 320-322). For instance, while high antigen doses drive 
the development o f Thl-like cells producing increased amounts o f IFN-y, low 
antigen doses induce T cells to switch to Th2-like cells mainly capable of producing 
IL-4 (323, 324). Moreover the presence of IL-12 at the time of Ag recognition 
elicits Thl T cell differentiation, a mechanism that requires the induction of the 
Thl-specific transcription factor T-bet. Similarly, the presence of IL-4 favours Th2 
T cell differentiation, and the expression of the Th2-specific transcription factor 
GATA-3 (291, 292, 294, 325, 326). Finally, also cell proliferation plays a major 
role in regulating T cell differentiation (321, 322). Indeed, Bird et al. (321) 
demonstrated that, while the expression of IL-2 by antigen activated T cells was cell
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cycle independent, the expression of effector cytokines was acquired as a function 
of the number of cell divisions. In particular, IL-4 production occurred only in cells 
that had undergone at least three cell divisions, while IFN-y production required 
only one round of cell division.
In our cultures Ag-driven T cell expansion induced T h l T cell 
differentiation. Indeed, DOl l . lO ovalbumin-specific CD4^ T cell cultured for a 
week with Ag and irradiated syngeneic splenocytes, were mainly capable of 
producing IFN-y upon restimulation. Similar results were obtained by using purified 
CD4^ T cells optimally stimulated by CD3/CD28-coated beads, suggesting that, in 
the presence of optimal TCR/CD28 engagement, ovalbumin-specific CD4^ T cells 
naturally differentiated to IFN-y producing cells through a cell autonomous 
mechanism. In some experiments, a small fraction of the cells also spontaneously 
polarized to IL-4 producing cells (data not shown).
The addition of Rapamycin at the time of stimulation only delayed and did not 
inhibit either Ag/APC or CD3/CD28-induced T cell proliferation, as in the case of 
IL-2-stimulated A.E7 T cell clones, but drastically prevented T cell polarization. 
Indeed, when cells stimulated in the presence of Rapamycin were optimally re­
stimulated, they failed to secrete IFN-y (and IL-4 whenever this was detected in 
control culture). Similar results were obtained with CD8^ T cells. Indeed, while Ag- 
specific CD8  ^T cells proliferated in response to antigenic challenge and acquired 
both the ability to produce IFN-y and to lyse target cells upon restimulation, cells 
cultured in the presence of Rapamycin optimally expanded but lacked effector 
capabilities. These results indicate that, in the absence of proper mTor signalling, T 
cells fail to acquire effector function capabilities.
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It is now recognized that T cell differentiation occurs through different 
phases. Initially, the engagement of the TCR activates an immediate and global 
chromatin derepression program, which results in a low, but readily detectable 
transcription of both IL-4 and IFN-y genes (327). This transcriptional activity is 
associated with increased histone acétylation in both the IL-4 and IFN-y loci (328- 
330). As differentiation proceeds, cytokine-induced signals specifically determine 
the final commitment to one of the two Th subsets. This is determined by the 
silencing of the IL-4 gene in Thl cells, and of the /FA-ygene in Th2 cells, and by 
the maintenance of histone acétylation, and thus transcriptional competence, o f the 
specific cytokine genes (IL-4 gene for Th2 cells, and IFN-y gene for Thl cells) 
(292, 294, 325, 326). It is interesting that Rapamycin-treated cells not only failed to 
express the cytokine proteins, but they were also unable to transcribe the mRNA for 
IFN-y and IL-4. In contrast to IFN-y and IL-4 mRNAs, the mRNA for IL-2 and 
TNF-a were normally induced, suggesting that Rapamycin-treated cells have a 
specific defect in the up-regulation of effector cytokine mRNAs. Moreover, in 
addition to IL-4, also the mRNA for IL-5 failed to be induced in the Rapamycin- 
treated cells. Since the IL-5 and IL-4 genes are located in the same gene cluster, it is 
tempting to speculate that activation in the presence of Rapamycin prevents the 
establishment o f transcriptional competence for entire genomic regions. Even 
though Rapamycin prevented T cell polarization, it did not result in T cell 
unresponsiveness. Indeed, CD4^ T cell activated and expanded in the presence of 
the drug, showed to be able to produce IL-2, and to proliferate upon Ag 
restimulation, and a fraction of the cells differentiated towards a Thl or a Th2 
phenotype, when restimulated in the presence of rIL-12 or rIL-4, respectively.
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When compared to naïve T cells, cells expanded in Rapamycin showed an increased 
surface expression of CD44, o f CD25, and reduced surface levels of CD62L. 
Moreover, cells expanded in the presence of Rapamycin showed a faster kinetic of 
TNF-a and IL-2 production (data not shown), and of proliferation (Fig. 30) when 
compared to naïve cells, suggesting that the cells are no longer naïve, but express a 
surface and functional phenotype consistent with Ag-experienced unpolarized T 
cells.
Several reasons might account for the ability of Rapamycin to inhibit T cell 
differentiation. In our cell cultures mTor-dependent signalling could interfere with 
either TCR/CD28-induced early differentiation (as proven by the fact that both of 
these receptors elicit phosphorylation o f the p70^^*  ^ via an mTor-dependent 
pathway), or at the level o f the cytokine-induced signalling. The ability o f 
Rapamycin to interfere with TCR/CD28-induced signals is supported by the 
observation that the drug inhibited both the production o f IL-2, as also reported 
elsewhere (108), and the proper up-regulation o f the a  and y chain of the high 
affinity IL-2R. It is also conceivable that Rapamycin might interfere with the poorly 
defined initial phase o f TCR-induced chromatin remodelling events, which is 
required for rendering effector cytokine genes accessible for subsequent 
transcription (327, 328). This possibility is supported by the recent finding that the 
Tor pathway is linked to E sal histone acetylase pathway, which leads to 
transcriptional activation of ribosomal protein (RP) in response to nutrient levels 
(331). Along the same line is the possibility that Rapamycin might inhibit 
TCR/CD28-mediated expression of the essential lineage specific transcription 
factors, such as T-bet and GATA-3, which in turn regulate chromatin remodelling
106
events on cytokine loci (292). Indeed, it was shown that T-bet is readily induced in 
naïve T cells by TCR triggering and by IFN-y-induced STATI signalling (332, 
333). T-bet expression leads to chromatin remodelling of the /FA-ygene, to the 
stabilization of its own expression (332, 334), and to suppression of IL-4 and IL-5 
production (335, 336). In addition to T-bet, also GATA-3 is rapidly induced by 
TCR triggering and by IL-4-induced STAT6 signalling (337). Once expressed, 
GATA-3 leads to chromatin remodelling o f the IL -4  gene, establishing 
transcriptional competence (338-340), it stabilizes its own expression (338, 339), 
and suppress Thl polarization (341). Our preliminary findings indicate that the 
addition of Rapamycin at the time of Ag-stimulation reduces, albeit to different 
extents, the transcription of both T-bet and GATA-3 mRNAs (data not shown), 
suggesting that proper mTor-signalling might indeed be required for the expression 
of the polarizing transcription factors. The reduced transcription o f T-bet and 
GATA-3 might also be due to the reduced up-regulation of the IL-2R and IL-4R 
common on the surface of the T cells at day 3, which support the possibility that 
Rapamycin prevents T cell differentiation by inhibiting the final cytokine-mediated 
T cell commitment. Indeed, even though Rapamycin prevented IL-2 secretion, 
neither the addition of recombinant IL-2, nor the addition o f recombinant IL-4 
restored the cell autonomous Thl T cell differentiation, and the IL-4 driven Th2 
differentiation. In contrast, the suboptimal IL-2R common y^  expression directly 
correlates with the functional impairment of the cells. Indeed, in the absence of the 
high affinity IL-2R, T cells might fail to receive the IL-2 driven signals enabling 
them to respond to cytokine-dependent expansion and polarization. Indeed, several 
data support the role for IL-2/IL-2R in T cell polarization. For instance, in the
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absence of IL-2, or IL-2RP-generated signalling, T cells fail to differentiate into 
IFN-y producing cells and to acquire CTL capabilities, both in vivo and in vitro 
(221, 282). Moreover, IL-2Rp‘^ ‘ T cells failed to respond to several recombinant 
cytokine in vitro, supporting the idea that IL-2 generated signals are required for 
proper T cell growth and maturation into functional effector T cells (282). 
Similarly, IL-2 has been shown to be crucial also for Th2 differentiation (293, 342). 
Furthermore, activation of STAT5A, a downstream target of the IL-2R, was linked 
to Th2 differentiation, via IL-4 and GATA-3 independent pathways (295). Since 
STAT5 and GATA-3 seem to favour Th2 polarization by distinct mechanisms 
(295), it is possible that Rapamycin, by inhibiting the early expression of the high 
affinity IL-2R, might prevent STAT5 activation, and by that might hamper T cell 
polarization. Consistent with the possibility that Rapamycin prevents T cell 
polarization by inhibiting up-regulation is the finding that Rapamycin failed to 
control IL-12-induced Thl differentiation, which occurs through a common y^ - 
independent (343), but STAT4-dependent pathway (344).
Finally, it is possible that Rapamycin, by delaying cell proliferation might prevent 
terminal differentiation. To this respect, Reiner and co-worker (321) reported that, 
to induce proper Th2 T cell differentiation, T cells had to complete at least three cell 
divisions. Our results dissociate cell cycle progression from differentiation. Indeed, 
in spite o f completing the same number of cell divisions, cells expanded in the 
presence of Rapamycin still failed to produce either IFN-y or IL-4. It is however 
possible that, by delaying cell cycle entry and the up-regulation of the common yc, 
Rapamycin might uncouple TCR and cytokine generated signals, which have to be 
delivered in close proximity to elicit proper T cell differentiation (345).
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Altogether these results indicate that progression through the cell cycle might 
be necessary, but not sufficient to drive T cell polarization, and that an mTor- 
dependent signal is critically required to elicit T cell polarization.
4.4 Concluding remarks
The results reported in this thesis demonstrate that mTor signalling plays a 
central role in T cell proliferation, antigen responsiveness, and differentiation, 
which are tightly regulated events during the development o f protective immunity. 
Moreover, by tracing the fate of single cells activated in the presence of the mTor 
inhibitor Rapamycin, we revealed a new mechanism at the base of the clinical 
activity of this drug. Indeed, even though additional studies will have to be 
performed in vivo to validate these in vitro generated findings, it is possible that the 
immunosuppressive activity of Rapamycin relies on the ability o f the drug to 
modulate, rather than suppress, adaptive immune responses.
109
Bibliography
1. Caux, C., C. Massacrier, B. Vanbervliet, B. Dubois, C. Van Kooten, I. 
Durand, and J. Banchereau. 1994. Activation o f human dendritic cells 
through CD40 cross-linking. J  Exp Med 180:1263.
2. Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufler, E. Kampgen, N.
Romani, and G. Schuler. 1996. High level IL-12 production by murine
dendritic cells: upregulation via MHC class II and CD40 molecules and
downregulation by IL-4 and IL-10. J  Exp Med 184:741.
3. Bourgeois, C., B. Rocha, and C. Tanchot. 2002. A role for CD40 expression 
on CD8+ T cells in the generation o f CD8+ T cell memory. Science  
2P7.2060.
4. Kawabe, T., T. Naka, K. Yoshida, T. Tanaka, H. Fujiwara, S. Suematsu, N. 
Yoshida, T. Kishimoto, and H. Kikutani. 1994. The immune responses in 
CD40-deficient mice: impaired immunoglobulin class switching and 
germinal center formation. Immunity 1:167.
5. Janeway, C. A., Jr. 2001. How the immune system works to protect the host 
from infection: a personal view. Proc Natl Acad Sci U SA  98:7461.
6. Davis, M. M., and P. J. Bjorkman. 1988. T-cell antigen receptor genes and T-
cell recognition. Nature 334:395.
I. Mueller, D. L., M. K. Jenkins, and R. H. Schwartz. 1989. Clonal expansion 
versus functional clonal inactivation: a costimulatory signalling pathway 
determines the outcome of T cell antigen receptor occupancy. Annu Rev 
Immunol 7:445.
8. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system 
of T cell costimulation. Annu Rev Immunol 14:233.
9. Sharpe, A. H., and G. J. Freeman. 2002. The B7-CD28 superfamily. Nat Rev 
Immunol 2:116.
10. Croft, M. 2003. Co-stimulatory members o f the TNFR family: keys to 
effective T-cell immunity? Nat Rev Immunol 3:609.
II . Watts, T. H., and M. A. DeBenedette. 1999. T cell co-stimulatory molecules 
other than CD28. Curr Opin Immunol 11:286.
12. Deeths, M. J., and M. F. Mescher. 1999. ICAM-1 and B7-1 provide similar 
but distinct costimulation for CD8+ T cells, while CD4+ T cells are poorly 
costimulated by ICAM-1. Eur J  Immunol 29:45.
13. Geginat, J., B. Clissi, M. Moro, P. Dellabona, J. R. Bender, and R. Pardi.
2000. CD28 and LFA-1 contribute to cyclosporin A-resistant T cell growth 
by stabilizing the IL-2 mRNA through distinct signaling pathways. Eur J  
Immunol 30:1136.
14. Ni, H. T., M. J. Deeths, and M. F. Mescher. 2001. LFA-1-mediated 
costimulation of CD8+ T cell proliferation requires phosphatidylinositol 3- 
kinase activity. J  Immunol 166:6523.
15. Sims, T. N., and M. L. Dustin. 2002. The immunological synapse: integrins 
take the stage. Immunol Rev 186:100.
110
16. Cerdan, C., Y. Martin, M. Courcoul, H. Brailly, C. Mawas, F. Birg, and D. 
Olive. 1992. Prolonged IL-2 receptor alpha/CD25 expression after T cell 
activation via the adhesion molecules CD2 and CD28. Demonstration of 
combined transcriptional and post-transcriptional regulation. J  Immunol
17. Cerdan, C., Y. Martin, M. Courcoul, C. Mawas, F. Birg, and D. Olive. 1995. 
CD28 costimulation regulates long-term expression of the three genes (alpha, 
beta, gamma) encoding the high-affinity IL2 receptor. Res Immunol 146:164.
18. Lindstein, T., C. H. June, J. A. Ledbetter, G. Stella, and C. B. Thompson.
1989. Regulation of lymphokine messenger RNA stability by a surface- 
mediated T cell activation pathway. Science 244:339.
19. Thompson, C. B., T. Lindsten, J. A. Ledbetter, S. L. Kunkel, H. A. Young, S. 
G. Emerson, J. M. Leiden, and C. H. June. 1989. CD28 activation pathway 
regulates the production of multiple T-cell-derived lymphokines/cytokines. 
Proc Natl Acad Sci U SA  86:1333.
20. Fraser, J. D., B. A. Irving, G. R. Crabtree, and A. Weiss. 1991. Regulation of 
interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. 
Science 251:313.
21. Gimmi, C. D., G. J. Freeman, J. G. Gribben, K. Sugita, A. S. Freedman, C. 
Morimoto, and L. M. Nadler. 1991. B-cell surface antigen B7 provides a 
costimulatory signal that induces T cells to proliferate and secrete interleukin
2. Proc Natl Acad Sci U SA  88:6575.
22. Linsley, P. S., W. Brady, L. Grosmaire, A. Aruffo, N. K. Damle, and J. A. 
Ledbetter. 1991. Binding of the B cell activation antigen B7 to CD28 
costimulates T cell proliferation and interleukin 2 mRNA accumulation. J  
Exp Med 173:721.
23. Boise, L. H., A. J. Mirm, P. J. Noel, C. H. June, M. A. Accavitti, T. Lindsten, 
and C. B. Thompson. 1995. CD28 costimulation can promote T cell survival 
by enhancing the expression of Bcl-XL. Immunity 3:87.
24. Chambers, C. A., and J. P. Allison. 1999. Costimulatory regulation of T cell 
function. Curr Opin Cell Biol 11:203.
25. Shahinian, A., K. Pfeffer, K. P. Lee, T. M. Kundig, K. Kishihara, A. 
Wakeham, K. Kawai, P. S. Ohashi, C. B. Thompson, and T. W. Mak. 1993. 
Differential T cell costimulatory requirements in CD28-deflcient mice. 
Science 261:609.
26. Kundig, T. M., A. Shahinian, K. Kawai, H. W. Mittrucker, E. Sebzda, M. F. 
Bachmann, T. W. Mak, and P. S. Ohashi. 1996. Duration of TCR stimulation 
determines costimulatory requirement of T cells. Immunity 5:41.
27. Lin, H., S. F. Bolling, P. S. Linsley, R. Q. Wei, D. Gordon, C. B. Thompson, 
and L. A. Turka. 1993. Long-term acceptance o f major histocompatibility 
complex mismatched cardiac allografts induced by CTLA4Ig plus donor- 
specific transfusion. JExp Med 178:1801.
28. Linsley, P. S., and J. A. Ledbetter. 1993. The role o f the CD28 receptor 
during T cell responses to antigen. Annu Rev Immunol 11:191.
29. Lenschow, D. J., Y. Zeng, J. R. Thistlethwaite, A. Montag, W. Brady, M. G. 
Gibson, P. S. Linsley, and J. A. Bluestone. 1992. Long-term survival o f 
xenogeneic pancreatic islet grafts induced by CTLA41g. Science 257:789.
I l l
30. Linsley, P. S., P. M. Wallace, J. Johnson, M. G. Gibson, J. L. Greene, J. A. 
Ledbetter, C. Singh, and M. A. Tepper. 1992. Immunosuppression in vivo by 
a soluble form of the CTLA-4 T cell activation molecule. Science 257:792.
31. Finck, B. K., P. S. Linsley, and D. Wofsy. 1994. Treatment o f murine lupus 
with CTLA4Ig. Science 265:1225.
32. Chen, L., S. Ashe, W. A. Brady, I. Hellstrom, K. E. Hellstrom, J. A. 
Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of antitumor 
immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 
and CTLA-4. Cell 71:1093.
33. Townsend, S. E., and J. P. Allison. 1993. Tumor rejection after direct
costimulation of CD8+ T cells by B7-transfected melanoma cells. Science
34. Moro, M., A. M. Gasparri, S. Pagano, M. Bellone, P. Tomaghi, F. Veglia, A.
Corti, G. Casorati, and P. Dellabona. 1999. Induction of therapeutic T-cell
immunity by tumor targeting with soluble recombinant B7-immunoglobulin 
costimulatory molecules. Cancer Res 59:2650.
35. Schwartz, R. H. 1990. A cell culture model for T lymphocyte clonal anergy. 
Science 248:1349.
36. Harding, F. A., J. G. McArthur, J. A. Gross, D. H. Raulet, and J. P. Allison. 
1992. CD28-mediated signalling co-stimulates murine T cells and prevents 
induction of anergy in T-cell clones. Nature 356:607.
37. Viola, A., and A. Lanzavecchia. 1996. T cell activation determined by T cell 
receptor number and tunable thresholds. Science 273:104.
38. Bachmann, M. F., K. McKall-Faienza, R. Schmits, D. Bouchard, J. Beach,
D. E. Speiser, T. W. Mak, and P. S. Ohashi. 1997. Distinct roles for LFA-1 
and CD28 during activation of naive T cells: adhesion versus costimulation. 
Immunity 7:549.
39. Ronchese, F., B. Hausmann, S. Hubele, and P. Lane. 1994. Mice transgenic 
for a soluble form of murine CTLA-4 show enhanced expansion o f antigen- 
specific CD4+ T cells and defective antibody production in vivo. J  Exp Med
40. Valitutti, S., S. Muller, M. Celia, E. Padovan, and A. Lanzavecchia. 1995. 
Serial triggering of many T-cell receptors by a few peptide-MHC complexes. 
Nature 375:148.
4L Valitutti, S., M. Dessing, K. Aktories, H. Gallati, and A. Lanzavecchia. 1995.
Sustained signaling leading to T cell activation results from prolonged T cell 
receptor occupancy. Role of T cell actin cytoskeleton. JExp Med 181:577.
42. Beeson, C., J. Rabinowitz, K. Tate, I. Gutgemann, Y. H. Chien, P. P. Jones, 
M. M. Davis, and H. M. McConnell. 1996. Early biochemical signals arise 
from low affinity TCR-ligand reactions at the cell-cell interface. J  Exp Med 
yg^.777.
43. lezzi, G., K. Karjalainen, and A. Lanzavecchia. 1998. The duration o f 
antigenic stimulation determines the fate o f naive and effector T cells. 
Immunity 8:89.
44. Acuto, O., and D. Cantrell. 2000. T cell activation and the cytoskeleton. 
Annu Rev Immunol 18:165.
45. Cantrell, D. A. 2002. T-cell antigen receptor signal transduction. 
Immunology 105:369.
112
46. Weiss, A., and D. R. Littman. 1994. Signal transduction by lymphocyte 
antigen receptors. Cell 76:263.
47. Pitcher, L. A., and N. S. van Oers. 2003. T-cell receptor signal transmission: 
who gives an ITAM? Trends Immunol 24:554.
48. Davis, S. J., and P. A. van der Merwe. 2001. The immunological synapse: 
required for T cell receptor signalling or directing T cell effector function? 
Curr Biol 11:R289.
49. Chu, D. H., C. T. Morita, and A. Weiss. 1998. The Syk family o f protein 
tyrosine kinases in T-cell activation and development. Immunol Rev 165:167.
50. Duplay, P., M. Thome, F. Herve, and O. Acuto. 1994. p561ck interacts via its 
src homology 2 domain with the ZAP-70 kinase. JExp Med 179:1163.
51. Iwashima, M., B. A. Irving, N. S. van Oers, A. C. Chan, and A. Weiss. 1994. 
Sequential interactions of the TOR with two distinct cytoplasmic tyrosine 
kinases. Science 263:1136.
52. Chan, A. C., M. Dalton, R. Johnson, G. H. Kong, T. Wang, R. Thoma, and T. 
Kurosaki. 1995. Activation of ZAP-70 kinase activity by phosphorylation of 
tyrosine 493 is required for lymphocyte antigen receptor function. Embo J
53. Qian, D., M. N. Mollenauer, and A. Weiss. 1996. Dominant-negative zeta- 
associated protein 70 inhibits T cell antigen receptor signaling. J  Exp Med
54. Heyeck, S. D., H. M. Wilcox, S. C. Bunnell, and L. J. Berg. 1997. Lck 
phosphorylates the activation loop tyrosine of the Itk kinase domain and 
activates Itk kinase activity. J  Biol Chem 272:25401.
55. Madrenas, J., L. A. Chau, J. Smith, J. A. Bluestone, and R. N. Germain.
1997. The efficiency of CD4 recruitment to ligand-engaged TCR controls the 
agonist/partial agonist properties o f peptide-MHC molecule ligands. J  Exp
7^5.279.
56. Turner, J. M., M. H. Brodsky, B. A. Irving, S. D. Levin, R. M. Perlmutter, 
and D. R. Littman. 1990. Interaction of the unique N-terminal region of 
tyrosine kinase p561ck with cytoplasmic domains o f CD4 and CD8 is 
mediated by cysteine motifs. Cell 60:755.
57. Myung, P. S., N. J. Boerthe, and G. A. Koretzky. 2000. Adapter proteins in 
lymphocyte antigen-receptor signaling. Curr Opin Immunol 12:256.
58. Zhang, W., and L. E. Samelson. 2000. The role o f membrane-associated 
adaptors in T cell receptor signalling. Semin Immunol 12:35.
59. Genot, E., and D. A. Cantrell. 2000. Ras regulation and function in 
lymphocytes. Curr Opin Immunol 12:289.
60. Cantrell, D. A. 2003. GTPases and T cell activation. Immunol Rev 192:122.
61. Cooper, J. A. 1994. MAP kinase pathways. Straight and narrow or tortuous 
and intersecting? Curr Biol 4:1118.
62. Marshall, C. J. 1994. MAP kinase kinase kinase, MAP kinase kinase and 
MAP kinase. Curr Opin Genet Dev 4:82.
63. Hunter, T., and M. Karin. 1992. The regulation o f transcription by 
phosphorylation. Cell 70:375.
64. Scharenberg, A. M., O. El-Hillal, D. A. Fruman, L. O. Beitz, Z. Li, S. Lin, I. 
Gout, L. C. Cantley, D. J. Rawlings, and J. P. K inet. 1998. 
Phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-
113
dependent calcium signaling pathway: a target for SHIP-mediated inhibitory 
signals. Embo J  17:1961.
65. Schaeffer, E. M., J. Debnath, G. Yap, D. Me Vicar, X. C. Liao, D. R. 
Littman, A. Sher, H. E. Varmus, M. J. Lenardo, and P. L. Schwartzberg.
1999. Requirement for Tec kinases Rlk and Itk in T cell receptor signaling 
and immunity. Science 284:638.
66. Finco, T. S., T. Kadlecek, W. Zhang, L. E. Samelson, and A. Weiss. 1998. 
LAT is required for TCR-mediated activation of PLCgammal and the Ras 
pathway. Immunity 9:617.
67. Clements, J. L., B. Yang, S. E. Ross-Barta, S. L. Eliason, R. F. Hrstka, R. A. 
Williamson, and G. A. Koretzky. 1998. Requirement for the leukocyte- 
specific adapter protein SLP-76 for normal T cell development. Science
68. Crabtree, G. R. 1999. Generic signals and specific outcomes: signaling 
through Ca2+, calcineurin, and NF-AT. Cell 96:611.
69. Negulescu, P. A., T. B. Krasieva, A. Khan, H. H. Kerschbaum, and M. D. 
Cahalan. 1996. Polarity of T cell shape, motility, and sensitivity to antigen. 
Immunity 4:421.
70. Shaw, A. S., and M. L. Dustin. 1997. Making the T cell receptor go the 
distance: a topological view of T cell activation. Immunity 6:361.
71. Mellor, H., and P. J. Parker. 1998. The extended protein kinase C 
superfamily. BiochemJ 332 ( Pt 2):281.
72. Altman, A., N. Isakov, and G. Baier. 2000. Protein kinase Ctheta: a new 
essential superstar on the T-cell stage. Immunol Today 21:567.
73. Arendt, C. W., B. Albrecht, T. J. Soos, and D. R. Littman. 2002. Protein 
kinase C-theta;: signaling from the center of the T-cell synapse. Curr Opin 
Immunol 14:323.
74. Bi, K., Y. Tanaka, N. Coudronniere, K. Sugie, S. Hong, M. J. van Stipdonk, 
and A. Altman. 2001. Antigen-induced translocation o f PKC-theta to 
membrane rafts is required for T cell activation. Nat Immunol 2:556.
75. Villalba, M., N. Coudronniere, M. Deckert, E. Teixeiro, P. Mas, and A. 
Altman. 2000. A novel functional interaction between Vav and PKCtheta is 
required for TCR-induced T cell activation. Immunity 12:151.
76. Ebinu, J. O., S. L. Stang, C. Teixeira, D. A. Bottorff, J. Hooton, P. M. 
Blumberg, M. Barry, R. C. Bleakley, H. L. Ostergaard, and J. C. Stone.
2000. RasGRP links T-cell receptor signaling to Ras. Blood 95:3199.
77. Rameh, L. E., and L. C. Cantley. 1999. The role of phosphoinositide 3- 
kinase lipid products in cell function. J  Biol Chem 274:8347.
78. Ward, S. G., and D. A. Cantrell. 2001. Phosphoinositide 3-kinases in T 
lymphocyte activation. Curr Opin Immunol 13:332.
79. Cantrell, D. 1996. T cell antigen receptor signal transduction pathways. Annu 
Rev Immunol 14:259.
80. Zhang, W., J. Sloan-Lancaster, J. Kitchen, R. P. Trible, and L. E. Samelson.
1998. LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to 
cellular activation. Cell 92:83.
81. Rameh, L. E., A. Arvidsson, K. L. Carraway, 3rd, A. D. Couvillon, G. 
Rathbun, A. Crompton, B. VanRenterghem, M. P. Czech, K. S. 
Ravichandran, S. J. Burakoff, D. S. Wang, C. S. Chen, and L. C. Cantley.
114
1997. A comparative analysis o f the phosphoinositide binding specificity of 
pleckstrin homology domains. J  Biol Chem 272:22059.
82. Scharenberg, A. M., and J. P. Kinet. 1998. PtdIns-3,4,5-P3: a regulatory 
nexus between tyrosine kinases and sustained calcium signals. Cell 94:5.
83. Toker, A., and A. C. Newton. 2000. Cellular signaling: pivoting around 
PDK-1. Cell 103:185.
84. Vanhaesebroeck, B., and D. R. Alessi. 2000. The PI3K-PDK1 connection: 
more than just a road to PKB. BiochemJ 346 Pt 3:561.
85. Tybulewicz, V. L., L. Ardouin, A. Prisco, and L. F. Reynolds. 2003. V avl: a 
key signal transducer downstream of the TCR. Immunol Rev 192:42.
86. Williams, M. R., J. S. Arthur, A. Balendran, J. van der Kaay, V. Poli, P. 
Cohen, and D. R. Alessi. 2000. The role of 3-phosphoinositide-dependent 
protein kinase 1 in activating AGC kinases defined in embryonic stem cells. 
Curr Biol 10:439.
87. Montagne, J., M. J. Stewart, H. Stocker, E. Hafen, S. C. Kozma, and G. 
Thomas. 1999. Drosophila S6 kinase: a regulator o f cell size. Science
88. Volarevic, S., M. J. Stewart, B. Ledermann, F. Zilberman, L. Terracciano, E. 
Montini, M. Grompe, S. C. Kozma, and G. Thomas. 2000. Proliferation, but 
not growth, blocked by conditional deletion of 40S ribosomal protein S6. 
Science 288:2045.
89. Brennan, P., J. W. Babbage, B. M. Burgering, B. Groner, K. Reif, and D. A. 
Cantrell. 1997. Phosphatidylinositol 3-kinase couples the interleukin-2 
receptor to the cell cycle regulator E2F. Immunity 7:679.
90. Brennan, P., J. W. Babbage, G. Thomas, and D. Cantrell. 1999. p70(s6k) 
integrates phosphatidylinositol 3-kinase and rapamycin-regulated signals for 
E2F regulation in T lymphocytes. Mol Cell Biol 19:4729.
91. Jones, R. G., M. Parsons, M. Bonnard, V. S. Chan, W. C. Yeh, J. R.
Woodgett, and P. S. Ohashi. 2000. Protein kinase B regulates T lymphocyte
survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo. J  
Exp Med 191:1721.
92. Parsons, M. J., R. G. Jones, M. S. Tsao, B. Odermatt, P. S. Ohashi, and J. R.
Woodgett. 2001. Expression of active protein kinase B in T cells perturbs 
both T and B cell homeostasis and promotes inflammation. J  Immunol
93. Cohen, P., D. R. Alessi, and D. A. Cross. 1997. PD K l, one o f the missing
links in insulin signal transduction? FEBS Lett 410:3.
94. Beals, C. R., C. M. Sheridan, C. W. Turck, P. Gardner, and G. R. Crabtree.
1997. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. 
Science 275:1930.
95. Han, J., K. Luby-Phelps, B. Das, X. Shu, Y. Xia, R. D. Mosteller, U. M. 
Krishna, J. R. Falck, M. A. White, and D. Brock. 1998. Role of substrates 
and products of PI 3-kinase in regulating activation of Rac-related guanosine 
triphosphatases by Vav. Science 279:558.
96. Frauwirth, K. A., and C. B. Thompson. 2002. Activation and inhibition of 
lymphocytes by costimulation. J  Clin Invest 109:295.
97. Tuosto, L., and O. Acuto. 1998. CD28 affects the earliest signaling events 
generated by TCR engagement. Eur J  Immunol 28:2131.
115
98. Wulfing, C., and M. M. Davis. 1998. A receptor/cytoskeletal movement 
triggered by costimulation during T cell activation. Science 282:2266.
99. Viola, A., S. Schroeder, Y. Sakakibara, and A. Lanzavecchia. 1999. T 
lymphocyte costimulation mediated by reorganization o f membrane 
microdomains. Science 283:680.
100. Hutchcroft, J. E., and B. E. Bierer. 1994. A ctivation-dependent
phosphorylation of the T-lymphocyte surface receptor CD28 and associated 
proteins. Proc Natl Acad Sci U SA  91:3260.
101. August, A., S. Gibson, Y. Kawakami, T. Kawakami, G. B. Mills, and B. 
Dupont. 1994. CD28 is associated with and induces the immediate tyrosine
phosphorylation and activation of the Tec family kinase ITK/EMT in the
human Jurkat leukemic T-cell line. Proc Natl Acad Sci U SA  91:9347.
102. Acuto, O., and F. Michel. 2003. CD28-mediated co-stimulation: a
quantitative support for TCR signalling. Nat Rev Immunol 3:939.
103. Rudd, C. E. 1996. Upstream-downstream: CD28 cosignaling pathways and T 
cell function. Immunity 4:527.
104. Ward, S. G., J. Westwick, N. D. Hall, and D. M. Sansom. 1993. Ligation of 
CD28 receptor by B7 induces formation o f D-3 phosphoinositides in T 
lymphocytes independently o f T cell receptor/CD3 activation. Eur J  
Immunol 23:2572.
105. Woodrow, M. A., S. Rayter, J. Downward, and D. A. Cantrell. 1993. p21ras 
function is important for T cell antigen receptor and protein kinase C 
regulation of nuclear factor of activated T cells. J  Immunol 150:3853.
106. Kane, L. P., P. G. Andres, K. C. Howland, A. K. Abbas, and A. Weiss. 2001. 
Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and 
IFN-gamma but not TH2 cytokines. Nat Immunol 2:37.
107. Pai, S. Y., V. Calvo, M. Wood, and B. E. Bierer. 1994. Cross-linking CD28 
leads to activation of 70-kDa S6 kinase. Eur J  Immunol 24:2364.
108. Ghosh, P., M. A. Buchholz, S. Yano, D. Taub, and D. L. Longo. 2002. Effect 
o f rapamycin on the cyclosporin A-resistant CD28-mediated costimulatory 
pathway. Blood 99:4517.
109. Klasen, S., F. Pages, J. F. Peyron, D. A. Cantrell, and D. Olive. 1998. Two 
distinct regions of the CD28 intracytoplasmic domain are involved in the 
tyrosine phosphorylation of Vav and GTPase activating protein-associated 
p62 protein. Int Immunol 10:481.
110. Davis, R. J. 2000. Signal transduction by the JNK group o f MAP kinases. 
Cg// 703.25P.
111. Su, B., E. Jacinto, M. Hibi, T. Kallunki, M. Karin, and Y. Ben-Neriah. 1994. 
JNK is involved in signal integration during costimulation of T lymphocytes. 
Cg// 77.727.
112. Rincon, M., and R. A. Flavell. 1994. AP-1 transcriptional activity requires 
both T-cell receptor-mediated and co-stimulatory signals in primary T 
lymphocytes. Embo J  13:4370.
113. Liao, X. C., S. Fournier, N. Killeen, A. Weiss, J. P. Allison, and D. R. 
Littman. 1997. Itk negatively regulates induction o f T cell proliferation by 
CD28 costimulation. JExp Med 186:221.
114. Crabtree, G. R. 1989. Contingent genetic regulatory events in T lymphocyte 
activation. Science 243:355.
116
115. Alberola-Ila, J., S. Takaki, J. D. Kerner, and R. M. Perlmutter. 1997. 
Differential signaling by lymphocyte antigen receptors. Annu Rev Immunol 
15:125.
116. Ullman, K. S., J. P. Northrop, C. L. Verweij, and G. R. Crabtree. 1990. 
Transmission of signals from the T lymphocyte antigen receptor to the genes 
responsible for cell proliferation and immune function: the missing link. 
Annu Rev Immunol 8:421.
117. Ho, S., N. Clipstone, L. Timmermann, J. Northrop, I. Graef, D. Fiorentino, J. 
Nourse, and G. R. Crabtree. 1996. The mechanism of action of cyclosporin A 
and FK506. Clin Immunol Immunopathol 80:S40.
118. Karin, M., Z. Liu, and E. Zandi. 1997. AP-1 function and regulation. Curr 
Opin Cell Biol 9:240.
119. Hill, C. S., and R. Treisman. 1995. Transcriptional regulation by 
extracellular signals: mechanisms and specificity. Cell 80:199.
120. Isakov, N., and A. Altman. 2002. Protein kinase C(theta) in T cell activation. 
Annu Rev Immunol 20:761.
121. Janknecht, R., W. H. Ernst, V. Pingoud, and A. Nordheim. 1993. Activation 
of ternary complex factor Elk-1 by MAP kinases. Embo J  12:5097.
122. Kortenjann, M., O. Thomae, and P. E. Shaw. 1994. Inhibition of v-raf- 
dependent c-fos expression and transformation by a kinase-defective mutant 
of the mitogen-activated protein kinase Erk2. Mol Cell Biol 14:4815.
123. Coffer, P., M. de Jonge, A. Mettouchi, B. Binetruy, J. Ghysdael, and W. 
Kruijer. 1994. junB promoter regulation: Ras mediated transactivation by c- 
Ets-1 and c-Ets-2. Oncogene 9:911.
124. Hibi, M., A. Lin, T. Smeal, A. Minden, and M. Karin. 1993. Identification of 
an oncoprotein- and UV-responsive protein kinase that binds and potentiates 
the c-Jun activation domain. Genes Dev 7:2135.
125. Li, W., C. D. Whaley, J. L. Bonnevier, A. Mondino, M. E. Martin, K. M. 
Aagaard-Tillery, and D. L. Mueller. 2001. CD28 signaling augments Elk-1- 
dependent transcription at the c-fos gene during antigen stimulation. J  
Immunol 167:827.
126. Chen, C. Y., F. Del Gatto-Konczak, Z. Wu, and M. Karin. 1998. 
Stabilization of interleukin-2 mRNA by the c-Jun NH2-terminal kinase 
pathway. Science 280:1945.
127. Rao, A. 1994. NF-ATp: a transcription factor required for the co-ordinate 
induction of several cytokine genes. Immunol Today 15:274.
128. Macian, F., C. Garcia-Rodriguez, and A. Rao. 2000. Gene expression elicited 
by NFAT in the presence or absence of cooperative recruitment o f Fos and 
Jun. Embo J  19:4783.
129. Macian, F., C. Lopez-Rodriguez, and A. Rao. 2001. Partners in transcription: 
NFAT and AP-1. Oncogene 20:2476.
130. Clipstone, N. A., and G. R. Crabtree. 1992. Identification of calcineurin as a 
key signalling enzyme in T-lymphocyte activation. Nature 357:695.
131. Rayter, S. L, M. Woodrow, S. C. Lucas, D. A. Cantrell, and J. Downward. 
1992. p21ras mediates control o f IL-2 gene promoter function in T cell 
activation. Embo J  11:4549.
117
132. Genot, E. M., P. J. Parker, and D. A. Cantrell. 1995. Analysis of the role of 
protein kinase C-alpha, -epsilon, and -zeta in T cell activation. J  Biol Chem 
270.9,333.
133. Sun, Z., C. W. Arendt, W. Ellmeier, E. M. Schaeffer, M. J. Sunshine, L. 
Gandhi, J. Annes, D. Petrzilka, A. Kupfer, P. L. Schwartzberg, and D. R. 
Littman. 2000. PKC-theta is required for TCR-induced NF-kappaB 
activation in mature but not immature T lymphocytes. Nature 404:402.
134. Karin, M., and Y. Ben-Neriah. 2000. Phosphorylation meets ubiquitination: 
the control ofNF-[kappa]B activity. Annu Rev Immunol 18:621.
135. Costello, P. S., A. E. Walters, P. J. Mee, M. Turner, L. F. Reynolds, A. 
Prisco, N. Sarner, R. Zamoyska, and V. L. Tybulewicz. 1999. The Rho- 
family GTP exchange factor Vav is a critical transducer o f T cell receptor 
signals to the calcium, ERK, and NF-kappaB pathways. Proc Natl Acad Sci 
US'X Pd.3033.
136. Ghosh, P., T. H. Tan, N. R. Rice, A. Sica, and H. A. Young. 1993. The 
interleukin 2 CD28-responsive complex contains at least three members of 
the NF kappa B family: c-Rel, p50, and p65. Proc Natl Acad Sci U S A  
PO.VdPd.
137. Pfeuffer, L, S. Klein-Hessling, A. Heinfling, S. Chuvpilo, C. Escher, T. 
Brabletz, B. Hentsch, H. Schwarzenbach, P. Matthias, and E. Serfling. 1994. 
Octamer factors exert a dual effect on the IL-2 and IL-4 promoters. J  
Immunol 153:5572.
138. Kamps, M. P., L. Corcoran, J. H. LeBowitz, and D. Baltimore. 1990. The 
promoter of the human interleukin-2 gene contains two octamer-binding sites 
and is partially activated by the expression of Oct-2. Mol Cell Biol 10:5464.
139. Pardee, A. B. 1989. G1 events and regulation of cell proliferation. Science 
2^d.'d03.
140. Turner, J. M. 1993. IL-2-dependent induction of G1 cyclins in primary T 
cells is not blocked by rapamycin or cyclosporin A. Int Immunol 5:1199.
141. Minami, Y., T. Kono, T. Miyazaki, and T. Taniguchi. 1993. The IL-2
receptor complex: its structure, function, and target genes. Annu Rev
Immunol 11:245.
142. Reed, S. I. 1992. The role of p34 kinases in the G1 to S-phase transition. 
Annu Rev Cell Biol 8:529.
143. Pines, J. 1993. Cyclins and cyclin-dependent kinases: take your partners. 
Trends Biochem Sci 18:195.
144. Sherr, C. J. 1993. Mammalian G1 cyclins. Cell 73:1059.
145. Sherr, C. J., and J. M. Roberts. 1999. CDK inhibitors: positive and negative
regulators of G 1-phase progression. Genes Dev 13:1501.
146. Ruas, M., and G. Peters. 1998. The pl6INK4a/CDKN2A tumor suppressor 
and its relatives. Biochim Biophys Acta 1378:F115.
147. Hengst, L., and S. I. Reed. 1998. Inhibitors of the Cip/Kip family. Curr Top 
Microbiol Immunol 227:25.
148. Shaulian, E., and M. Karin. 2001. AP-1 in cell proliferation and survival. 
Oncogene 20:2390.
149. Vermeulen, K., Z. N. Bememan, and D. R. Van Bockstaele. 2003. Cell cycle 
and apoptosis. Cell Prolif36:165.
118
150. Hartwell, L. H., and T. A. Weinert. 1989. Checkpoints: controls that ensure 
the order of cell cycle events. Science 246:629.
151. Weinert, T. A., and L. H. Hartwell. 1988. The RAD9 gene controls the cell 
cycle response to DNA damage in Saccharomyces cerevisiae. Science 
2^7.377.
152. Dasso, M., and J. W. Newport. 1990. Completion of DNA replication is 
monitored by a feedback system that controls the initiation of mitosis in 
vitro: studies in Xenopus. Cell 61:811.
153. Hoyt, M. A., L. Totis, and B. T. Roberts. 1991. S. cerevisiae genes required 
for cell cycle arrest in response to loss of microtubule function. Cell 66:507.
154. Li, R., and A. W. Murray. 1991. Feedback control o f mitosis in budding 
yeast. Cell 66:519.
155. Pardee, A. B. 1974. A restriction point for control o f normal animal cell 
proliferation. Proc Natl Acad Sci U SA  71:1286.
156. Firpo, E. J., A. Koff, M. J. Solomon, and J. M. Roberts. 1994. Inactivation of 
a Cdk2 inhibitor during interleukin 2-induced proliferation of human T 
lymphocytes. Mol Cell Biol 14:4889.
157. Kato, J. Y., M. Matsuoka, K. Polyak, J. Massague, and C. J. Sherr. 1994. 
Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kipl) o f 
cyclin-dependent kinase 4 activation. Cell 79:487.
158. Agrawal, D., P. Hauser, F. McPherson, F. Dong, A. Garcia, and W. J. 
Pledger. 1996. Repression of p27kipl synthesis by platelet-derived growth 
factor in BALB/c 3T3 cells. Mol Cell Biol 16:4327.
159. Winston, J., F. Dong, and W. J. Pledger. 1996. Differential modulation of G1 
cyclins and the Cdk inhibitor p27kipl by platelet-derived growth factor and 
plasma factors in density-arrested fibroblasts. JBiol Chem 271:11253.
160. Taya, Y. 1997. RB kinases and RB-binding proteins: new points o f view. 
Trends Biochem Sci 22:14.
161. Chellappan, S. P., S. Hiebert, M. Mudryj, J. M. Horowitz, and J. R. Nevins.
1991. The E2F transcription factor is a cellular target for the RB protein. Cell 
65:1053.
162. Weinberg, R. A. 1995. The retinoblastoma protein and cell cycle control. 
C e//^7.323.
163. DeGregori, J., T. Kowalik, and J. R. Nevins. 1995. Cellular targets for 
activation by the E2F1 transcription factor include DNA synthesis- and 
Gl/S-regulatory genes. Mol Cell Biol 15:4215.
164. Botz, J., K. Zerfass-Thome, D. Spitkovsky, H. Delius, B. Vogt, M. Eilers, A. 
Hatzigeorgiou, and P. Jansen-Durr. 1996. Cell cycle regulation of the murine 
cyclin E gene depends on an E2F binding site in the promoter. Mol Cell Biol 
7d.'3^07.
165. Montagnoli, A., F. Fiore, E. Eytan, A. C. Carrano, G. F. Draetta, A. Hershko, 
and M. Pagano. 1999. Ubiquitination of p27 is regulated by Cdk-dependent 
phosphorylation and trimeric complex formation. Genes Dev 13:1181.
166. Tsvetkov, L. M., K. H. Yeh, S. J. Lee, H. Sun, and H. Zhang. 1999. 
p27(Kipl) ubiquitination and degradation is regulated by the SCF(Skp2) 
complex through phosphorylated Thrl87 in p27. Curr Biol 9:661.
119
167. Lundberg, A. S., and R. A. Weinberg. 1998. Functional inactivation of the 
retinoblastoma protein requires sequential modification by at least two 
distinct cyclin-cdk complexes. Mol Cell Biol 18:753.
168. Modiano, J. F., J. Domenico, A. Szepesi, J. J. Lucas, and E. W. Gelfand.
1994. Differential requirements for interleukin-2 distinguish the expression 
and activity of the cyclin-dependent kinases Cdk4 and Cdk2 in human T 
cells. JBiol Chem 269:32972.
169. Morice, W. G., G. Wiederrecht, G. J. Brunn, J. J. Siekierka, and R. T. 
Abraham. 1993. Rapamycin inhibition of interleukin-2-dependent p33cdk2 
and p34cdc2 kinase activation in T lymphocytes. JBiol Chem 268:22737.
170. Nourse, J., E. Firpo, W. M. Flanagan, S. Coats, K. Polyak, M. H. Lee, J. 
Massague, G. R. Crabtree, and J. M. Roberts. 1994. Interleukin-2-mediated 
elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by 
rapamycin. Nature 372:570.
171. Nelson, B. H., and D. M. Willerford. 1998. Biology of the interleukin-2 
receptor. Adv Immunol 70:1.
172. Nakarai, T., M. J. Robertson, M. Streuli, Z. Wu, T. L. Ciardelli, K. A. Smith,
and J. Ritz. 1994. Interleukin 2 receptor gamma chain expression on resting
and activated lymphoid cells. JExp Med 180:241.
173. Nelson, B. H., J. D. Lord, and P. D. Greenberg. 1994. Cytoplasmic domains 
of the interleukin-2 receptor beta and gamma chains mediate the signal for T- 
cell proliferation. Nature 369:333.
174. Karnitz, L. M., and R. T. Abraham. 1996. Interleukin-2 receptor signaling 
mechanisms. Adv Immunol 61:147.
175. Lord, J. D., B. C. McIntosh, P. D. Greenberg, and B. H. Nelson. 1998. The
IL-2 receptor promotes proliferation, bcl-2 and bcl-x induction, but not cell 
viability through the adapter molecule She. J  Immunol 161:4627.
176. Lord, J. D., B. C. McIntosh, P. D. Greenberg, and B. H. Nelson. 2000. The 
IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, 
bcl-2, and bcl-x genes through the trans-activation domain o f Stat5. J  
Immunol 164:2533.
177. Leonard, W. J., and J. J. O'Shea. 1998. Jaks and STATs: biological 
implications. Annu Rev Immunol 16:293.
178. Greenland, A. C., M. O. Morales, B. L. Viviano, H. Yan, J. Krolewski, and 
R. D. Schreiber. 1995. Stat recruitment by tyrosine-phosphorylated cytokine 
receptors: an ordered reversible affinity-driven process. Immunity 2:677.
179. Moriggl, R., D. J. Topham, S. Teglund, V. Sexl, C. McKay, D. Wang, A. 
Hoffmeyer, J. van Deursen, M. Y. Sangster, K. D. Bunting, G. C. Grosveld, 
and J. N. Ihle. 1999. Stat5 is required for IL-2-induced cell cycle progression 
of peripheral T cells. Immunity 10:249.
180. Friedmann, M. C., T. S. Migone, S. M. Russell, and W. J. Leonard. 1996. 
Different interleukin 2 receptor beta-chain tyrosines couple to at least two 
signaling pathways and synergistically mediate interleukin 2-induced 
proliferation. Proc Natl Acad Sci U SA  93:2077.
181. Izquierdo Pastor, M., K. Reif, and D. Cantrell. 1995. The regulation and 
function of p21ras during T-cell activation and growth. Immunol Today
120
182. Gadina, M., C. Sudarshan, R. Visconti, Y. J. Zhou, H. Gu, B. G. Neel, and J. 
J. O'Shea. 2000. The docking molecule gab2 is induced by lymphocyte 
activation and is involved in signaling by interleukin-2 and interleukin-15 
but not other common gamma chain-using cytokines. J  Biol Chem
183. Gu, H., H. Maeda, J. J. Moon, J. D. Lord, M. Yoakim, B. H. Nelson, and B. 
G. Neel. 2000. New role for She in activation of the phosphatidylinositol 3- 
kinase/Akt pathway. Mol Cell Biol 20:7109.
184. Steelman, L. S., S. C. Pohnert, J. G. Shelton, R. A. Franklin, F. E. Bertrand, 
and J. A. McCubrey. 2004. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and 
BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18:189.
185. Reif, K., B. M. Burgering, and D. A. Cantrell. 1997. Phosphatidylinositol 3- 
kinase links the interleukin-2 receptor to protein kinase B and p70 S6 kinase. 
JBiol Chem 272:14426.
186. Karnitz, L. M., L. A. Bums, S. L. Sutor, J. Blenis, and R. T. Abraham. 1995. 
Interleukin-2 triggers a novel phosphatidylinositol 3-kinase-dependent MEK 
activation pathway. Mol Cell Biol 15:3049.
187. Stephens, L., K. Anderson, D. Stokoe, H. Erdjument-Bromage, G. F. Painter,
A. B. Holmes, P. R. Gaffney, C. B. Reese, F. McCormick, P. Tempst, J. 
Coadwell, and P. T. Hawkins. 1998. Protein kinase B kinases that mediate 
phosphatidylinositol 3,4,5-trisphosphate-dependent activation o f protein 
kinase B. Science 279:710.
188. Pullen, N., P. B. Dennis, M. Andjelkovic, A. Dufner, S. C. Kozma, B. A. 
Hemmings, and G. Thomas. 1998. Phosphoiylation and activation of p70s6k 
by PDKL Science 279:707.
189. Alessi, D. R., M. T. Kozlowski, Q. P. Weng, N. Morrice, and J. Avruch.
1998. 3-Phosphoinositide-dependent protein kinase 1 (PDKl) phosphorylates 
and activates the p70 S6 kinase in vivo and in vitro. Curr Biol 8:69.
190. Lim, M. A., C. K. Kikani, M. J. Wick, and L. Q. Dong. 2003. Nuclear 
translocation of 3'-phosphoinositide-dependent protein kinase 1 (PDK-1): a 
potential regulatory mechanism for PDK-1 function. Proc Natl Acad Sci U S
191. Kops, G. J., and B. M. Burgering. 1999. Forkhead transcription factors: new 
insights into protein kinase B (c-akt) signaling. J  Mol Med 77:656.
192. Dijkers, P. F., R. H. Medema, C. Pals, L. Banerji, N. S. Thomas, E. W. Lam,
B. M. Burgering, J. A. Raaijmakers, J. W. Lammers, L. Koenderman, and P. 
J. Coffer. 2000. Forkhead transcription factor FKHR-Ll modulates cytokine- 
dependent transcriptional regulation of p27(KIPl). Mol Cell Biol 20:9138.
193. Banerjee, P., M. F. Ahmad, J. R. Grove, C. Kozlosky, D. J. Price, and J. 
Avruch. 1990. Molecular structure o f a major insulin/mitogen-activated 70- 
kDa S6 protein kinase. Proc Natl Acad Sci U SA  87:8550.
194. Grove, J. R., P. Banerjee, A. Balasubramanyam, P. J. Coffer, D. J. Price, J. 
Avruch, and J. R. Woodgett. 1991. Cloning and expression of two human 
p70 S6 kinase polypeptides differing only at their amino termini. Mol Cell 
Biol 11:5541.
195. Kozma, S. C., S. Ferrari, P. Bassand, M. Siegmann, N. Totty, and G. 
Thomas. 1990. Cloning of the mitogen-activated S6 kinase from rat liver
121
reveals an enzyme of the second messenger subfamily. Proc Natl Acad Sci U 
5"^ ^7.
196. Reinhard, C., G. Thomas, and S. C. Kozma. 1992. A single gene encodes 
two isoforms of the p70 S6 kinase: activation upon mitogenic stimulation. 
Proc Natl Acad Sci U SA  89:4052.
197. Lee-Fruman, K. K., C. J. Kuo, J. Lippincott, N. Terada, and J. Blenis. 1999. 
Characterization of S6K2, a novel kinase homologous to S6K1. Oncogene
198. Jefferies, H. B., S. Fumagalli, P. B. Dennis, C. Reinhard, R. B. Pearson, and 
G. Thomas. 1997. Rapamycin suppresses STOP mRNA translation through 
inhibition ofp70s6k. Embo J  16:3693.
199. Thomas, G. 2002. The S6 kinase signaling pathway in the control o f 
development and growth. Biol Res 35:305.
200. Nasmyth, K. 1996. Retinoblastoma protein. Another role rolls in. Nature 
3^2.23.
201. Jefferies, H. B., and G. Thomas. 1994. Elongation factor-1 alpha mRNA is 
selectively translated following mitogenic stimulation. J  Biol Chem
269.^^367.
202. Terada, N., H. R. Patel, K. Takase, K. Kohno, A. C. Nairn, and E. W. 
Gelfand. 1994. Rapamycin selectively inhibits translation o f mRNAs 
encoding elongation factors and ribosomal proteins. Proc Natl Acad Sci U S 
X P7.77477.
203. Fieitman, J., N. R. M ow a, and M. N. Hall. 1991. Targets for cell cycle arrest 
by the immunosuppressant rapamycin in yeast. Science 253:905.
204. Raught, B., A. C. Gingras, and N. Sonenberg. 2001. The target of rapamycin 
(TOR) proteins. Proc Natl Acad Sci U SA  98:7037.
205. Keith, C. T., and S. L. Schreiber. 1995. PIK-related kinases: DNA repair, 
recombination, and cell cycle checkpoints. Science 270:50.
206. Schmelzle, T., and M. N. Hall. 2000. TOR, a central controller o f cell 
growth. Cell 103:253.
207. liboshi, Y., P. J. Papst, H. Kawasome, H. Hosoi, R. T. Abraham, P. J. 
Houghton, and N. Terada. 1999. Amino acid-dependent control o f p70(s6k). 
Involvement o f tRNA aminoacylation in the regulation. J  Biol Chem
274.-70P2.
208. Dennis, P. B., A. Jaeschke, M. Saitoh, B. Fowler, S. C. Kozma, and G. 
Thomas. 2001. Mammalian TOR: a homeostatic ATP sensor. Science  
2P4.7702.
209. McManus, E. J., and D. R. Alessi. 2002. TSC1-TSC2: a complex tale o f 
PKB-mediated S6K regulation. Nat Cell Biol 4:E214.
210. Krymskaya, V. P. 2003. Tumour suppressors hamartin and tuberin: 
intracellular signalling. Cell Signal 15:729.
211. Hara, K., Y. Maruki, X. Long, K. Yoshino, N. Oshiro, S. Hidayat, C. 
Tokunaga, J. Avruch, and K. Yonezawa. 2002. Raptor, a binding partner of 
target of rapamycin (TOR), mediates TOR action. Cell 110:177.
212. Kim, D. H., D. D. Sarbassov, S. M. Ali, J. E. King, R. R. Latek, H. 
Erdjument-Bromage, P. Tempst, and D. M. Sabatini. 2002. mTOR interacts 
with raptor to form a nutrient-sensitive complex that signals to the cell 
growth machinery. Cell 110:163.
122
213. Horton, L. E., M. Bushell, D. Barth-Baus, V. J. Tilleray, M. J. Clemens, and 
J. O. Hensold. 2002. p53 activation results in rapid déphosphorylation of the 
eIF4E-binding protein 4E-BP1, inhibition of ribosomal protein S6 kinase and 
inhibition of translation initiation. Oncogene 21:5325.
214. Gonzalez-Garcia, A., E. Garrido, C. Hernandez, B. Alvarez, C. Jimenez, D. 
A. Cantrell, N. Pullen, and A. C. Carrera. 2002. A new role for the p85- 
phosphatidylinositol 3-kinase regulatory subunit linking FRAP to p70 S6 
kinase activation. JBiol Chem 277:1500.
215. Thomas, G., and M. N. Hall. 1997. TOR signalling and control o f cell 
growth. Curr Opin Cell Biol 9:782.
216. Tan, A., P. Bitterman, N. Sonenberg, M. Peterson, and V. Polunovsky. 2000. 
Inhibition of Myc-dependent apoptosis by eukaryotic translation initiation 
factor 4E requires cyclin D l. Oncogene 19:1437.
217. Brown, E. J., M. W. Albers, T. B. Shin, K. Ichikawa, C. T. Keith, W. S. 
Lane, and S. L. Schreiber. 1994. A mammalian protein targeted by G l- 
arresting rapamycin-receptor complex. Nature 369:756.
218. Sabatini, D. M., H. Erdjument-Bromage, M. Lui, P. Tempst, and S. H. 
Snyder. 1994. RAFTl: a mammalian protein that binds to FKBP12 in a 
rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78:35.
219. Edinger, A. L., and C. B. Thompson. 2002. Akt maintains cell size and 
survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell
220. Wells, A. D., H. Gudmundsdottir, and L. A. Turka. 1997. Following the fate 
of individual T cells throughout activation and clonal expansion. Signals 
from T cell receptor and CD28 differentially regulate the induction and 
duration of a proliferative response. J  Clin Invest 100:3173.
221. Khoruts, A., A. Mondino, K. A. Pape, S. L. Reiner, and M. K. Jenkins. 1998. 
A natural immunological adjuvant enhances T cell clonal expansion through 
a CD28-dependent, interleukin (IL)-2-independent mechanism. J  Exp Med 
7^7.225.
222. Schorle, H., T. Holtschke, T. Hunig, A. Schimpl, and I. Horak. 1991. 
Development and function of T cells in mice rendered interleukin-2 deficient 
by gene targeting. Nature 352:621.
223. Tivol, E. A., F. Borriello, A. N. Schweitzer, W. P. Lynch, J. A. Bluestone, 
and A. H. Sharpe. 1995. Loss o f  CTLA-4 leads to m assive 
lymphoproliferation and fatal multiorgan tissue destruction, revealing a 
critical negative regulatory role of CTLA-4. Immunity 3:541.
224. Boonen, G. J., A. M. van Dijk, L. F. Verdonck, R. A. van Lier, G. Rijksen, 
and R. H. Medema. 1999. CD28 induces cell cycle progression by IL-2- 
independent down-regulation of p27kipl expression in human peripheral T 
lymphocytes. Eur J  Immunol 29:789.
225. Boulougouris, G., J. D. McLeod, Y. I. Patel, C. N. Ellwood, L. S. Walker, 
and D. M. Sansom. 1999. IL-2-independent activation and proliferation in 
human T cells induced by CD28. J  Immunol 163:1809.
226. Appleman, L. J., A. Berezovskaya, I. Grass, and V. A. Boussiotis. 2000. 
CD28 costimulation mediates T cell expansion via IL-2-independent and IL- 
2-dependent regulation of cell cycle progression. J  Immunol 164:144.
123
227. Appleman, L. J., A. A. van Puijenbroek, K. M. Shu, L. M. Nadler, and V. A. 
Boussiotis. 2002. CD28 costimulation mediates down-regulation of p27kipl 
and cell cycle progression by activation of the PI3K/PKB signaling pathway 
in primary human T cells. J  Immunol 168:2729.
228. Houssaint, E., and M. Flajnik. 1990. The role o f thymic epithelium in the 
acquisition of tolerance. Immunol Today 11:357.
229. Ikuta, K., N. Uchida, J. Friedman, and I. L. Weissman. 1992. Lymphocyte 
development from stem cells. Annu Rev Immunol 10:759.
230. Miller, C., J. A. Ragheb, and R. H. Schwartz. 1999. Anergy and cytokine- 
mediated suppression as distinct superantigen-induced tolerance mechanisms 
in vivo. JExp Med 190:53.
231. Nossal, G. J., and B. L. Pike. 1980. Clonal anergy: persistence in tolerant 
mice of antigen-binding B lymphocytes incapable o f responding to antigen 
or mitogen. Proc Natl Acad Sci U SA  77:1602.
232. Lamb, J. R., B. J. Skidmore, N. Green, J. M. Chiller, and M. Feldmann. 
1983. Induction of tolerance in influenza virus-immune T lymphocyte clones 
with synthetic peptides of influenza hemagglutinin. JExp Med 157:1434.
233. Quill, H., and R. H. Schwartz. 1987. Stimulation of normal inducer T cell 
clones with antigen presented by purified la molecules in planar lipid 
membranes: specific induction o f a long-lived state o f proliferative 
nonresponsiveness. J  Immunol 138:3704.
234. Jenkins, M. K., and R. H. Schwartz. 1987. Antigen presentation by 
chemically modified splenocytes induces antigen- specific T cell 
unresponsiveness in vitro and in vivo. JExp Med 165:302.
235. Mueller, D. L., M. K. Jenkins, and R. H. Schwartz. 1989. An accessory cell- 
derived costimulatory signal acts independently o f protein kinase C 
activation to allow T cell proliferation and prevent the induction o f 
unresponsiveness. J  Immunol 142:2617.
236. Jenkins, M. K., C. A. Chen, G. Jung, D. L. Mueller, and R. H. Schwartz. 
1990. Inhibition o f antigen-specific proliferation o f type 1 murine T cell 
clones after stimulation with immobilized anti-CD3 monoclonal antibody. J  
Immunol 144:16.
237. Jenkins, M. K., D. M. Pardoll, J. Mizuguchi, T. M. Chused, and R. H. 
Schwartz. 1987. Molecular events in the induction of a nonresponsive state 
in interleukin 2-producing helper T-lymphocyte clones. Proc Natl Acad Sci
238. Rammensee, H. G., R. Kroschewski, and B. Frangoulis. 1989. Clonal anergy 
induced in mature V beta 6+ T lymphocytes on immunizing M is-lb  mice 
with M is-la expressing cells. Nature 339:541.
239. Kawabe, Y., and A. Ochi. 1990. Selective anergy of V beta 8+,CD4+ T cells 
in Staphylococcus enterotoxin B-primed mice. JExp Med 172:1065.
240. Rellahan, B. L., L. A. Jones, A. M. Kruisbeek, A. M. Fry, and L. A. Matis. 
1990. In vivo induction of anergy in peripheral V beta 8+ T cells by 
staphylococcal enterotoxin B. JExp Med 172:1091.
241. Kearney, E. R., K. A. Pape, D. Y. Loh, and M. K. Jenkins. 1994. 
Visualization of peptide-specific T cell immunity and peripheral tolerance 
induction in vivo. Immunity 1:327.
124
242. Pape, K. A., A. Khoruts, E. Ingulli, A. Mondino, R. Merica, and M. K. 
Jenkins. 1998. Antigen-specific CD4+ T cells that survive after the induction 
of peripheral tolerance possess an intrinsic lymphokine production defect. 
Novartis Found Symp 215:103.
243. Pape, K. A., R. Merica, A. Mondino, A. Khoruts, and M. K. Jenkins. 1998. 
Direct evidence that functionally impaired CD4+ T cells persist in vivo 
following induction of peripheral tolerance. J  Immunol 160:4719.
244. Kang, S. M., B. Beverly, A. C. Tran, K. Brorson, R. H. Schwartz, and M. J. 
Lenardo. 1992. Transactivation by AP-1 is a molecular target of T cell clonal 
anergy. Science 257:1134.
245. Mondino, A., C. D. Whaley, D. R. DeSilva, W. Li, M. K. Jenkins, and D. L. 
Mueller. 1996. Defective transcription of the IL-2 gene is associated with 
impaired expression of c-Fos, FosB, and JunB in anergic T helper 1 cells. J  
Immunol 157:2048.
246. Fields, P. E., T. F. Gajewski, and F. W. Fitch. 1996. Blocked Ras activation 
in anergic CD4+ T cells. Science 271:1276.
247. Li, W., C. D. Whaley, A. Mondino, and D. L. Mueller. 1996. Blocked signal 
transduction to the ERK and JNK protein kinases in anergic CD4+ T cells. 
Science 271:1272.
248. Sundstedt, A., M. Sigvardsson, T. Leanderson, G. Hedlund, T. Kalland, and 
M. Dohlsten. 1996. In vivo anergized CD4+ T cells express perturbed AP-1 
and NF-kappa B transcription factors. Proc Natl Acad Sci U SA  93:979.
249. Becker, J. C., T. Brabletz, T. Kirchner, C. T. Conrad, E. B. Brocker, and R. 
A. Reisfeld. 1995. Negative transcriptional regulation in anergic T cells. 
Proc Natl Acad Sci U SA  92:2375.
250. Powell, J. D., C. G. Lerner, G. R. Ewoldt, and R. H. Schwartz. 1999. The - 
180 site o f the IL-2 promoter is the target of CREB/CREM binding in T cell 
anergy. J  Immunol 163:6631.
251. Telander, D. G., E. N. Malvey, and D. L. Mueller. 1999. Evidence for 
repression of IL-2 gene activation in anergic T cells. J  Immunol 162:1460.
252. Gajewski, T. F., P. Fields, and F. W. Fitch. 1995. Induction of the increased 
Fyn kinase activity in anergic T helper type 1 clones requires calcium and 
protein synthesis and is sensitive to cyclosporin A. Eur J  Immunol 25:1836.
253. Gajewski, T. F., D. Qian, P. Fields, and F. W. Fitch. 1994. Anergic T- 
lymphocyte clones have altered inositol phosphate, calcium, and tyrosine 
kinase signaling pathways. Proc Natl Acad Sci U SA  91:38.
254. Quill, H., M. P. Riley, E. A. Cho, J. E. Casnellie, J. C. Reed, and T. Torigoe.
1992. Anergic Thl cells express altered levels of the protein tyrosine kinases 
p561ck and p59fyn. J  Immunol 149:2887.
255. Appleman, L. J., and V. A. Boussiotis. 2003. T cell anergy and 
costimulation. Immunol Rev 192:161.
256. Sloan-Lancaster, J., B. D. Evavold, and P. M. Allen. 1993. Induction of T- 
cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. 
Nature 363:156.
257. Madrenas, J., R. L. Wange, J. L. Wang, N. Isakov, L. E. Samelson, and R. N. 
Germain. 1995. Zeta phosphorylation without ZAP-70 activation induced by 
TCR antagonists or partial agonists. Science 267:515.
125
258. Boussiotis, V. A., D. L. Barber, B. J. Lee, J. G. Gribben, G. J. Freeman, and 
L. M. Nadler. 1996. Differential association of protein tyrosine kinases with 
the T cell receptor is linked to the induction of anergy and its prevention by 
B7 family-mediated costimulation. JExp Med 184:365.
259. Macian, F., F. Garcia-Cozar, S. H. Im, H. F. Horton, M. C. Byrne, and A. 
Rao. 2002. Transcriptional mechanisms underlying lymphocyte tolerance.
260. Anandasabapathy, N., G. S. Ford, D. Bloom, C. Holness, V. Paragas, C. 
Seroogy, H. Skrenta, M. Hollenhorst, C. G. Fathman, and L. Soares. 2003. 
GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is 
expressed in anergic CD4+ T cells. Immunity 18:535.
261. Garcia-Sanz, J. A., and D. Lenig. 1996. Translational control o f interleukin 2 
messenger RNA as a molecular mechanism of T cell anergy. J  Exp Med 
7^4.7 JP.
262. DeSilva, D. R., K. B. Urdahl, and M. K. Jenkins. 1991. Clonal anergy is 
induced in vitro by T cell receptor occupancy in the absence of proliferation. 
J  Immunol 147:3261.
263. Beverly, B., S. M. Kang, M. J. Lenardo, and R. H. Schwartz. 1992. Reversal 
o f in vitro T cell clonal anergy by IL-2 stimulation. Int Immunol 4:661.
264. Gilbert, K. M., and W. O. Weigle. 1993. Thl cell anergy and blockade in 
G la  phase of the cell cycle. J  Immunol 151:1245.
265. Powell, J. D., C. G. Lerner, and R. H. Schwartz. 1999. Inhibition o f cell 
cycle progression by rapamycin induces T cell clonal anergy even in the 
presence of costimulation. J  Immunol 162:2775.
266. Essery, G., M. Feldmann, and J. R. Lamb. 1988. Interleukin-2 can prevent 
and reverse antigen-induced unresponsiveness in cloned human T 
lymphocytes. Immunology 64:413.
267. Jenkins, M. K. 1992. The role o f cell division in the induction of clonal 
anergy. Immunol Today 13:69.
268. Boussiotis, V. A., G. J. Freeman, P. A. Taylor, A. Berezovskaya, I. Grass, B. 
R. Blazar, and L. M. Nadler. 2000. p27kip 1 functions as an anergy factor 
inhibiting interleukin 2 transcription and clonal expansion o f alloreactive 
human and mouse helper T lymphocytes. Nat Med 6:290.
269. Jackson, S. K., A. DeLoose, and K. M. Gilbert. 2001. Induction of anergy in 
Thl cells associated with increased levels of cyclin-dependent kinase 
inhibitors p21Cipl and p27Kipl. J  Immunol 166:952.
270. Murphy, K. M., A. B. Heimberger, and D. Y. Loh. 1990. Induction by 
antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. 
Science 250:1720.
271. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Be van, and 
F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive 
selection. Cell 76:17.
272. Hecht, T. T., D. L. Longo, and L. A. Matis. 1983. The relationship between 
immune interferon production and proliferation in antigen-specific, MHC- 
restricted T cell lines and clones. J  Immunol 131:1049.
273. Leo, O., M. Foo, D. H. Sachs, L. E. Samelson, and J. A. Bluestone. 1987. 
Identification of a monoclonal antibody specific for a murine T3 polypeptide. 
Proc Natl Acad Sci U SA 84:1374.
126
274. Gross, J. A., T. St John, and J. P. Allison. 1990. The murine homologue of 
the T lymphocyte antigen CD28. Molecular cloning and cell surface 
expression. J  Immunol 144:3201.
275. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of 
the head of bacteriophage T4. Nature 227:680.
276. Bellone, M., D. Cantarella, P. Castiglioni, M. C. Crosti, A. Ronchetti, M. 
Moro, M. P. Garancini, G. Casorati, and P. Dellabona. 2000. Relevance of 
the tumor antigen in the validation o f three vaccination strategies for 
melanoma. J  Immunol 165:2651.
277. Karre, K., H. G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective 
rejection of H-2-defîcient lymphoma variants suggests alternative immune 
defence strategy. Nature 319:675.
278. Hobbs, M. V., W. O. Weigle, D. J. Noonan, B. E. Torbett, R. J. McEvilly, R. 
J. Koch, G. J. Cardenas, and D. N. Ernst. 1993. Patterns o f cytokine gene 
expression by CD4+ T cells from young and old mice. J  Immunol 150:3602.
279. Guidotti, L. G., and F. V. Chisari. 1999. Cytokine-induced viral purging— 
role in viral pathogenesis. Curr Opin Microbiol 2:388.
280. Sitia, G., M. Isogawa, K. Kakimi, S. F. Wieland, F. V. Chisari, and L. G. 
Guidotti. 2002. Depletion of neutrophils blocks the recruitment o f antigen- 
nonspecific cells into the liver without affecting the antiviral activity o f 
hepatitis B virus-specific cytotoxic T lymphocytes. Proc Natl Acad Sci U SA  
PP. 73777.
281. Lyons, A. B., and C. R. Parish. 1994. Determination of lymphocyte division 
by flow cytometry. J  Immunol Methods 171:131.
282. Malek, T. R., A. Yu, P. Scibelli, M. G. Lichtenheld, and E. K. Codias. 2001. 
Broad programming by IL-2 receptor signaling for extended growth to 
multiple cytokines and functional maturation of antigen-activated T cells. J  
Immunol 166:1675.
283. Wells, A. D., M. C. Walsh, D. Sankaran, and L. A. Turka. 2000. T cell 
effector function and anergy avoidance are quantitatively linked to cell 
division. J  Immunol 165:2432.
284. Boussiotis, V. A., D. L. Barber, T. Nakarai, G. J. Freeman, J. G. Gribben, G. 
M. Bernstein, A. D. D'Andrea, J. Ritz, and L. M. Nadler. 1994. Prevention of 
T cell anergy by signaling through the gamma c chain of the IL-2 receptor. 
Science 266:1039.
285. Terada, N., K. Takase, P. Papst, A. C. Nairn, and E. W. Gelfand. 1995. 
Rapamycin inhibits ribosomal protein synthesis and induces G1 prolongation 
in mitogen-activated T lymphocytes. J  Immunol 155:3418.
286. Pullen, N., and G. Thomas. 1997. The modular phosphorylation and 
activation of p70s6k. FEBS Lett 410:78.
287. Pearson, R. B., P. B. Dennis, J. W. Han, N. A. Williamson, S. C. Kozma, R.
E. Wettenhall, and G. Thomas. 1995. The principal target of rapamycin- 
induced p70s6k inactivation is a novel phosphorylation site within a 
conserved hydrophobic domain. Embo J  14:5279.
288. Dufner, A., and G. Thomas. 1999. Ribosomal S6 kinase signaling and the 
control of translation. Exp Cell Res 253:100.
127
289. Guy, G. R., R. Philip, and Y. H. Tan. 1994. Analysis o f cellular 
phosphoproteins by two-dimensional gel electrophoresis: applications for 
cell signaling in normal and cancer cells. Electrophoresis 15:417.
290. Vanasek, T. L., A. Khoruts, T. Zell, and D. L. Mueller. 2001. Antagonistic 
roles for CTLA-4 and the mammalian target of rapamycin in the regulation 
of clonal anergy: enhanced cell cycle progression promotes recall antigen 
responsiveness. J  Immunol 167:5636.
291. Murphy, K. M., W. Ouyang, J. D. Farrar, J. Yang, S. Ranganath, H. Asnagli, 
M. Afkarian, and T. L. Murphy. 2000. Signaling and transcription in T 
helper development. Annu Rev Immunol 18:451.
292. Murphy, K. M., and S. L. Reiner. 2002. The lineage decisions o f helper T 
cells. Nat Rev Immunol 2:933.
293. Le Gros, G., S. Z. Ben-Sasson, R. Seder, F. D. Finkelman, and W. E. Paul.
1990. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: 
IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J  
Exp Med 172:921.
294. O'Garra, A. 1998. Cytokines induce the development o f functionally 
heterogeneous T helper cell subsets. Immunity 8:275.
295. Zhu, J., J. Cote-Sierra, L. Guo, and W. E. Paul. 2003. Stat5 activation plays a 
critical role in Th2 differentiation. Immunity 19:739.
296. Leonard, W. J., and J. X. Lin. 2000. Cytokine receptor signaling pathways. J  
Allergy Clin Immunol 105:877.
291. Powell, J. D., D. Bruniquel, and R. H. Schwartz. 2001. TCR engagement in
the absence of cell cycle progression leads to T cell anergy independent of 
p27(Kipl). Eur J  Immunol 31:3737.
298. Kneitz, B., T. Herrmann, S. Yonehara, and A. Schimpl. 1995. Normal clonal 
expansion but impaired Fas-mediated cell death and anergy induction in 
interleukin-2-deficient mice. Eur J  Immunol 25:2572.
299. Claret, F. X., M. Hibi, S. Dhut, T. Toda, and M. Karin. 1996. A new group of 
conserved coactivators that increase the specificity o f AP-1 transcription 
factors. Nature 383:453.
300. Jenkins, M. K., D. M. Pardoll, J. Mizuguchi, H. Quill, and R. H. Schwartz. 
1987. T-cell unresponsiveness in vivo and in vitro: fine specificity o f 
induction and molecular characterization of the unresponsive state. Immunol 
Rev 95:113.
301. Ferrari, S., W. Bannwarth, S. J. Morley, N. F. Totty, and G. Thomas. 1992. 
Activation of p70s6k is associated with phosphorylation o f four clustered 
sites displaying Ser/Thr-Pro motifs. Proc Natl Acad Sci U SA  89:7282.
302. Mukhopadhyay, N. K., D. J. Price, J. M. Kyriakis, S. Pelech, J. Sanghera, 
and J. Avruch. 1992. An array o f insulin-activated, proline-directed 
serine/threonine protein kinases phosphorylate the p70 S6 kinase. J  Rm/ 
Chem 267:3325.
303. Han, J. W., R. B. Pearson, P. B. Dennis, and G. Thomas. 1995. Rapamycin, 
wortmannin, and the methylxanthine SQ20006 inactivate p70s6k by inducing 
dephosphorylation of the same subset of sites. JBiol Chem 270:21396.
304. Weng, Q. P., K. Andrabi, A. Klippel, M. T. Kozlowski, L. T. Williams, and 
J. Avruch. 1995. Phosphatidylinositol 3-kinase signals activation of p70 S6
128
kinase in situ through site-specific p70 phosphorylation. Proc Natl Acad Sci 
P2."3744.
305. Burnett, P. E., R. K. Barrow, N. A. Cohen, S. H. Snyder, and D. M. Sabatini.
1998. RAFTl phosphorylation of the translational regulators p70 S6 kinase 
and 4E-BP1. Proc Natl Acad Sci U SA  95:1432.
306. Isotani, S., K. Hara, C. Tokunaga, H. Inoue, J. Avruch, and K. Yonezawa.
1999. Immunopurified mammalian target o f rapamycin phosphorylates and 
activates p70 S6 kinase alpha in vitro. JBiol Chem 274:34493.
307. Belham, C., M. J. Comb, and J. Avruch. 2001. Identification of the NIMA 
family kinases NEK6/7 as regulators of the p70 ribosomal S6 kinase. Curr 
Biol 11:1155.
308. Peterson, R. T., B. N. Desai, J. S. Hardwick, and S. L. Schreiber. 1999. 
Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated 
by inhibition of FKBP12-rapamycinassociated protein. Proc Natl Acad Sci U
Pd. 443&.
309. Gingras, A. C., S. P. Gygi, B. Raught, R. D. Polakiewicz, R. T. Abraham, M.
F. Hoekstra, R. Aebersold, and N. Sonenberg. 1999. Regulation of 4E-BP1 
phosphorylation: a novel two-step mechanism. Genes Dev 13:1422.
310. Chuang, E., T. S. Fisher, R. W. Morgan, M. D. Robbins, J. M. Duerr, M. G. 
Vander Heiden, J. P. Gardner, J. E. Hambor, M. J. Neveu, and C. B. 
Thompson. 2000. The CD28 and CTLA-4 receptors associate with the 
serine/threonine phosphatase PP2A. Immunity 13:313.
311. Razi-Wolf, Z., G. A. Hollander, and H. Reiser. 1996. Activation of CD4+ T 
lymphocytes form interleukin 2-deficient mice by costimulatory B7 
molecules. Proc Natl Acad Sci U SA  93:2903.
312. Abraham, R. T., and G. J. Wiederrecht. 1996. Immunopharmacology of 
rapamycin. Annu Rev Immunol 14:483.
313. Terada, N., R. A. Franklin, J. J. Lucas, J. Blenis, and E. W. Gelfand. 1993. 
Failure of rapamycin to block proliferation once resting cells have entered 
the cell cycle despite inactivation of p70 S6 kinase. JB iol Chem 268:12062.
314. Slavik, J. M., D. G. Lim, S. J. Burakoff, and D. A. Hafler. 2004. Rapamycin- 
resistant proliferation of CD8+ T cells correlates with p27kipl down- 
regulation and bcl-xL induction, and is prevented by an inhibitor of 
phosphoinositide 3-kinase activity. JBiol Chem 279:910.
315. Abbas, A. K., K. M. Murphy, and A. Sher. 1996. Functional diversity o f 
helper T lymphocytes. Nature 383:787.
316. Ho, I. C., and L. H. Glimcher. 2002. Transcription: tantalizing times for T 
cells. Cell 109 Suppl:S109.
317. Mosmann, T. R., H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. 
Coffman. 1986. Two types o f murine helper T cell clone. I. Definition 
according to profiles of lymphokine activities and secreted proteins. J  
Immunol 136:2348.
318. Mosmann, T. R., and R. L. Coffman. 1989. THl and TH2 cells: different 
patterns of lymphokine secretion lead to different functional properties. Annu 
Rev Immunol 7:145.
319. Sher, A., and R. L. Coffinan. 1992. Regulation of immunity to parasites by T 
cells and T cell-derived cytokines. Annu Rev Immunol 10:385.
129
320. Constant, S. L., and K. Bottomly. 1997. Induction of Thl and Th2 CD4+ T 
cell responses: the alternative approaches. Annu Rev Immunol 15:297.
321. Bird, J. J., D. R. Brown, A. C. Mullen, N. H. Moskowitz, M. A. Mahowald, 
J. R. Sider, T. F. Gajewski, C. R. Wang, and S. L. Reiner. 1998. Helper T 
cell differentiation is controlled by the cell cycle. Immunity 9:229.
322. Gett, A. V., and P. D. Hodgkin. 1998. Cell division regulates the T cell 
cytokine repertoire, revealing a mechanism underlying immune class 
regulation. Proc Natl Acad Sci U SA  95:9488.
323. Constant, S., C. Pfeiffer, A. Woodard, T. Pasqualini, K. Bottomly, N. 
Schweitzer, J. West, P. Ranney, D. Leitenberg, D. D. Lu, B. R. Smith, D. 
Sant'Angelo, T. Taylor, D. Levin, and R. Flavell. 1995. Extent o f T cell 
receptor ligation can determine the functional differentiation of naive CD4+ 
T cells
B lymphocytes can be competent antigen-presenting cells for priming CD4+ 
T cells to protein antigens in vivo
CD4 and CD45 regulate qualitatively distinct patterns o f calcium 
mobilization in individual CD4+ T cells
Peptide and protein antigens require distinct antigen-presenting cell subsets 
for the priming of CD4+ T cells. JExp Med 182:1591.
324. Hosken, N. A., K. Shibuya, A. W. Heath, K. M. Murphy, and A. O'Garra.
1995. The effect o f antigen dose on CD4+ T helper cell phenotype 
development in a T cell receptor-alpha beta-transgenic model. J  Exp Med 
7^2. 7379.
325. Avni, O., and A. Rao. 2000. T cell differentiation: a mechanistic view. Curr 
Opin Immunol 12:654.
326. Ansel, K. M., D. U. Lee, and A. Rao. 2003. An epigenetic view of helper T 
cell differentiation. Nat Immunol 4:616.
327. Grogan, J. L., M. Mohrs, B. Harmon, D. A. Lacy, J. W. Sedat, and R. M. 
Locksley. 2001. Early transcription and silencing of cytokine genes underlie 
polarization of T helper cell subsets. Immunity 14:205.
328. Agarwal, S., and A. Rao. 1998. Modulation of chromatin structure regulates 
cytokine gene expression during T cell differentiation. Immunity 9:765.
329. Agarwal, S., J. P. Viola, and A. Rao. 1999. Chromatin-based regulatory 
mechanisms governing cytokine gene transcription. J  Allergy Clin Immunol 
703.PP0.
330. Fields, P. E., S. T. Kim, and R. A. Flavell. 2002. Cutting edge: changes in 
histone acétylation at the IL-4 and IFN-gamma loci accompany Thl/Th2 
differentiation. J  Immunol 169:647.
331. Rohde, J. R., and M. E. Cardenas. 2003. The tor pathway regulates gene 
expression by linking nutrient sensing to histone acétylation. Mol Cell Biol 
2 3 . 3 2 P .
332. Afkarian, M., J. R. Sedy, J. Yang, N. G. Jacobson, N. Cereb, S. Y. Yang, T. 
L. Murphy, and K. M. Murphy. 2002. T-bet is a STAT 1-induced regulator of 
IL-12R expression in naive CD4+ T cells. Nat Immunol 3:549.
333. Lighvani, A. A., D. M. Frucht, D. Jankovic, H. Yamane, J. Aliberti, B. D. 
Hissong, B. V. Nguyen, M. Gadina, A. Sher, W. E. Paul, and J. J. O'Shea.
2001. T-bet is rapidly induced by interferon-gamma in lymphoid and 
myeloid cells. Proc Natl Acad Sci U SA  98:15137.
130
334. Mullen, A. C., F. A. High, A. S. Hutchins, H. W. Lee, A. V. Villarino, D. M. 
Livingston, A. L. Kung, N. Cereb, T. P. Yao, S. Y. Yang, and S. L. Reiner.
2001. Role of T-bet in commitment o f THl cells before IL-12-dependent 
selection. Science 292:1907.
335. Szabo, S. J., S. T. Kim, G. L. Costa, X. Zhang, C. G. Fathman, and L. H. 
Glimcher. 2000. A novel transcription factor, T-bet, directs Thl lineage 
commitment. Cell 100:655.
336. Szabo, S. J., B. M. Sullivan, C. Stemmann, A. R. Satoskar, B. P. Sleckman, 
and L. H. Glimcher. 2002. Distinct effects o f T-bet in TH l lineage 
commitment and IFN-gamma production in CD4 and CD8 T cells. Science 
293.33^.
337. Ouyang, W., S. H. Ranganath, K. Weindel, D. Bhattacharya, T. L. Murphy, 
W. C. Sha, and K. M. Murphy. 1998. Inhibition o f T hl development 
mediated by GATA-3 through an IL-4-independent mechanism. Immunity 
P. 743.
338. Ouyang, W., M. Lohning, Z. Gao, M. Assenmacher, S. Ranganath, A. 
Radbruch, and K. M. Murphy. 2000. Stat6-independent GATA-3 
autoactivation directs IL-4-independent Th2 development and commitment. 
Immunity 12:27.
339. Lee, H. J., N. Takemoto, H. Kurata, Y. Kamogawa, S. Miyatake, A. O'Garra, 
and N. Arai. 2000. GATA-3 induces T helper cell type 2 (Th2) cytokine 
expression and chromatin remodeling in committed Thl cells. J  Exp Med 
7P2.703.
340. Takemoto, N., Y. Kamogawa, H. Jun Lee, H. Kurata, K. I. Arai, A. O'Garra, 
N. Arai, and S. Miyatake. 2000. Cutting edge: chromatin remodeling at the 
IL-4/IL-13 intergenic regulatory region for Th2-specific cytokine gene 
cluster. J  Immunol 165:6687.
341. Usui, T., R. Nishikomori, A. Kitani, and W. Strober. 2003. GATA-3 
suppresses Thl development by downregulation o f Stat4 and not through 
effects on IL-12Rbeta2 chain or T-bet. Immunity 18:415.
342. Ben-Sasson, S. Z., G. Le Gros, D. H. Conrad, F. D. Finkelman, and W. E. 
Paul. 1990. IL-4 production by T cells from naive donors. IL-2 is required 
for IL-4 production. J  Immunol 145:1127.
343. Presky, D. H., H. Yang, L. J. Minetti, A. O. Chua, N. Nabavi, C. Y. Wu, M. 
K. Gately, and U. Gubler. 1996. A functional interleukin 12 receptor 
complex is composed of two beta-type cytokine receptor subunits. Proc Natl
P3.74002.
344. Sinigaglia, F., D. D'Ambrosio, P. Panina-Bordignon, and L. Rogge. 1999. 
Regulation o f the IL-12/IL-12R axis: a critical step in T-helper cell 
differentiation and effector function. Immunol Rev 170:65.
345. Richter, A., M. Lohning, and A. Radbruch. 1999. Instruction for cytokine 
expression in T helper lymphocytes in relation to proliferation and cell cycle 
progression. JExp Med 190:1439.
131
Reproduced with permission of copyright owner. Further reproduction prohibited without permission.
